

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 June 2010 (24.06.2010)

(10) International Publication Number  
WO 2010/070094 A1

(51) International Patent Classification:  
*C07K 16/22* (2006.01) *A61P 21/00* (2006.01)  
*A61K 39/395* (2006.01)

US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **ZHANG, Hong** [CN/US]; GlaxoSmithKline, 1250 S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426 (US).

(21) International Application Number:

PCT/EP2009/067515

(74) Agent: **BHOGAL, Jasber, Kaur**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date:

18 December 2009 (18.12.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/138,980 19 December 2008 (19.12.2008) US

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ASHMAN, Claire** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **BEATON, Andrew** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **ELLIS, Jonathan, Henry** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **HAN, Bajin** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **KIRBY, Ian** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **KULL, Frederick** [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **LEWIS, Alan** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **LINDLEY, Kathryn, Mason** [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **ORECCHIA, Martin, Anibal** [IT/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **SHEN, Ying** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durham, NC 27709 (US). **WILSON, Paul** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **XU, Tian Shun** [US/

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2010/070094 A1

(54) Title: MYOSTATIN BINDING PROTEINS

(57) Abstract: Description of antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. Furthermore, description of the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with any one or a combination of decreased muscle mass, muscle strength and muscle function.

## MYOSTATIN BINDING PROTEINS

## FIELD OF INVENTION

The present invention relates to antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, 5 pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with any one or a combination of decreased muscle mass, muscle strength and muscle function.

## BACKGROUND OF THE INVENTION

10 Myostatin, also known as Growth and Differentiation Factor (GDF-8), is a member of the Transforming Growth Factor-beta (TGF- $\beta$ ) superfamily and is a negative regulator of muscle mass. Myostatin is highly conserved throughout evolution and the sequences of human, chicken, mouse and rat are 100% identical in the mature C-terminal domain. Myostatin is synthesised as a precursor protein that 15 contains a signal sequence, a pro-peptide domain and a C-terminal domain. Secreted, circulating forms of myostatin include the active mature C-terminal domain and an inactive form comprising the mature C-terminal domain in a latent complex associated with the pro-peptide domain and/or other inhibitory proteins.

20 There are a number of different diseases, disorders and conditions that are associated with reduced muscle mass, muscle strength and muscle function. Increased exercise and better nutrition are the mainstays of current therapy for the treatment of such diseases. Unfortunately, the benefits of increased physical activity are seldom realised due to poor persistence and compliance on the part of patients. Also, exercise can be difficult, painful or impossible for some patients. Moreover there may be 25 insufficient muscular exertion associated with exercise to produce any beneficial effect on muscle. Nutritional interventions are only effective if there are underlying dietary deficiencies and the patient has an adequate appetite. Due to these limitations, treatments for diseases associated with decreases in any one or a combination of muscle mass, muscle strength, and muscle function with more widely attainable 30 benefits are a substantial unmet need.

Antibodies to myostatin have been described (WO 2008/030706, WO 2007/047112, WO 2007/044411, WO 2006/116269, WO 2005/094446, WO 2004/037861, WO 03/027248 and WO 94/21681). Also, Wagner *et al.* (Ann Neurol. (2008) 63(5): 561-71) describe no improvements in exploratory end points of muscle strength or function in adult muscular dystrophies (Becker muscular dystrophy, facioscapulohumeral dystrophy, and limb-girdle muscular dystrophy) when using one of the anti-myostatin antibodies described.

Therefore, there remains a need for more effective therapies for the treatment or prophylaxis of diseases associated with decreases in any one or a combination of muscle mass, muscle strength, and muscle function.

## SUMMARY OF THE INVENTION

The present invention provides an antigen binding protein which specifically binds to myostatin. The antigen binding protein can be used to treat or prevent a disease associated with any one or a combination of decreased muscle mass, muscle strength, and muscle function.

The present invention provides an antigen binding protein which specifically binds to myostatin and comprises CDRH3 of SEQ ID NO: 3 or a variant CDRH3.

The present invention also provides an antigen binding protein which specifically binds to myostatin and comprises the corresponding CDRH3 of the variable domain sequence of SEQ ID NO: 7, or a variant CDRH3 thereof.

The present invention also provides an antigen binding protein which specifically binds to myostatin and comprises a binding unit H3 comprising Kabat residues 95-101 of SEQ ID NO: 7, or a variant H3.

The present invention also provides an antigen binding protein which specifically binds to myostatin and comprises:

- (i) a heavy chain variable region selected from SEQ ID NO: 7 or SEQ ID NO: 25; and/or a light chain variable region selected from SEQ ID NO: 8 or SEQ ID NO: 21; or a variant heavy chain variable region or light chain variable region with 75% or greater sequence identity; or

- (ii) a heavy chain of SEQ ID NO: 26; and/or a light chain selected from SEQ ID NO: 27 or SEQ ID NO: 37; or a variant heavy chain or light chain with 75% or greater sequence identity.

5 The present invention also provides an antigen binding protein which specifically binds to myostatin and comprises:

- (i) a heavy chain variable region selected from any one of SEQ ID NO: 12, 13 or 14; and/or a light chain variable region selected from any one of SEQ ID NO: 15, 16, 17, 18 or 24; or a variant heavy chain variable region or light chain variable region with 75% or greater sequence identity; or

- 10 (ii) a heavy chain selected from any one of SEQ ID NO: 28, 29, 30, 98 or 99; and/or a light chain selected from any one of SEQ ID NO: 31, 32, 33, 34 or 40; or a variant heavy chain or light chain with 75% or greater sequence identity.

15 The invention also provides a nucleic acid molecule which encodes an antigen binding protein as defined herein. The invention also provides an expression vector comprising a nucleic acid molecule as defined herein. The invention also provides a recombinant host cell comprising an expression vector as defined herein. The invention also provides a method for the production of an antigen binding protein as defined herein which method comprises the step of culturing a host cell as defined  
20 above and recovering the antigen binding protein. The invention also provides a pharmaceutical composition comprising an antigen binding protein thereof as defined herein and a pharmaceutically acceptable carrier.

25 The invention also provides a method of treating a subject afflicted with a disease which reduces muscle mass, muscle strength and/or muscle function, which method comprises the step of administering an antigen binding protein as defined herein.

30 The invention provides a method of treating a subject afflicted with sarcopenia, cachexia, muscle-wasting, disuse muscle atrophy, HIV, AIDS, cancer, surgery, burns, trauma or injury to muscle bone or nerve, obesity, diabetes (including type II diabetes mellitus), arthritis, chronic renal failure (CRF), end stage renal disease (ESRD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), elective joint repair, multiple sclerosis (MS), stroke, muscular dystrophy,

motor neuron neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, osteoporosis, osteoarthritis, fatty acid liver disease, liver cirrhosis, Addison's disease, Cushing's syndrome, acute respiratory distress syndrome, steroid induced muscle wasting, myositis or scoliosis, which method comprises the step of administering an antigen binding protein as described herein.

The invention provides a method of increasing muscle mass, increasing muscle strength, and/or improving muscle function in a subject which method comprises the step of administering an antigen binding protein as defined herein.

The invention provides an antigen binding protein as described herein for use in the treatment of a subject afflicted with a disease which reduces any one or a combination of muscle mass, muscle strength and muscle function.

The invention provides an antigen binding protein as described herein for use in the treatment of sarcopenia, cachexia, muscle-wasting, disuse muscle atrophy, HIV, AIDS, cancer, surgery, burns, trauma or injury to muscle bone or nerve, obesity, diabetes (including type II diabetes mellitus), arthritis, chronic renal failure (CRF), end stage renal disease (ESRD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), elective joint repair, multiple sclerosis (MS), stroke, muscular dystrophy, motor neuron neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, osteoporosis, osteoarthritis, fatty acid liver disease, liver cirrhosis, Addison's disease, Cushing's muscle wasting, myositis or scoliosis.

The invention provides an antigen binding protein as described herein for use in a method of increasing muscle mass, increasing muscle strength, and/or improving syndrome, acute respiratory distress syndrome, steroid induced muscle function in a subject.

The invention provides the use of an antigen binding protein as described herein in the manufacture of a medicament for use in the treatment of a subject afflicted with a disease which reduces any one or a combination of muscle mass, muscle strength and muscle function.

The invention provides the use of an antigen binding protein as described herein in the manufacture of a medicament for use in the treatment of sarcopenia, cachexia, muscle-wasting, disuse muscle atrophy, HIV, AIDS, cancer, surgery, burns, trauma or injury to muscle bone or nerve, obesity, diabetes (including type II diabetes

mellitus), arthritis, chronic renal failure (CRF), end stage renal disease (ESRD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), elective joint repair, multiple sclerosis (MS), stroke, muscular dystrophy, motor neuron neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, 5 osteoporosis, osteoarthritis, fatty acid liver disease, liver cirrhosis, Addison's disease, Cushing's muscle wasting, myositis or scoliosis.

The invention provides the use of an antigen binding protein as described herein in the manufacture of a medicament for use in a method of increasing muscle mass, increasing muscle strength, and/or improving syndrome, acute respiratory 10 distress syndrome, steroid induced muscle function in a subject.

## BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the LC/MS analysis for purified mature myostatin: predicted Molecular Weight (MW) 12406.25 Da, observed MW 24793.98 Da, which indicates a dimerised molecule with nine pairs of disulphide bonds, matching the predicted 15 myostatin monomer with nine cysteine residues.

Figure 2 shows a 4-12% NuPAGE Bis-Tris gel with MOPS buffer. Lane 1: mature myostatin reduced with DTT. Lane 2: mature myostatin non-reduced without DTT. Lane 3: Mark 12 protein standard.

Figure 3A shows dose response curves demonstrating myostatin (R&D 20 Systems and in-house myostatin species) induced activation of cell signalling, resulting in luciferase expression after 6 hours in a dose dependent manner in A204 cells. Figure 3B shows dose response curves demonstrating in-house myostatin induced activation of cell signalling, resulting in luciferase expression in a dose dependent manner in A204 cells, on different test occasions as represented by data 25 obtained on different days.

Figure 4 shows 10B3 binding to mature myostatin, latent complex and mature myostatin released from latent complex by ELISA.

Figure 5 shows inhibition of myostatin binding to ActRIIb by 10B3 and 10B3 chimera.

30 Figure 6 shows the 10B3 and 10B3 chimera inhibition of myostatin-induced activation of cell signalling, resulting in decreased luciferase expression in A204 cells.

Figure 7 shows the *in vivo* effects of 10B3 on body weight (A) and lean mass (B) in mice.

Figure 8 shows the *in vivo* effects of 10B3 on muscle mass in gastrocnemius (A), quadriceps (B), and extensor digitorum longus (EDL) (C) in mice.

5 Figure 9 shows the *ex vivo* effects of 10B3 on muscle contractility in EDL, showing tetanic force (A) and tetanic force corrected by muscle mass (B).

Figure 10A shows the binding of humanised anti-myostatin antibody variants (in CHOK1 supernatants) and 10B3C to myostatin by ELISA. Figure 10B is derived from Figure 10A and displays antibodies containing the H2 and/or L2 chains and  
10 10B3 chimera.

Figure 11 shows the binding of purified H0L0, H1L2 and H2L2 humanised anti-myostatin antibody variants and 10B3C to myostatin by ELISA.

Figure 12 shows 10B3, 10B3C, H0L0 and H2L2 inhibition of myostatin-induced activation of cell signalling, resulting in luciferase expression in A204 cells.

15 Figure 13 shows the binding of purified H2L2-N54D, H2L2-N54Q, H2L2-C91S, H2L2-N54D-C91S and H2L2-N54Q-C91S humanised anti-myostatin antibody variants, H2L2 and 10B3C (HCLC) to myostatin by ELISA.

Figure 14 shows the binding of purified H2L2-N54Q, H2L2-C91S, H2L2-N54Q-C91S humanised anti-myostatin antibody variants, H2L2, H0L0 and 10B3C (HCLC) to myostatin by ELISA.

Figure 15 shows the H2L2-N54Q, H2L2-C91S, H2L2-N54Q-C91S humanised anti-myostatin antibody variants, H0L0, H2L2 and 10B3C inhibition of myostatin-induced activation of cell signalling, resulting in luciferase expression in A204 cells.

25 Figure 16 shows binding of the H2L2 humanised anti-myostatin antibody to myostatin following treatment of the antibody with or without ammonium bicarbonate which can induce deamidation of the antibody.

Figure 17 shows binding of the H2L2-N54Q humanised anti-myostatin antibody variant to myostatin following treatment of the antibody with or without ammonium bicarbonate which can induce deamidation of the antibody.

Figure 18 shows binding of the H2L2-C91S humanised anti-myostatin antibody variant to myostatin following treatment of the antibody with or without ammonium bicarbonate which can induce deamidation of the antibody.

5 Figure 19 shows binding of the H2L2-N54Q-C91S humanised anti-myostatin antibody variant to myostatin following treatment of the antibody with or without ammonium bicarbonate which can induce deamidation of the antibody.

Figure 20 shows binding of the H0L0 humanised anti-myostatin antibody to myostatin following treatment of the antibody with or without ammonium bicarbonate which can induce deamidation of the antibody.

10 Figure 21 shows the binding activity in the myostatin capture ELISA of the eleven affinity purified CDRH3 variants; and H2L2-C91S, H0L0, HcLc (10B3 chimera) and a negative control monoclonal antibody which were used as control antibodies.

15 Figure 22 shows the binding activity in the myostatin binding ELISA of the five affinity purified CDRH2 variants; and H2L2-C91S\_F100G\_Y, H2L2-C91S, HcLc (10B3 chimera) and a negative control monoclonal antibody which were used as control antibodies.

Figure 23 shows the effect of 10B3 and control antibody treatment on body weight in C-26 tumour bearing mice from day 0 to day 25.

20 Figure 24 shows the effect of 10B3 and control antibody treatment on total body fat (A), epididymal fat pad (B), and lean mass (C), in C-26 tumour bearing mice.

Figure 25 shows the effect of 10B3 and control antibody treatment on lower limb muscle strength, which was measured by the contraction force upon the electrical stimulation of sciatic nerve on the mid thigh in C-26 tumour bearing mice.

25 Figure 26 shows the effect of 10B3 and control antibody treatment in sham operated and tenotomy surgery on mouse tibialis anterior (TA) muscle.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an antigen binding protein which specifically binds to myostatin, for example homodimeric mature myostatin. The antigen binding protein may bind to and neutralise myostatin, for example human myostatin. The 5 antigen binding protein may be an antibody, for example a monoclonal antibody.

Myostatin and GDF-8 both refer to any one of: the full-length unprocessed precursor form of myostatin; mature myostatin which results from post-translational cleavage of the C-terminal domain, in latent and non-latent (active) forms. The term myostatin also refers to any fragments and variants of myostatin that retain one or 10 more biological activities associated with myostatin.

The full-length unprocessed precursor form of myostatin comprises pro-peptide and the C-terminal domain which forms the mature protein, with or without a signal sequence. Myostatin pro-peptide plus C-terminal domain is also known as polyprotein. The myostatin precursor may be present as a monomer or homodimer.

15 Mature myostatin is the protein that is cleaved from the C-terminus of the myostatin precursor protein, also known as the C-terminal domain. Mature myostatin may be present as a monomer, homodimer, or in a myostatin latent complex. Depending on conditions, mature myostatin may establish equilibrium between a combination of these different forms. The mature C-terminal domain sequences of 20 human, chicken, mouse and rat myostatin are 100% identical (see for example SEQ ID NO: 104). In one embodiment, the antigen binding protein of the invention binds to homodimeric, mature myostatin shown in SEQ ID NO: 104.

Myostatin pro-peptide is the polypeptide that is cleaved from the N-terminal domain of the myostatin precursor protein following cleavage of the signal sequence. 25 Pro-peptide is also known as latency-associated peptide (LAP). Myostatin pro-peptide is capable of non-covalently binding to the pro-peptide binding domain on mature myostatin. An example of the human pro-peptide myostatin sequence is provided in SEQ ID NO: 108.

Myostatin latent complex is a complex of proteins formed between mature 30 myostatin and myostatin pro-peptide or other myostatin-binding proteins. For example, two myostatin pro-peptide molecules can associate with two molecules of mature myostatin to form an inactive tetrameric latent complex. The myostatin latent

complex may include other myostatin-binding proteins in place of or in addition to one or both of the myostatin pro-peptides. Examples of other myostatin-binding proteins include follistatin, follistatin-related gene (FLRG) and Growth and Differentiation Factor-Associated Serum Protein 1 (GASP-1).

5 The myostatin antigen binding protein may bind to any one or any combination of precursor, mature, monomeric, dimeric, latent and active forms of myostatin. The antigen binding protein may bind mature myostatin in its monomeric and/or dimeric forms. The antigen binding protein may or may not bind myostatin when it is in a complex with pro-peptide and/or follistatin. Alternatively the antigen  
10 binding protein may or may not bind myostatin when it is in a complex with follistatin-related gene (FLRG) and/or Growth and Differentiation Factor-Associated Serum Protein 1 (GASP-1). For example, the antigen binding protein binds to mature dimeric myostatin.

15 The term “antigen binding protein” as used herein refers to antibodies, antibody fragments and other protein constructs, such as domains, which are capable of binding to myostatin.

20 The term “antibody” is used herein in the broadest sense to refer to molecules with an immunoglobulin-like domain and includes monoclonal, recombinant, polyclonal, chimeric, humanised, bispecific and heteroconjugate antibodies; a single variable domain, a domain antibody, antigen binding fragments, immunologically effective fragments, single chain Fv, diabodies, Tandabs™, etc (for a summary of alternative “antibody” formats see Holliger and Hudson, *Nature Biotechnology*, 2005, Vol 23, No. 9, 1126-1136).

25 The phrase “single variable domain” refers to an antigen binding protein variable domain (for example,  $V_H$ ,  $V_{HH}$ ,  $V_L$ ) that specifically binds an antigen or epitope independently of a different variable region or domain.

30 A “domain antibody” or “dAb” may be considered the same as a “single variable domain” which is capable of binding to an antigen. A single variable domain may be a human antibody variable domain, but also includes single antibody variable domains from other species such as rodent (for example, as disclosed in WO 00/29004), nurse shark and *Camelid*  $V_{HH}$  dAbs. Camelid  $V_{HH}$  are immunoglobulin single variable domain polypeptides that are derived from species including camel,

llama, alpaca, dromedary, and guanaco, which produce heavy chain antibodies naturally devoid of light chains. Such  $V_{HH}$  domains may be humanised according to standard techniques available in the art, and such domains are considered to be “domain antibodies”. As used herein  $V_H$  includes camelid  $V_{HH}$  domains.

5 As used herein the term “domain” refers to a folded protein structure which has tertiary structure independent of the rest of the protein. Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and/or of the domain. A “single variable domain” is a folded  
10 polypeptide domain comprising sequences characteristic of antibody variable domains. It therefore includes complete antibody variable domains and modified variable domains, for example, in which one or more loops have been replaced by sequences which are not characteristic of antibody variable domains, or antibody variable domains which have been truncated or comprise N- or C-terminal extensions,  
15 as well as folded fragments of variable domains which retain at least the binding activity and specificity of the full-length domain. A domain can bind an antigen or epitope independently of a different variable region or domain.

An antigen binding fragment may be provided by means of arrangement of one or more CDRs on non-antibody protein scaffolds such as a domain. A non-  
20 antibody protein scaffold or domain is one that has been subjected to protein engineering in order to obtain binding to a ligand other than its natural ligand, for example a domain which is a derivative of a scaffold selected from: CTLA-4 (Evibody); lipocalin; Protein A derived molecules such as Z-domain of Protein A (Affibody, SpA), A-domain (Avimer/Maxibody); heat shock proteins such as GroEl and GroES; transferrin (trans-body); ankyrin repeat protein (DARPin); peptide aptamer; C-type lectin domain (Tetranectin); human  $\gamma$ -crystallin and human ubiquitin (affilins); PDZ domains; scorpion toxinkunitz type domains of human protease inhibitors; and fibronectin (adnectin); which has been subjected to protein engineering in order to obtain binding to a ligand other than its natural ligand.

30 CTLA-4 (Cytotoxic T Lymphocyte-associated Antigen 4) is a CD28-family receptor expressed on mainly CD4+ T-cells. Its extracellular domain has a variable domain-like Ig fold. Loops corresponding to CDRs of antibodies can be substituted with heterologous sequence to confer different binding properties. CTLA-4 molecules

engineered to have different binding specificities are also known as Evibodies. For further details see *Journal of Immunological Methods* 248 (1-2), 31-45 (2001).

Lipocalins are a family of extracellular proteins which transport small hydrophobic molecules such as steroids, bilins, retinoids and lipids. They have a rigid  $\beta$ -sheet secondary structure with a number of loops at the open end of the canonical structure which can be engineered to bind to different target antigens. Anticalins are between 160-180 amino acids in size, and are derived from lipocalins. For further details see *Biochim Biophys Acta* 1482: 337-350 (2000), US7250297B1 and US20070224633.

An affibody is a scaffold derived from Protein A of *Staphylococcus aureus* which can be engineered to bind to an antigen. The domain consists of a three-helical bundle of approximately 58 amino acids. Libraries have been generated by randomisation of surface residues. For further details see *Protein Eng. Des. Sel.* 17, 455-462 (2004) and EP1641818A1.

Avimers are multidomain proteins derived from the A-domain scaffold family. The native domains of approximately 35 amino acids adopt a defined disulphide bonded structure. Diversity is generated by shuffling of the natural variation exhibited by the family of A-domains. For further details see *Nature Biotechnology* 23(12), 1556 - 1561 (2005) and *Expert Opinion on Investigational Drugs* 16(6), 909-917 (June 2007).

A transferrin is a monomeric serum transport glycoprotein. Transferrins can be engineered to bind different target antigens by insertion of peptide sequences, such as one or more CDRs, in a permissive surface loop. Examples of engineered transferrin scaffolds include the Trans-body. For further details see *J. Biol. Chem* 274, 24066-24073 (1999).

Designed Ankyrin Repeat Proteins (DARPins) are derived from Ankyrin which is a family of proteins that mediate attachment of integral membrane proteins to the cytoskeleton. A single ankyrin repeat is a 33 residue motif consisting of two  $\alpha$ -helices and a  $\beta$ -turn. They can be engineered to bind different target antigens by: randomising residues in the first  $\alpha$ -helix and a  $\beta$ -turn of each repeat; or insertion of peptide sequences, such as one or more CDRs. Their binding interface can be increased by increasing the number of modules (a method of affinity maturation). For

further details see J. Mol. Biol. 332, 489-503 (2003), PNAS 100(4), 1700-1705 (2003) and J. Mol. Biol. 369, 1015-1028 (2007) and US20040132028A1.

5 Fibronectin is a scaffold which can be engineered to bind to antigen. Adnectins consists of a backbone of the natural amino acid sequence of the 10th domain of the 15 repeating units of human fibronectin type III (FN3). Three loops at one end of the  $\beta$ -sandwich can be engineered to enable an Adnectin to specifically recognize a therapeutic target of interest. For further details see Protein Eng. Des. Sel. 18, 435-444 (2005), US20080139791, WO2005056764 and US6818418B1.

10 Peptide aptamers are combinatorial recognition molecules that consist of a constant scaffold protein, typically thioredoxin (TrxA) which contains a constrained variable peptide loop inserted at the active site. For further details see Expert Opin. Biol. Ther. 5, 783-797 (2005).

15 Microbodies are derived from naturally occurring microproteins of 25-50 amino acids in length which contain 3-4 cysteine bridges; examples of microproteins include KalataB1 and conotoxin and knottins. The microproteins have a loop which can be engineered to include up to 25 amino acids without affecting the overall fold of the microprotein. For further details of engineered knottin domains, see WO2008098796.

20 Other binding domains include proteins which have been used as a scaffold to engineer different target antigen binding properties include human  $\gamma$ -crystallin and human ubiquitin (affilins), kunitz type domains of human protease inhibitors, PDZ-domains of the Ras-binding protein AF-6, scorpion toxins (charybdotoxin), C-type lectin domain (ttranectins) are reviewed in Chapter 7 – Non-Antibody Scaffolds from Handbook of Therapeutic Antibodies (2007, edited by Stefan Dubel) and Protein 25 Science 15:14-27 (2006). Binding domains of the present invention could be derived from any of these alternative protein domains and any combination of the CDRs of the present invention grafted onto the domain.

30 An antigen binding fragment or an immunologically effective fragment may comprise partial heavy or light chain variable sequences. Fragments are at least 5, 6, 8 or 10 amino acids in length. Alternatively the fragments are at least 15, at least 20, at least 50, at least 75, or at least 100 amino acids in length.

The term “specifically binds” as used throughout the present specification in relation to antigen binding proteins means that the antigen binding protein binds to myostatin with no or insignificant binding to other (for example, unrelated) proteins. The term however does not exclude the fact that the antigen binding proteins may also 5 be cross-reactive with closely related molecules (for example, Growth and Differentiation Factor-11). The antigen binding proteins described herein may bind to myostatin with at least 2, 5, 10, 50, 100, or 1000 fold greater affinity than they bind to closely related molecules, such as GDF-11.

The binding affinity or equilibrium dissociation constant ( $K_D$ ) of the antigen 10 binding protein-myostatin interaction may be 100 nM or less, 10 nM or less, 2 nM or less or 1 nM or less. Alternatively the  $K_D$  may be between 5 and 10 nM; or between 1 and 2 nM. The  $K_D$  may be between 1 pM and 500 pM; or between 500 pM and 1 nM. The binding affinity of the antigen binding protein is determined by the association 15 rate constant ( $k_a$ ) and the dissociation rate constant ( $k_d$ ) ( $K_D = k_d/k_a$ ). The binding affinity may be measured by BIACore<sup>TM</sup>, for example by antigen capture with myostatin coupled onto a CM5 chip by primary amine coupling and antibody capture onto this surface. The BIACore<sup>TM</sup> method described in Example 2.3 may be used to measure binding affinity. Alternatively, the binding affinity can be measured by FORTEbio, for example by antigen capture with myostatin coupled onto a CM5 20 needle by primary amine coupling and antibody capture onto this surface. The FORTEbio method described in Example 5.1 may be used to measure binding affinity. However, due to the nature of the binding of the antigen binding protein of the invention to myostatin, binding affinity may be used for ranking purposes.

The  $k_d$  may be  $1 \times 10^{-3} \text{ s}^{-1}$  or less,  $1 \times 10^{-4} \text{ s}^{-1}$  or less, or  $1 \times 10^{-5} \text{ s}^{-1}$  or less. The  $k_d$  25 may be between  $1 \times 10^{-5} \text{ s}^{-1}$  and  $1 \times 10^{-4} \text{ s}^{-1}$ ; or between  $1 \times 10^{-4} \text{ s}^{-1}$  and  $1 \times 10^{-3} \text{ s}^{-1}$ . A slow  $k_d$  may result in a slow dissociation of the antigen binding protein-ligand complex and improved neutralisation of the ligand.

The term “neutralises” as used throughout the present specification means that the biological activity of myostatin is reduced in the presence of an antigen binding 30 protein as described herein in comparison to the activity of myostatin in the absence of the antigen binding protein, *in vitro* or *in vivo*. Neutralisation may be due to one or more of blocking myostatin binding to its receptor, preventing myostatin from activating its receptor, down regulating myostatin or its receptor, or affecting effector

functionality. Neutralisation may be due to blocking myostatin binding to its receptor and therefore preventing myostatin from activating its receptor.

Myostatin activity includes one or more of the growth, regulatory and morphogenetic activities associated with active myostatin, for example modulating 5 muscle mass, muscle strength and muscle function. Further activities associated with active myostatin may include modulation of muscle fibre number, muscle fibre size, muscle regeneration, muscle fibrosis, the proliferation rate of myoblasts, myogenic differentiation; activation of satellite cells, proliferation of satellite cells, self renewal of satellite cells; synthesis or catabolism of proteins involved in muscle growth and 10 function. The muscle may be skeletal muscle.

The reduction or inhibition in biological activity may be partial or total. A neutralising antigen binding protein may neutralise the activity of myostatin by at least 20%, 30% 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99% or 100% relative to myostatin activity in 15 the absence of the antigen binding protein. In functional assays (such as the neutralisation assays described below),  $IC_{50}$  is the concentration that reduces a biological response by 50% of its maximum.

Neutralisation may be determined or measured using one or more assays known to the skilled person or as described herein. For example, antigen binding 20 protein binding to myostatin can be assessed in a sandwich ELISA, by BIACore<sup>TM</sup>, FMAT, FORTEbio<sup>TM</sup>, or similar *in vitro* assays such as surface Plasmon resonance.

An ELISA-based receptor binding assay can be used to determine the neutralising activity of the antigen binding protein by measuring myostatin binding to soluble ActRIIb receptor immobilised on a plate in the presence of the antigen binding 25 protein (for more detail see Example 2.5). The receptor neutralisation assay is a sensitive method which is available for differentiating molecules with  $IC_{50}$ s lower than 1nM on the basis of potency. It is, however, itself sensitive to the precise concentration of binding-competent biotinylated myostatin. Hence,  $IC_{50}$  values in the range of from 0.1 nM to 5 nM may be obtained, for example, from 0.1 nM to 3 nM, or 30 from 0.1 nM to 2 nM, or from 0.1 nM to 1 nM.

Alternatively, a cell-based receptor binding assay can be used to determine the neutralising activity of the antigen binding protein by measuring inhibition of receptor

binding, downstream signalling and gene activation. For example, neutralising antigen binding proteins can be identified by their ability to inhibit myostatin-induced luciferase activity in Rhabdomyosarcoma cells (A204) transfected with a construct encoding a luciferase gene under the control of a PAI-1 specific promoter, also known 5 as the myostatin responsive reporter gene assay (for more detail see Example 1.2).

10 *In vivo* neutralisation may be determined using a number of different assays in animals which demonstrate changes in any one or a combination of muscle mass, muscle strength, and muscle function. For example, body weight, muscle mass (such as lean muscle mass), muscle contractility (for example tetanic force), grip strength, an animal's ability to suspend itself, and swim test, can be used in isolation or in any combination to assess the neutralising activity of the myostatin antigen binding protein. For example the muscle mass of the following muscles may be determined: 15 gastrocnemius, quadriceps, triceps, extensor digitorum longus (EDL), tibialis anterior (TA) and soleus.

20 It will be apparent to those skilled in the art that the term "derived" is intended to define not only the source in the sense of it being the physical origin for the material but also to define material which is structurally identical to the material but which does not originate from the reference source. Thus "residues found in the donor antibody" need not necessarily have been purified from the donor antibody.

25 By isolated it is intended that the molecule, such as an antigen binding protein, is removed from the environment in which it may be found in nature. For example, the molecule may be purified away from substances with which it would normally exist in nature. For example, the antigen binding protein can be purified to at least 95%, 96%, 97%, 98% or 99%, or greater with respect to a culture media containing the antigen binding protein.

A "chimeric antibody" refers to a type of engineered antibody which contains a naturally-occurring variable region (light chain and heavy chains) derived from a donor antibody in association with light and heavy chain constant regions derived from an acceptor antibody.

30 A "humanised antibody" refers to a type of engineered antibody having one or more of its CDRs derived from a non-human donor immunoglobulin, the remaining immunoglobulin-derived parts of the molecule being derived from one or more human

immunoglobulin(s). In addition, framework support residues may be altered to preserve binding affinity (see, e.g., Queen et al. Proc. Natl Acad Sci USA, 86:10029-10032 (1989), Hodgson et al. Bio/Technology, 9:421 (1991)). A suitable human acceptor antibody may be one selected from a conventional database, e.g., the 5 KABAT® database, Los Alamos database, and Swiss Protein database, by homology to the nucleotide and amino acid sequences of the donor antibody. A human antibody characterized by a homology to the framework regions of the donor antibody (on an amino acid basis) may be suitable to provide a heavy chain constant region and/or a heavy chain variable framework region for insertion of the donor CDRs. A suitable 10 acceptor antibody capable of donating light chain constant or variable framework regions may be selected in a similar manner. It should be noted that the acceptor antibody heavy and light chains are not required to originate from the same acceptor antibody. The prior art describes several ways of producing such humanised 15 antibodies, see for example EP-A-0239400 and EP-A-054951.

15 The term “donor antibody” refers to an antibody which contributes the amino acid sequences of its variable regions, one or more CDRs, or other functional fragments or analogs thereof to a first immunoglobulin partner. The donor therefore provides the altered immunoglobulin coding region and resulting expressed altered 20 antibody with the antigenic specificity and neutralising activity characteristic of the donor antibody.

25 The term “acceptor antibody” refers to an antibody which is heterologous to the donor antibody, which contributes all (or any portion) of the amino acid sequences encoding its heavy and/or light chain framework regions and/or its heavy and/or light chain constant regions to the first immunoglobulin partner. A human antibody may be the acceptor antibody.

The terms “ $V_H$ ” and “ $V_L$ ” are used herein to refer to the heavy chain variable region and light chain variable region respectively of an antigen binding protein.

30 “CDRs” are defined as the complementarity determining region amino acid sequences of an antigen binding protein. These are the hypervariable regions of immunoglobulin heavy and light chains. There are three heavy chain and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus,

"CDRs" as used herein refers to all three heavy chain CDRs, all three light chain CDRs, all heavy and light chain CDRs, or at least two CDRs.

Throughout this specification, amino acid residues in variable domain sequences and full length antibody sequences are numbered according to the Kabat numbering convention, unless otherwise specified. Similarly, the terms "CDR", "CDRL1", "CDRL2", "CDRL3", "CDRH1", "CDRH2", "CDRH3" used in the Examples follow the Kabat numbering convention. For further information, see Kabat et al., Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987).

10 It will be apparent to those skilled in the art that there are alternative numbering conventions for amino acid residues in variable domain sequences and full length antibody sequences. There are also alternative numbering conventions for CDR sequences, for example those set out in Chothia et al. (1989) *Nature* 342: 877-883. The structure and protein folding of the antibody may mean that other residues are  
15 considered part of the CDR sequence and would be understood to be so by a skilled person. Therefore, the term "corresponding CDR" is used herein to refer to a CDR sequence using any numbering convention, for example those set out in Table 1.

Other numbering conventions for CDR sequences available to a skilled person include "AbM" (University of Bath) and "contact" (University College London) methods. The minimum overlapping region using at least two of the Kabat, Chothia, AbM and contact methods can be determined to provide the "minimum binding unit".  
20 The minimum binding unit may be a sub-portion of a CDR.

Table 1 below represents one definition using each numbering convention for each CDR or binding unit. The Kabat numbering scheme is used in Table 1 to number  
25 the variable domain amino acid sequence. It should be noted that some of the CDR definitions may vary depending on the individual publication used.

Table 1

	Kabat CDR	Chothia CDR	AbM CDR	Contact CDR	Minimum binding unit
H1	31-35/35A/35B	26-32/33/34	26-35/35A/35B	30-35/35A/35B	31-32
H2	50-65	52-56	50-58	47-58	52-56
H3	95-102	95-102	95-102	93-101	95-101
L1	24-34	24-34	24-34	30-36	30-34
L2	50-56	50-56	50-56	46-55	50-55
L3	89-97	89-97	89-97	89-96	89-96

As used herein, the term "antigen binding site" refers to a site on an antigen binding protein which is capable of specifically binding to an antigen. This may be a 5 single domain (for example, an epitope-binding domain), or single-chain Fv (ScFv) domains or it may be paired V<sub>H</sub>/V<sub>L</sub> domains as can be found on a standard antibody.

The term "epitope" as used herein refers to that portion of the antigen that makes contact with a particular binding domain of the antigen binding protein. An epitope may be linear, comprising an essentially linear amino acid sequence from the 10 antigen. Alternatively, an epitope may be conformational or discontinuous. For example, a conformational epitope comprises amino acid residues which require an element of structural constraint. A discontinuous epitope comprises amino acid residues that are separated by other sequences, i.e. not in a continuous sequence in the antigen's primary sequence. In the context of the antigen's tertiary and quaternary 15 structure, the residues of a discontinuous epitope are near enough to each other to be bound by an antigen binding protein.

For nucleotide and amino acid sequences, the term "identical" or "sequence identity" indicates the degree of identity between two nucleic acid or two amino acid sequences, and if required when optimally aligned and compared with appropriate 20 insertions or deletions.

The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions/total number of positions times 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment 25 of the two sequences. The comparison of sequences and determination of percent

identity between two sequences can be accomplished using a mathematical algorithm, as described below.

The percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 5. 6. The percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 10 16, 14, 12, 10, 8, 6, or 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

15 In one method, a polynucleotide sequence may be identical to a reference polynucleotide sequence as described herein (see for example SEQ ID NO: 41-55), that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, such as at least 50, 60, 70, 75, 80, 85, 90, 95, 98, or 99% identical. Such alterations are selected from at least 20 one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of 25 nucleotide alterations is determined by multiplying the total number of nucleotides in the reference polynucleotide sequence as described herein (see for example SEQ ID NO: 41-55), by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in the reference polynucleotide sequence as described herein (see for example SEQ ID NO: 30 41-55), or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in the reference polynucleotide sequence as described herein (see for example SEQ ID NO: 41-55), and  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.75 for 75%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.98 for 98%, 0.99 for 99% or 1.00 for 100%, • is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ .

Similarly, a polypeptide sequence may be identical to a polypeptide reference sequence as described herein (see for example SEQ ID NO: 7-40, 98 or 99) that is be 10 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%, such as at least 50, 60, 70, 75, 80, 85, 90, 95, 98, or 99% identical. Such alterations are selected from the group consisting of at least one amino acid deletion, 15 substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number 20 of amino acids in the polypeptide sequence encoded by the polypeptide reference sequence as described herein (see for example SEQ ID NO: 7-40, 98 or 99) by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in the polypeptide reference sequence as described herein (see for example SEQ ID NO: 7-40 or 82-108, 25 98 or 99), or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in the reference polypeptide sequence as described herein (see for example SEQ ID NO: 7-40, 98 or 99), and  $y$  is, 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.75 for 30 75%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.98 for 98%, 0.99 for 99%, or 1.00 for 100%, • is the symbol for the multiplication operator, and wherein

any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

The % identity may be determined across the full length of the sequence, or any fragments thereof; and with or without any insertions or deletions.

5 The terms "peptide", "polypeptide" and "protein" each refers to a molecule comprising two or more amino acid residues. A peptide may be monomeric or polymeric.

10 It is well recognised in the art that certain amino acid substitutions are regarded as being "conservative". Amino acids are divided into groups based on common side-chain properties and substitutions within groups that maintain all or substantially all of the binding affinity of the antigen binding protein are regarded as conservative substitutions, see Table 2 below:

Table 2

<b>Side chain</b>	<b>Members</b>
Hydrophobic	met, ala, val, leu, ile
Neutral hydrophilic	cys, ser, thr
Acidic	asp, glu
Basic	asn, gln, his, lys, arg
Residues that influence chain orientation	gly, pro
Aromatic	trp, tyr, phe

15 The present invention provides an antigen binding protein which binds to myostatin and comprises CDRH3 of SEQ ID NO: 3; or a variant CDRH3 thereof (for example any one of SEQ ID NOS: 82-92, or 110). The antigen binding protein may also neutralise myostatin activity.

20 The present invention also provides an antigen binding protein which binds to myostatin and comprises CDRH2 of SEQ ID NO: 2; or a variant CDRH2 thereof (for example any one of SEQ ID NOS: 93-97). The antigen binding protein may also neutralise myostatin activity.

25 The antigen binding protein may further comprise in addition to the CDRH3 or CDRH2 sequences described above, one or more CDRs, or all CDRs, in any combination, selected from: CDRH1 (SEQ ID NO: 1), CDRH2 (SEQ ID NO: 2), CDRL1 (SEQ ID NO: 4), CDRL2 (SEQ ID NO: 5), and CDRL3 (SEQ ID NO: 6 or

109); or a variant thereof (for example any one of CDRH2 variants SEQ ID NOS: 93-97).

For example, the antigen binding protein may comprise CDRH3 (SEQ ID NO: 3) and CDRH1 (SEQ ID NO: 1), or variants thereof (for example any one of CDRH3 variants 5 82-92, or 110). The antigen binding protein may comprise CDRH3 (SEQ ID NO: 3) and CDRH2 (SEQ ID NO: 2), or variants thereof (for example any one of CDRH3 variants SEQ ID NOS: 82-92, or 110; or any one of CDRH2 variants SEQ ID NOS: 93-97). The antigen binding protein may comprise CDRH1 (SEQ ID NO: 1) and CDRH2 (SEQ ID NO: 2), and CDRH3 (SEQ ID NO: 3), or variants thereof (for 10 example any one of CDRH3 variants SEQ ID NOS: 82-92, or 110; or any one of CDRH2 variants SEQ ID NOS: 93-97).

The antigen binding protein may comprise CDRL1 (SEQ ID NO: 4) and CDRL2 (SEQ ID NO: 5), or variants thereof. The antigen binding protein may comprise CDRL2 (SEQ ID NO: 5) and CDRL3 (SEQ ID NO: 6 or 109), or variants thereof. The antigen binding protein may comprise CDRL1 (SEQ ID NO: 4), CDRL2 (SEQ ID NO: 5) and CDRL3 (SEQ ID NO: 6 or 109), or variants thereof.

The antigen binding protein may comprise CDRH3 (SEQ ID NO: 3) and CDRL3 (SEQ ID NO: 6 or 109), or variants thereof (for example any one of CDRH3 variants SEQ ID NOS: 82-92, or 110). The antigen binding protein may comprise 20 CDRH3 (SEQ ID NO: 3), CDRH2 (SEQ ID NO: 2) and CDRL3 (SEQ ID NO: 6 or 109), or variants thereof (for example any one of CDRH3 variants SEQ ID NOS: 82-92, or 110; or any one of CDRH2 variants SEQ ID NOS: 93-97). The antigen binding protein may comprise CDRH3 (SEQ ID NO: 3), CDRH2 (SEQ ID NO: 2), CDRL2 (SEQ ID NO: 5) and CDRL3 (SEQ ID NO: 6 or 109), or variants thereof (for example 25 any one of CDRH3 variants SEQ ID NOS: 82-92, or 110; or any one of CDRH2 variants SEQ ID NOS: 93-97).

The antigen binding protein may comprise CDRH1 (SEQ ID NO: 1), CDRH2 (SEQ ID NO: 2), CDRH3 (SEQ ID NO: 3), CDRL1 (SEQ ID NO: 4), CDRL2 (SEQ ID NO: 5) and CDRL3 (SEQ ID NO: 6). Alternatively, variant CDRs may be present, 30 such as any one of CDRH3 variants SEQ ID NOS: 82-92, or 110; or any one of CDRH2 variants SEQ ID NOS: 93-97; or CDRH3 variant SEQ ID NO: 109. For example, the antigen binding protein may comprise CDRH1 (SEQ ID NO: 1),

CDRH2 (SEQ ID NO: 95), CDRH3 (SEQ ID NO: 90), CDRL1 (SEQ ID NO: 4), CDRL2 (SEQ ID NO: 5) and CDRL3 (SEQ ID NO: 109).

5 The present invention also provides an antigen binding protein which binds to myostatin and comprises the corresponding CDRH3 of the variable domain sequence of SEQ ID NO: 7, or a variant CDRH3 thereof. The antigen binding protein may also neutralise myostatin activity. The antigen binding protein may be a chimeric or a humanised antibody.

10 The antigen binding protein may further comprise one or more, or all of the corresponding CDRs selected from the variable domain sequence of SEQ ID NO: 7 or SEQ ID NO: 8, or a variant CDR thereof.

15 For example, the antigen binding protein may comprise corresponding CDRH3 and corresponding CDRH1, or variants thereof. The antigen binding protein may comprise corresponding CDRH3 and corresponding CDRH2, or variants thereof. The antigen binding protein may comprise corresponding CDRH1, corresponding CDRH2, and corresponding CDRH3; or variants thereof.

20 The antigen binding protein may comprise corresponding CDRL1 and corresponding CDRL2, or variants thereof. The antigen binding protein may comprise corresponding CDRL2 and corresponding CDRL3, or variants thereof. The antigen binding protein may comprise corresponding CDRL1, corresponding CDRL2 and corresponding CDRL3, or variants thereof.

25 The antigen binding protein may comprise corresponding CDRH3 and corresponding CDRL3, or variants thereof. The antigen binding protein may comprise corresponding CDRH3, corresponding CDRH2 and corresponding CDRL3, or variants thereof. The antigen binding protein may comprise corresponding CDRH3, corresponding CDRH2, corresponding CDRL2 and corresponding CDRL3, or variants thereof.

The antigen binding protein may comprise corresponding CDRH1, corresponding CDRH2, corresponding CDRH3, corresponding CDRL1, corresponding CDRL2 and corresponding CDRL3, or variants thereof.

30 The corresponding CDRs can be defined by reference to Kabat (1987), Chothia (1989), AbM or contact methods. One definition of each of the methods can be found at Table 1 and can be applied to the reference heavy chain variable domain

SEQ ID NO: 7 and the reference light chain variable domain SEQ ID NO: 8 to determine the corresponding CDR.

The present invention also provides an antigen binding protein which binds to myostatin, and comprises a binding unit H3 comprising Kabat residues 95-101 of SEQ ID NO: 7, or a variant H3. The antigen binding protein may also neutralise myostatin.

The antigen binding protein may further comprise one or more or all binding units selected from: H1 comprising Kabat residues 31-32 of SEQ ID NO: 7, H2 comprising Kabat residues 52-56 of SEQ ID NO: 7, L1 comprising Kabat residues 30-34 of SEQ ID NO: 8, L2 comprising Kabat residues 50-55 of SEQ ID NO: 8 and L3 comprising Kabat residues 89-96 of SEQ ID NO: 8; or a variant binding unit.

For example, the antigen binding protein may comprise a binding unit H3 and a binding unit H1, or variants thereof. The antigen binding protein may comprise a binding unit H3 and a binding unit H2, or variants thereof. The antigen binding protein may comprise a binding unit H1, a binding unit H2, and a binding unit H3; or variants thereof.

The antigen binding protein may comprise a binding unit L1 and a binding unit L2, or variants thereof. The antigen binding protein may comprise a binding unit L2 and a binding unit L3, or variants thereof. The antigen binding protein may comprise a binding unit L1, a binding unit L2, and a binding unit L3; or variants thereof.

The antigen binding protein may comprise a binding unit H3 and a binding unit L3, or variants thereof. The antigen binding protein may comprise a binding unit H3, a binding unit H2, and a binding unit L3; or variants thereof. The antigen binding protein may comprise a binding unit H3, a binding unit H2, a binding unit L2, and a binding unit L3; or variants thereof.

The antigen binding protein may comprise a binding unit H1, a binding unit H2, a binding unit H3, a binding unit L1, a binding unit L2, and a binding unit L3; or variants thereof.

A CDR variant or variant binding unit includes an amino acid sequence modified by at least one amino acid, wherein said modification can be chemical or a partial alteration of the amino acid sequence (for example by no more than 10 amino

acids), which modification permits the variant to retain the biological characteristics of the unmodified sequence. For example, the variant is a functional variant which binds to myostatin. A partial alteration of the CDR amino acid sequence may be by deletion or substitution of one to several amino acids, or by addition or insertion of 5 one to several amino acids, or by a combination thereof (for example by no more than 10 amino acids). The CDR variant or binding unit variant may contain 1, 2, 3, 4, 5 or 6 amino acid substitutions, additions or deletions, in any combination, in the amino acid sequence. The CDR variant or binding unit variant may contain 1, 2 or 3 amino acid substitutions, insertions or deletions, in any combination, in the amino acid 10 sequence. The substitutions in amino acid residues may be conservative substitutions, for example, substituting one hydrophobic amino acid for an alternative hydrophobic amino acid. For example leucine may be substituted with valine, or isoleucine.

The CDRs L1, L2, L3, H1 and H2 tend to structurally exhibit one of a finite number of main chain conformations. The particular canonical structure class of a 15 CDR is defined by both the length of the CDR and by the loop packing, determined by residues located at key positions in both the CDRs and the framework regions (structurally determining residues or SDRs). Martin and Thornton (1996; *J Mol Biol* 263:800-815) have generated an automatic method to define the “key residue” canonical templates. Cluster analysis is used to define the canonical classes for sets of 20 CDRs, and canonical templates are then identified by analysing buried hydrophobics, hydrogen-bonding residues, and conserved glycines and prolines. The CDRs of antibody sequences can be assigned to canonical classes by comparing the sequences to the key residue templates and scoring each template using identity or similarity matrices.

25 Examples of CDR canonicals, where the amino acid before the Kabat number is the original amino acid sequence of SEQ ID NO: 14 or 24 and the amino acid sequence at the end of the Kabat number is the substituted amino acid, include:

CDRH1 canonicals: Y32I, Y32H, Y32F, Y32T, Y32N, Y32C, Y32E, Y32D, F33Y, F33A, F33W, F33G, F33T, F33L, F33V, M34I, M34V, M34W, H35E, H35N, H35Q, 30 H35S, H35Y, H35T;

CDRH2 canonicals: N50R, N50E, N50W, N50Y, N50G, N50Q, N50V, N50L, N50K, N50A, I51L, I51V, I51T, I51S, I51N, Y52D, Y52L, Y52N, Y52S, Y53A, Y53G,

Y53S, Y53K, Y53T, Y53N, N54S, N54T, N54K, N54D, N54G, V56Y, V56R, V56E, V56D, V56G, V56S, V56A, N58K, N58T, N58S, N58D, N58R, N58G, N58F, N58Y;

CDRH3 canonicals: V102Y, V102H, V102I, V102S, V102D, V102G;

CDRL1 canonicals: D28N, D28S, D28E, D28T, I29V, N30D, N30L, N30Y, N30V,

5 N30I, N30S, N30F, N30H, N30G, N30T, S31N, S31T, S31K, S31G, Y32F, Y32N, Y32A, Y32H, Y32S, Y32R, L33M, L33V, L33I, L33F, S34A, S34G, S34N, S34H, S34V, S34F;

CDRL2 canonicals: A51T, A51G, A51V;

CDRL3 canonicals: L89Q, L89S, L89G, L89F, Q90N, Q90H, S91N, S91F, S91G,

10 S91R, S91D, S91H, S91T, S91Y, S91V, D92N, D92Y, D92W, D92T, D92S, D92R, D92Q, D92H, D92A, E93N, E93G, E93H, E93T, E93S, E93R, E93A, F94D, F94Y, F94T, F94V, F94L, F94H, F94N, F94I, F94W, F94P, F94S, L96P, L96Y, L96R, L96I, L96W, L96F.

There may be multiple variant CDR canonical positions per CDR, per 15 corresponding CDR, per binding unit, per heavy or light chain variable region, per heavy or light chain, and per antigen binding protein, and therefore any combination of substitution may be present in the antigen binding protein of the invention, provided that the canonical structure of the CDR is maintained.

Other examples of CDR variants or variant binding units include (using the 20 Kabat numbering scheme, where the amino acid before the Kabat number is the original amino acid sequence of SEQ ID NO: 14 or 24 and the amino acid sequence at the end of the Kabat number is the substituted amino acid):

H2: G55D, G55L, G55S, G55T, G55V;

25 H3: Y96L, G99D, G99S, G100A\_K, P100B\_F, P100B\_I, W100E\_F, F100G\_N, F100G\_S, F100G\_Y, V102N, V102S;

L3: C91S.

For example an antigen binding protein of the invention which binds to myostatin may comprise CDRH3 of SEQ ID NO: 90. The antigen binding protein may further comprise CDRH2 of any one of SEQ ID NO: 93-97. In particular, the 30 CDRH2 may be SEQ ID NO: 95. The antigen binding protein may also comprise CDRL3 of SEQ ID NO: 109. The antigen binding protein may further comprise any

one or a combination or all of CDRH1 (SEQ ID NO: 1), CDRL1 (SEQ ID NO: 4), and CDRL2 (SEQ ID NO: 5). The antigen binding protein may also neutralise myostatin activity.

5 The antigen binding protein comprising the CDRs, corresponding CDRs, variant CDRs, binding units or variant binding units described, may display a potency for binding to myostatin, as demonstrated by EC50, of within 10 fold, or within 5 fold of the potency demonstrated by 10B3 or 10B3 chimera (heavy chain: SEQ ID NO: 7 or 25, light chain: SEQ ID NO: 8). Potency for binding to myostatin, as demonstrated by EC50, may be carried out by an ELISA assay.

10 The antigen binding protein may or may not have a substitution at amino acid Kabat position 54 of the heavy chain from asparagine (N) to aspartate (D) or glutamine (Q). The antigen binding protein variant may or may not have a substitution at amino acid position 91 of the light chain from cysteine (C) to serine (S). For example, the antigen binding protein has a serine (S) residue at position 91 of the light 15 chain and an asparagine (N) at position 54 of the heavy chain.

20 The antigen binding protein variable heavy chain may have a serine (S) or Threonine (T) amino acid residue at position 28; and/or a threonine (T) or glutamine (Q) amino acid residue at position 105. The antigen binding protein variable light chain may have an arginine (R) or glycine (G) amino acid residue at position 16; and/or a tyrosine (Y) or phenylalanine (F) amino acid residue at position 71; and/or an 25 alanine (A) or glutamine (Q) amino acid residue at position 100. For example, the antigen binding protein may comprise serine (S) at position 28, glutamine (Q) at position 105 of the variable heavy chain; and/or glycine (G) at position 16, tyrosine (Y) at position 71, and glutamine (Q) at position 100 of the variable light chain.

25 As discussed above, the particular canonical structure class of a CDR is defined by both the length of the CDR and by the loop packing, determined by residues located at key positions in both the CDRs and the framework regions. Thus in addition to the CDRs listed in SEQ ID NO: 1-3, variant CDRs listed in SEQ ID NO: 82-97 and SEQ ID NO 109, corresponding CDRs, binding units, or variants 30 thereof, the canonical framework residues of an antigen binding protein of the invention may include (using Kabat numbering):

Heavy chain: V, I or G at position 2; L or V at position 4; L, I, M or V at position 20; C at position 22; T, A, V, G or S at position 24; G at position 26; I, F, L or S at position 29; W at position 36; W or Y at position 47; I, M, V or L at position 48; I, L, F, M or V at position 69; A, L, V, Y or F at position 78; L or M at position 80; Y or F at position 90; C at position 92; and/or R, K, G, S, H or N at position 94; and/or

Light chain: I, L or V at position 2; V, Q, L or E at position 3; M or L at position 4; C at position 23; W at position 35; Y, L or F at position 36; S, L, R or V at position 46; Y, H, F or K at position 49; Y or F at position 71; C at position 88; and/or F at position 98.

Any one, any combination, or all of the framework positions described above may be present in the antigen binding protein of the invention. There may be multiple variant framework canonical positions per heavy or light chain variable region, per heavy or light chain, and per antigen binding protein, and therefore any combination may be present in the antigen binding protein of the invention, provided that the canonical structure of the framework is maintained.

For example, the heavy chain variable framework may comprise V at position 2, L at position 4, V at position 20, C at position 22, A at position 24, G at position 26, F at position 29, W at position 36, W at position 47, M at position 48, M at position 69, A at position 78, M at position 80, Y at position 90, C at position 92, and R at position 94. For example, the light chain variable framework may comprise I at position 2, Q at position 3, M at position 4, C at position 23, W at position 35, F at position 36, S at position 46, Y at position 49, Y at position 71, C at position 88 and F at position 98.

One or more of the CDRs, corresponding CDRs, variant CDRs or binding units described herein may be present in the context of a human framework, for example as a humanised or chimeric variable domain.

The humanised heavy chain variable domain may comprise the CDRs listed in SEQ ID NO: 1-3; variant CDRs listed in SEQ ID NO: 82-97 and 110, and SEQ ID NO 109; corresponding CDRs; binding units; or variants thereof, within an acceptor antibody framework having 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% identity in the

framework regions to the human acceptor variable domain sequence in SEQ ID NO: 10. The humanised light chain variable domain may comprise the CDRs listed in SEQ ID NO: 4-6; variant CDRs listed in SEQ ID NO: 82-97 and 110, and SEQ ID NO 109; corresponding CDRs; binding units; or variants thereof, within an acceptor antibody framework having 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% identity in the framework regions to the human acceptor variable domain sequence in SEQ ID NO: 11. In both SEQ ID NO: 10 and SEQ ID NO: 11 the position of CDRH3 has been denoted by X. The 10 X residues in SEQ ID NO: 10 and SEQ ID NO: 11, are a placeholder for the location of the CDR, and not a measure of the number of amino acid sequences in each CDR.

10 The invention also provides an antigen binding protein which binds to myostatin and comprises a heavy chain variable region selected from SEQ ID NO: 7 or 25. The antigen binding protein may comprise a light chain variable region selected from SEQ ID NO: 8 or 21.

15 The invention also provides an antigen binding protein which binds to myostatin and comprises any one of the following heavy chain and light chain variable region combinations: 10B3 (SEQ ID NO: 7 and SEQ ID NO: 8), 10B3C (SEQ ID NO: 25 and SEQ ID NO: 8), or 10B3C-C91S (SEQ ID NO: 25 and SEQ ID NO: 21). The antigen binding protein may also neutralise myostatin.

20 The invention also provides an antigen binding protein which binds to myostatin and comprises a heavy chain variable region selected from any one of SEQ ID NO: 12, 13, 14, 22 and 23. The antigen binding protein may comprise a light chain variable region selected from any one of SEQ ID NO: 15, 16, 17, 18 or 24. Any of the heavy chain variable regions may be combined with any of the light chain variable regions. The antigen binding protein may also neutralise myostatin.

25 The antigen binding protein may comprise any one of the following heavy chain and light chain variable region combinations: H0L0 (SEQ ID NO: 12 and SEQ ID NO: 15), H0L1 (SEQ ID NO: 12 and SEQ ID NO: 16), H0L2 (SEQ ID NO: 12 and SEQ ID NO: 17), H0L3 (SEQ ID NO: 12 and SEQ ID NO: 18), H1L0 (SEQ ID NO: 13 and SEQ ID NO: 15), H1L1 (SEQ ID NO: 13 and SEQ ID NO: 16), H1L2 (SEQ ID NO: 13 and SEQ ID NO: 17), H1L3 (SEQ ID NO: 13 and SEQ ID NO: 18),

H2L0 (SEQ ID NO: 14 and SEQ ID NO: 15), H2L1 (SEQ ID NO: 14 and SEQ ID NO: 16), H2L2 (SEQ ID NO: 14 and SEQ ID NO: 17), H2L3 (SEQ ID NO: 14 and SEQ ID NO: 18), H2L2-C91S (SEQ ID NO: 14 and SEQ ID NO: 24).

5 The antibody heavy chain variable region may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% identity to any one of SEQ ID NO: 7, 25, 12, 13, 14, 19, 20, 22 or 23.

The antibody light chain variable region may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater, or 100% identity to any one of SEQ ID NO: 8, 15, 16, 17, 18, 21 or 24.

10 The percentage identity of the variants of SEQ ID NO: 7, 25, 12, 13, 14, 19, 20, 22, 23, 8, 15, 16, 17, 18, 21 or 24 may be determined across the full length of the sequence.

15 The antibody heavy chain variable region may be a variant of any one of SEQ ID NO: 7, 25, 12, 13, 14, 19, 20, 22 or 23 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions. The antibody light chain variable region may be a variant of any one of SEQ ID NO: 8, 15, 16, 17, 18, 21 or 24 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions.

20 For example, the canonical CDRs and canonical framework residue substitutions described above may also be present in the variant heavy or light chain variable regions as variant sequences that are at least 75% identical or which contain up to 30 amino acid substitutions.

25 The substitution may comprise any one of the following: Y96L, G99D, G99S, G100A\_K, P100B\_F, P100B\_I, W100E\_F, F100G\_N, F100G\_S, F100G\_Y, V102N, and V102S; in any one of the antibody heavy chain variable regions described above. In addition to any one of the substitutions described, the antibody heavy chain variable region may also comprise any one of the following substitutions: G55D, G55L, G55S, G55T or G55V, in any one of the antibody heavy chain variable regions described above.

30 The antibody heavy chain variable region may have the sequence of SEQ ID NO: 14 with the substitution F100G\_Y. In addition to the substitution F100G\_Y, any one of the following substitutions G55D, G55L, G55S, G55T or G55V may also be

present. In particular, the antibody heavy chain variable region may have the sequence of SEQ ID NO: 14 with the following substitution: F100G\_Y; or F100G\_Y and G55S. The antibody heavy chain variable region may be paired with the light chain variable region of the sequence of SEQ ID NO: 24.

5 Any of the heavy chain variable regions may be combined with a suitable human constant region. Any of the light chain variable regions may be combined with a suitable constant region.

The invention also provides an antigen binding protein which binds to myostatin and comprises any one of the following heavy chain and light chain 10 combinations: 10B3C (SEQ ID NO: 26 and SEQ ID NO: 27), or 10B3C-C91S (SEQ ID NO: 26 and SEQ ID NO: 37). The antigen binding protein may also neutralise myostatin.

The invention also provides an antigen binding protein which binds to myostatin and comprises a heavy chain selected from any one of SEQ ID NO: 28, 29, 15 30, 35, 36, 38, 39, 98 or 99. The antigen binding protein may comprise a light chain selected from any one of SEQ ID NO: 31, 32, 33, 34 or 40. Any of the heavy chains may be combined with any of the light chains. The antigen binding protein may also neutralise myostatin.

The antigen binding protein may comprise any one of the following heavy 20 chain and light chain combinations: H0L0 (SEQ ID NO: 28 and SEQ ID NO: 31), H0L1 (SEQ ID NO: 28 and SEQ ID NO: 32), H0L2 (SEQ ID NO: 28 and SEQ ID NO: 33), H0L3 (SEQ ID NO: 28 and SEQ ID NO: 34), H1L0 (SEQ ID NO: 29 and SEQ ID NO: 31), H1L1 (SEQ ID NO: 29 and SEQ ID NO: 32), H1L2 (SEQ ID NO: 29 and SEQ ID NO: 33), H1L3 (SEQ ID NO: 29 and SEQ ID NO: 34), H2L0 (SEQ 25 ID NO: 30 and SEQ ID NO: 31), H2L1 (SEQ ID NO: 30 and SEQ ID NO: 32), H2L2 (SEQ ID NO: 30 and SEQ ID NO: 33), H2L3 (SEQ ID NO: 30 and SEQ ID NO: 34), H2L2-C91S (SEQ ID NO: 30 and SEQ ID NO: 40), H2L2-C91S\_F100G\_Y Fc disabled (SEQ ID NO: 98 and SEQ ID NO: 40), or H2L2-C91S\_G55S-F100G\_Y Fc disabled (SEQ ID NO: 99 and SEQ ID NO: 40).

30 The antibody heavy chain may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% identity to any one of SEQ ID NO: 26, 28, 29, 30, 35, 36, 38, 39, 98 or 99. The

antibody light chain may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater, or 100% identity to any one of SEQ ID NO: 27, 31, 32, 33, 34, 37 or 40.

5 The percentage identity of the variants of SEQ ID NO: 26, 28, 29, 30, 35, 36, 38, 39, 98, 99, 27, 31, 32, 33, 34, 37 or 40 may be determined across the length of the sequence.

10 The antibody heavy chain may be a variant of any one of SEQ ID NO: 26, 28, 29, 30, 35, 36, 38, 39, 98 or 99 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions. The antibody light chain may be a variant of any one of SEQ ID NO: 27, 31, 32, 33, 34, 37 or 40 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions.

15 For example, the canonical CDRs and canonical framework residue substitutions described above may also be present in the variant heavy or light chains as variant sequences that are at least 75% identical or which contain up to 30 amino acid substitutions.

20 The substitution may comprise any one of the following: Y96L, G99D, G99S, G100A\_K, P100B\_F, P100B\_I, W100E\_F, F100G\_S, F100G\_N, F100G\_Y, V102N, and V102S; in any one of the antibody heavy chains described above. In addition to any one of the substitutions described, the antibody heavy chain may also comprise any one of the following substitutions: G55D, G55L, G55S, G55T or G55V, in any one of the antibody heavy chains described above.

25 The antibody heavy chain may have the sequence of SEQ ID NO: 30 with the substitution F100G\_Y. In addition to the substitution F100G\_Y, any one of the following substitutions G55D, G55L, G55S, G55T or G55V may also be present. In particular, the antibody heavy chain may have the sequence of SEQ ID NO: 30 with the following substitution: F100G\_Y; or F100G\_Y and G55S. The antibody heavy chain may be paired with the light chain of the sequence of SEQ ID NO: 40.

30 Antigen binding proteins as described above, for example variants with a partial alteration of the sequence by chemical modification and/or insertion, deletion or substitution of one or more amino acid residues, or those with 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, or 99% or

greater identity to any of the sequences described above, may display a potency for binding to myostatin, as demonstrated by EC50, of within 10 fold, or within 5 fold of the potency demonstrated by 10B3 or 10B3 chimera (heavy chain: SEQ ID NO: 7 or 25, light chain: SEQ ID NO: 8). Potency for binding to myostatin, as demonstrated by 5 EC50, may be carried out by an ELISA assay.

The antigen binding proteins of the invention may be Fc disabled. One way to achieve Fc disablement comprises the substitutions of alanine residues at positions 235 and 237 (EU index numbering) of the heavy chain constant region. For example, the antigen binding protein may be Fc disabled and comprise the sequence of SEQ ID 10 NO: 98 (humanised heavy chain: H2\_F100G\_Y Fc disabled); or SEQ ID NO: 99 (humanised heavy chain: H2\_G55S - F100G\_Y Fc disabled). Alternatively, the antigen binding protein may be Fc enabled and not comprise the alanine substitutions at positions 235 and 237.

The antigen binding protein may bind to myostatin and compete for binding to 15 myostatin with a reference antibody comprising a heavy chain variable region sequence of SEQ ID NO: 7 or 25, and a light chain variable region sequence of SEQ ID NO: 8; wherein the antigen binding protein does not bind to a peptide fragment of myostatin. The peptide fragment of myostatin may consist of SEQ ID NO: 81 (CCTPTKMSPINMLY). The peptide fragment of myostatin may be any fragment 20 consisting of up to 14 amino acids of the myostatin sequence. The peptide fragment of myostatin may be linear. The peptide fragment of myostatin may be any fragment of the myostatin sequence, including the full length sequence, wherein the peptide fragment is linear. This may be assessed using the method described in Example 2.4 using an SRU BIND reader and biotinylated peptides captured onto a streptavidin 25 coated biosensor plate.

Alternatively, the antigen binding protein may bind to myostatin and compete for binding to myostatin with a reference antibody comprising a heavy chain variable region sequence of SEQ ID NO: 7 or 25, and a light chain variable region sequence of SEQ ID NO: 8; wherein the antigen binding protein does not bind to an artificial 30 peptide sequence consisting of SEQ ID NO: 74 (artificial myostatin linear peptide 37 – SGSGCCTPTKMSPINMLY). The artificial peptide sequence may consist of any one of the sequences described in Table 7. The artificial peptide sequence may be linear. This may be assessed using the method described in Example 2.4 using an

SRU BIND reader and biotinylated peptides captured onto a streptavidin coated biosensor plate.

The reference antibody may comprise the following heavy chain and light chain combination: 10B3C (SEQ ID NO: 26 and SEQ ID NO: 27). The heavy chain sequence SEQ ID NO: 26 comprises the variable domain sequence SEQ ID NO: 25; and the light chain sequence SEQ ID NO: 27 comprises the variable domain sequence SEQ ID NO: 8.

Competition between the antigen binding protein and the reference antibody may be determined by competition ELISA. Competition for neutralisation of myostatin may be determined by any one or a combination of: competition for binding to myostatin, for example as determined by ELISA, FMAT or BIACore; competition for inhibition of myostatin binding to the ActRIIb receptor; and competition for inhibition of cell signalling resulting in luciferase expression in an A204 assay. A competing antigen binding protein may bind to the same epitope, an overlapping epitope, or an epitope in close proximity of the epitope to which the reference antibody binds.

The antigen binding protein may not bind significantly to the myostatin peptide fragment or artificial peptide sequence. The antigen binding protein may not bind to the myostatin peptide fragment or artificial peptide sequence at a ratio range of 1:1 to 1:10, of antigen binding protein to peptide, respectively.

Binding or lack of binding between the antigen binding protein and the myostatin peptide fragment or artificial peptide sequence may be determined by ELISA or by SDS PAGE using reducing conditions. For example, binding or lack of binding of the antigen binding protein to the linear full length myostatin sequence may be determined by reducing SDS PAGE.

The antigen binding proteins described herein may not bind to a peptide fragment of myostatin. The peptide fragment of myostatin may consist of SEQ ID NO: 81 (CCTPTKMSPINMLY). The peptide fragment of myostatin may be any fragment consisting of up to 14 amino acids of the myostatin sequence. The peptide fragment of myostatin may be linear. The peptide fragment of myostatin may be any fragment of the myostatin sequence, including the full length sequence, wherein the sequence is linear. This may be assessed using the method described in Example 2.4

using an SRU BIND reader and biotinylated peptides captured onto a streptavidin coated biosensor plate.

Alternatively, the antigen binding proteins described herein may not bind to an artificial peptide sequence consisting of SEQ ID NO: 74 (artificial myostatin linear peptide 37 – SGSGCCTPTKMSPINMLY). The artificial peptide sequence may consist of any one of the sequences described in Table 7. The artificial peptide sequence may be linear. This may be assessed using the method described in Example 2.4 using an SRU BIND reader and biotinylated peptides captured onto a streptavidin coated biosensor plate.

10 The antigen binding protein may not bind significantly to the myostatin peptide fragment or artificial peptide sequence. The antigen binding protein may not bind to the myostatin peptide fragment or artificial peptide sequence at a ratio range of 1:1 to 1:10, respectively.

15 Binding or lack of binding between the antigen binding protein and the myostatin peptide fragment or artificial peptide sequence may be determined by ELISA or by SDS PAGE using reducing conditions. For example, binding or lack of binding of the antigen binding protein to the linear full length myostatin sequence may be determined by reducing (i.e. denaturing) SDS PAGE. For example, the method described in Example 2.4 using an SRU BIND reader and biotinylated 20 peptides captured onto a streptavidin coated biosensor plate may be employed. The data in Example 2.4 suggest that 10B3 may bind a conformational sequence which may prove beneficial in the binding and neutralisation of native myostatin *in vivo* for therapeutic treatment.

25 The epitope of myostatin to which the antigen binding proteins described herein bind may be a conformational or discontinuous epitope. The antigen binding proteins described herein may not bind to a linear epitope on myostatin, for example the antigen binding protein may not bind to a reduced or denatured sample of myostatin. The conformational or discontinuous epitope may be identical to, similar to, or overlap with the myostatin receptor binding site. The epitope may be accessible 30 when myostatin is in its mature form and as part of a dimer with another myostatin molecule (homodimer). The epitope may also be accessible when myostatin is in its mature form and as part of a tetramer with other myostatin binding molecules as

described. The epitope may be distributed across two myostatin polypeptides. This type of discontinuous epitope may comprise sequences from each myostatin molecule. The sequences may, in the context of the dimer's tertiary and quaternary structure, be near enough to each other to form an epitope and be bound by an antigen binding protein. Conformational and/or discontinuous epitopes may be identified by known methods for example CLIPS<sup>TM</sup> (Pepscan Systems).

Subsequent analysis of the myostatin binding site of 10B3C using Pepscan, Chemically Linked Immunogenic Peptides on Scaffolds (CLIPS) technology, suggest that the "PRGSAGPCCTPTKMS" amino acid sequence of myostatin may be the binding site for the chimeric antibody. The Pepscan methodology uses constrained peptides.

The antigen binding protein may have a half life of at least 6 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 7 days, or at least 9 days *in vivo* in humans, or in a murine animal model.

The myostatin polypeptide to which the antigen binding protein binds may be a recombinant polypeptide. Myostatin may be in solution or may be attached to a solid surface. For example, myostatin may be attached to beads such as magnetic beads. Myostatin may be biotinylated. The biotin molecule conjugated to myostatin may be used to immobilize myostatin on a solid surface by coupling biotinstreptavidin on the solid surface.

The antigen binding protein may be derived from rat, mouse, primate (e.g. cynomolgus, Old World monkey or Great Ape) or human. The antigen binding protein may be a humanised or chimeric antibody.

The antigen binding protein may comprise a constant region, which may be of any isotype or subclass. The constant region may be of the IgG isotype, for example IgG1, IgG2, IgG3, IgG4 or variants thereof. The antigen binding protein constant region may be IgG1.

Mutational changes to the Fc effector portion of the antibody can be used to change the affinity of the interaction between the FcRn and antibody to modulate antibody turnover. The half life of the antibody can be extended *in vivo*. This would be beneficial to patient populations as maximal dose amounts and maximal dosing frequencies could be achieved as a result of maintaining *in vivo* IC50 for longer

periods of time. The Fc effector function of the antibody may be removed, in its entirety or in part, since myostatin is a soluble target. This removal may result in an increased safety profile.

The antigen binding protein comprising a constant region may have reduced 5 ADCC and/or complement activation or effector functionality. The constant domain may comprise a naturally disabled constant region of IgG2 or IgG4 isotype or a mutated IgG1 constant domain. Examples of suitable modifications are described in EP0307434. One way to achieve Fc disablement comprises the substitutions of alanine residues at positions 235 and 237 (EU index numbering) of the heavy chain 10 constant region.

The antigen binding protein may comprise one or more modifications selected from a mutated constant domain such that the antibody has enhanced effector functions/ ADCC and/or complement activation. Examples of suitable modifications are described in Shields et al. J. Biol. Chem (2001) 276:6591-6604, Lazar et al. PNAS 15 (2006) 103:4005-4010 and US6737056, WO2004063351 and WO2004029207.

The antigen binding protein may comprise a constant domain with an altered glycosylation profile such that the antigen binding protein has enhanced effector functions/ ADCC and/or complement activation. Examples of suitable methodologies to produce an antigen binding protein with an altered glycosylation profile are 20 described in WO2003/011878, WO2006/014679 and EP1229125.

The present invention also provides a nucleic acid molecule which encodes an antigen binding protein as described herein. The nucleic acid molecule may comprise a sequence encoding (i) one or more CDRHs, the heavy chain variable sequence, or the full length heavy chain sequence; and (ii) one or more CDRLs, the light chain 25 variable sequence, or the full length light chain sequence, with (i) and (ii) on the same nucleic acid molecule. Alternatively, the nucleic acid molecule which encodes an antigen binding protein described herein may comprise sequences encoding (a) one or more CDRHs, the heavy chain variable sequence, or the full length heavy chain sequence; or (b) one or more CDRLs, the light chain variable sequence, or the full 30 length light chain sequence, with (a) and (b) on separate nucleic acid molecules.

The nucleic acid molecule which encodes the heavy chain may comprise SEQ ID NO: 41. The nucleic acid molecule which encodes the light chain may comprise SEQ ID NO: 42 or SEQ ID NO: 52.

The nucleic acid molecule which encodes the heavy chain may comprise any 5 one of SEQ ID NO: 43, 44 or 45. The nucleic acid molecule which encodes the light chain may comprise any one of SEQ ID NO: 46, 47, 48, 49 or 55. The nucleic acid molecule(s) which encodes the antigen binding protein may comprise any one of the following heavy chain and light chain combinations: H0L0 (SEQ ID NO: 43 and SEQ ID NO: 46), H0L1 (SEQ ID NO: 43 and SEQ ID NO: 47), H0L2 (SEQ ID NO: 43 and SEQ ID NO: 48), H0L3 (SEQ ID NO: 43 and SEQ ID NO: 49), H1L0 (SEQ ID NO: 44 and SEQ ID NO: 46), H1L1 (SEQ ID NO: 44 and SEQ ID NO: 47), H1L2 (SEQ ID NO: 44 and SEQ ID NO: 48), H1L3 (SEQ ID NO: 44 and SEQ ID NO: 49), H2L0 (SEQ ID NO: 45 and SEQ ID NO: 46), H2L1 (SEQ ID NO: 45 and SEQ ID NO: 47), H2L2 (SEQ ID NO: 45 and SEQ ID NO: 48), H2L3 (SEQ ID NO: 45 and SEQ ID NO: 49), H2L2-C91S (SEQ ID NO: 45 and SEQ ID NO: 55).

The nucleic acid molecules described above may also encode a heavy chain with any one of the following substitutions: Y96L, G99D, G99S, G100A\_K, P100B\_F, P100B\_I, W100E\_F, F100G\_N, F100G\_Y, F100G\_S, V102N, and V102S. In addition to, or as an alternative to, any one of the substitutions described, the 20 nucleic acid molecules may also encode heavy chains comprising any one of the following substitutions: G55D, G55L, G55S, G55T or G55V. The nucleic acid molecules described above may also encode a light chain with the following substitution: C91S.

The nucleic acid molecule may have the sequence of SEQ ID NO: 45 with a 25 substitution that encodes F100G\_Y. In addition to the substitution F100G\_Y, any one of the following substitutions G55D, G55L, G55S, G55T or G55V may also be present. In particular, the nucleic acid molecule may have the sequence of SEQ ID NO: 45 with a substitution that encodes: F100G\_Y, or F100G\_Y and G55S. The nucleic acid molecule that encodes the heavy chain may be paired with a nucleic acid 30 molecule of the sequence of SEQ ID NO: 55 that encodes the light chain.

The present invention also provides an expression vector comprising a nucleic acid molecule as described herein. Also provided is a recombinant host cell comprising an expression vector as described herein.

The antigen binding protein described herein may be produced in a suitable host cell. A method for the production of the antigen binding protein as described herein may comprise the step of culturing a host cell as described herein and recovering the antigen binding protein. A recombinant transformed, transfected, or transduced host cell may comprise at least one expression cassette, whereby said expression cassette comprises a polynucleotide encoding a heavy chain of the antigen binding protein described herein and further comprises a polynucleotide encoding a light chain of the antigen binding protein described herein. Alternatively, a recombinant transformed, transfected or transduced host cell may comprise at least one expression cassette, whereby a first expression cassette comprises a polynucleotide encoding a heavy chain of the antigen binding protein described herein and further comprise a second cassette comprising a polynucleotide encoding a light chain of the antigen binding protein described herein. A stably transformed host cell may comprise a vector comprising one or more expression cassettes encoding a heavy chain and/or a light chain of the antigen binding protein described herein. For example such host cells may comprise a first vector encoding the light chain and a second vector encoding the heavy chain.

The host cell may be eukaryotic, for example mammalian. Examples of such cell lines include CHO or NS0. The host cell may be a non-human host cell. The host cell may be a non-embryonic host cell. The host cell may be cultured in a culture media, for example serum- free culture media. The antigen binding protein may be secreted by the host cell into the culture media. The antigen binding protein can be purified to at least 95% or greater (e.g. 98% or greater) with respect to said culture media containing the antigen binding protein.

A pharmaceutical composition comprising the antigen binding protein and a pharmaceutically acceptable carrier may be provided. A kit-of-parts comprising the pharmaceutical composition together with instructions for use may be provided. For convenience, the kit may comprise the reagents in predetermined amounts with instructions for use.

## Antibody Structures

### Intact Antibodies

5 The light chains of antibodies from most vertebrate species can be assigned to one of two types called Kappa and Lambda based on the amino acid sequence of the constant region. Depending on the amino acid sequence of the constant region of their heavy chains, human antibodies can be assigned to five different classes, IgA, IgD, IgE, IgG and IgM. IgG and IgA can be further subdivided into subclasses, IgG1, IgG2, IgG3 and IgG4; and IgA1 and IgA2. Species variants exist with mouse and rat having at least IgG2a, IgG2b.

10 The more conserved portions of the variable region are called Framework regions (FR). The variable domains of intact heavy and light chains each comprise four FR connected by three CDRs. The CDRs in each chain are held together in close proximity by the FR regions and with the CDRs from the other chain contribute to the formation of the antigen binding site of antibodies.

15 The constant regions are not directly involved in the binding of the antibody to the antigen but exhibit various effector functions such as participation in antibody dependent cell-mediated cytotoxicity (ADCC), phagocytosis via binding to Fc $\gamma$  receptor, half-life/clearance rate via neonatal Fc receptor (FcRn) and complement dependent cytotoxicity via the C1q component of the complement cascade.

20 The human IgG2 constant region has been reported to essentially lack the ability to activate complement by the classical pathway or to mediate antibody-dependent cellular cytotoxicity. The IgG4 constant region has been reported to lack the ability to activate complement by the classical pathway and mediates antibody-dependent cellular cytotoxicity only weakly. Antibodies essentially lacking these 25 effector functions may be termed 'non-lytic' antibodies.

### Human antibodies

30 Human antibodies may be produced by a number of methods known to those of skill in the art. Human antibodies can be made by the hybridoma method using human myeloma or mouse-human heteromyeloma cells lines see Kozbor (1984) J. Immunol 133, 3001, and Brodeur, Monoclonal Antibody Production Techniques and Applications, 51-63 (Marcel Dekker Inc, 1987). Alternative methods include the use

of phage libraries or transgenic mice both of which utilize human variable region repertoires (see Winter (1994) *Annu. Rev. Immunol.* 12: 433-455; Green (1999) *J. Immunol. Methods* 231: 11-23).

Several strains of transgenic mice are now available wherein their mouse immunoglobulin loci has been replaced with human immunoglobulin gene segments (see Tomizuka (2000) *PNAS* 97: 722-727; Fishwild (1996) *Nature Biotechnol.* 14: 845-851; Mendez (1997) *Nature Genetics*, 15: 146-156). Upon antigen challenge such mice are capable of producing a repertoire of human antibodies from which antibodies of interest can be selected.

10 Phage display technology can be used to produce human antigen binding proteins (and fragments thereof), see McCafferty (1990) *Nature* 348: 552-553 and Griffiths et al. (1994) *EMBO* 13: 3245-3260.

15 The technique of affinity maturation (Marks *Bio/technol.* (1992) 10: 779-783) may be used to improve binding affinity wherein the affinity of the primary human antibody is improved by sequentially replacing the H and L chain variable regions with naturally occurring variants and selecting on the basis of improved binding affinities. Variants of this technique such as “epitope imprinting” are now also available, see for example WO 93/06213; Waterhouse (1993) *Nucl. Acids Res.* 21: 2265-2266.

20 Chimeric and Humanised Antibodies

Chimeric antibodies are typically produced using recombinant DNA methods. DNA encoding the antibodies (e.g. cDNA) is isolated and sequenced using conventional procedures (e.g. by using oligonucleotide probes that are capable of binding specifically to genes encoding the H and L chains of the antibody. Hybridoma cells serve as a typical source of such DNA. Once isolated, the DNA is placed into expression vectors which are then transfected into host cells such as *E. coli*, COS cells, CHO cells or myeloma cells that do not otherwise produce immunoglobulin protein to obtain synthesis of the antibody. The DNA may be modified by substituting the coding sequence for human L and H chains for the corresponding non-human (e.g. murine) H and L constant regions, see for example Morrison (1984) *PNAS* 81: 6851.

30 A large decrease in immunogenicity can be achieved by grafting only the CDRs of a non-human (e.g. murine) antibodies (“donor” antibodies) onto human

framework ("acceptor framework") and constant regions to generate humanised antibodies (see Jones et al. (1986) *Nature* 321: 522-525; and Verhoeyen et al. (1988) *Science* 239: 1534-1536). However, CDR grafting *per se* may not result in the complete retention of antigen-binding properties and it is frequently found that some 5 framework residues (sometimes referred to as "back mutations") of the donor antibody need to be preserved in the humanised molecule if significant antigen-binding affinity is to be recovered (see Queen et al. (1989) *PNAS* 86: 10,029-10,033; Co et al. (1991) *Nature* 351: 501-502). In this case, human variable regions showing the greatest sequence homology to the non-human donor antibody are chosen from a 10 database in order to provide the human framework (FR). The selection of human FRs can be made either from human consensus or individual human antibodies. Where necessary, key residues from the donor antibody can be substituted into the human acceptor framework to preserve CDR conformations. Computer modelling of the antibody maybe used to help identify such structurally important residues, see WO 15 99/48523.

Alternatively, humanisation maybe achieved by a process of "veneering". A statistical analysis of unique human and murine immunoglobulin heavy and light chain variable regions revealed that the precise patterns of exposed residues are different in human and murine antibodies, and most individual surface positions have 20 a strong preference for a small number of different residues (see Padlan et al. (1991) *Mol. Immunol.* 28: 489-498; and Pedersen et al. (1994) *J. Mol. Biol.* 235: 959-973). Therefore it is possible to reduce the immunogenicity of a non-human Fv by replacing exposed residues in its framework regions that differ from those usually found in human antibodies. Because protein antigenicity may be correlated with surface 25 accessibility, replacement of the surface residues may be sufficient to render the mouse variable region "invisible" to the human immune system (see also Mark et al. (1994) in *Handbook of Experimental Pharmacology* Vol. 113: The pharmacology of Monoclonal Antibodies, Springer-Verlag, 105-134). This procedure of humanisation is referred to as "veneering" because only the surface of the antibody is altered, the 30 supporting residues remain undisturbed. Further alternative approaches include that set out in WO04/006955 and the procedure of Humaneering<sup>TM</sup> (Kalobios) which makes use of bacterial expression systems and produces antibodies that are close to

human germline in sequence (Alfenito-M Advancing Protein Therapeutics January 2007, San Diego, California).

#### Bispecific antigen binding proteins

A bispecific antigen binding protein is an antigen binding protein having 5 binding specificities for at least two different epitopes. Methods of making such antigen binding proteins are known in the art. Traditionally, the recombinant production of bispecific antigen binding proteins is based on the co-expression of two immunoglobulin H chain-L chain pairs, where the two H chains have different binding specificities, see Millstein et al. (1983) *Nature* 305: 537-539; WO 93/08829; 10 and Traunecker et al. (1991) *EMBO* 10: 3655-3659. Because of the random assortment of H and L chains, a potential mixture of ten different antibody structures are produced of which only one has the desired binding specificity. An alternative approach involves fusing the variable domains with the desired binding specificities to heavy chain constant region comprising at least part of the hinge region, CH2 and 15 CH3 regions. The CH1 region containing the site necessary for light chain binding may be present in at least one of the fusions. DNA encoding these fusions, and if desired the L chain are inserted into separate expression vectors and are then co-transfected into a suitable host organism. It is possible though to insert the coding sequences for two or all three chains into one expression vector. In one approach, the 20 bispecific antibody is composed of a H chain with a first binding specificity in one arm and a H-L chain pair, providing a second binding specificity in the other arm, see WO 94/04690. Also see Suresh et al. (1986) *Methods in Enzymology* 121: 210.

#### Antigen Binding Fragments

Fragments lacking the constant region lack the ability to activate complement 25 by the classical pathway or to mediate antibody-dependent cellular cytotoxicity. Traditionally such fragments are produced by the proteolytic digestion of intact antibodies by e.g. papain digestion (see for example, WO 94/29348) but may be produced directly from recombinantly transformed host cells. For the production of ScFv, see Bird et al. (1988) *Science* 242: 423-426. In addition, antigen binding 30 fragments may be produced using a variety of engineering techniques as described below.

Fv fragments appear to have lower interaction energy of their two chains than Fab fragments. To stabilise the association of the  $V_H$  and  $V_L$  domains, they have been linked with peptides (Bird et al. (1988) *Science* 242: 423-426; Huston et al. (1988) *PNAS* 85(16): 5879-5883), disulphide bridges (Glockshuber et al. (1990) *Biochemistry* 29: 1362-1367) and "knob in hole" mutations (Zhu et al. (1997) *Protein Sci.*, 6: 781-788). ScFv fragments can be produced by methods well known to those skilled in the art, see Whitlow et al. (1991) *Methods Companion Methods Enzymol*, 2: 97-105 and Huston et al. (1993) *Int. Rev. Immunol* 10: 195-217. ScFv may be produced in bacterial cells such as *E. coli* or in eukaryotic cells. One disadvantage of ScFv is the monovalency of the product, which precludes an increased avidity due to polyvalent binding, and their short half-life. Attempts to overcome these problems include bivalent  $(ScFv')_2$  produced from ScFv containing an additional C-terminal cysteine by chemical coupling (Adams et al. (1993) *Can. Res* 53: 4026-4034; and McCartney et al. (1995) *Protein Eng.* 8: 301-314) or by spontaneous site-specific dimerisation of ScFv containing an unpaired C-terminal cysteine residue (see Kipriyanov et al. (1995) *Cell. Biophys* 26: 187-204). Alternatively, ScFv can be forced to form multimers by shortening the peptide linker to 3 to 12 residues to form "diabodies", see Holliger et al. (1993) *PNAS* 90: 6444-6448. Reducing the linker still further can result in ScFv trimers ("triabodies", see Kortt et al. (1997) *Protein Eng* 10: 423-433) and tetramers ("tetrabodies", see Le Gall et al. (1999) *FEBS Lett*, 453: 164-168). Construction of bivalent ScFv molecules can also be achieved by genetic fusion with protein dimerising motifs to form "miniantibodies" (see Pack et al. (1992) *Biochemistry* 31: 1579-1584) and "minibodies" (see Hu et al. (1996) *Cancer Res*. 56: 3055-3061). ScFv-Sc-Fv tandems  $((ScFv)_2)$  may also be produced by linking two ScFv units by a third peptide linker, see Kurucz et al. (1995) *J. Immol*. 154: 4576-4582. Bispecific diabodies can be produced through the noncovalent association of two single chain fusion products consisting of  $V_H$  domain from one antibody connected by a short linker to the  $V_L$  domain of another antibody, see Kipriyanov et al. (1998) *Int. J. Can* 77: 763-772. The stability of such bispecific diabodies can be enhanced by the introduction of disulphide bridges or "knob in hole" mutations as described supra or by the formation of single chain diabodies (ScDb) wherein two hybrid ScFv fragments are connected through a peptide linker see Kontermann et al. (1999) *J. Immunol. Methods* 226:179-188. Tetravalent bispecific molecules are available by e.g. fusing a ScFv fragment to the CH3 domain of an IgG molecule or to

a Fab fragment through the hinge region, see Coloma et al. (1997) *Nature Biotechnol.* 15: 159-163. Alternatively, tetravalent bispecific molecules have been created by the fusion of bispecific single chain diabodies (see Alt et al. (1999) *FEBS Lett* 454: 90-94. Smaller tetravalent bispecific molecules can also be formed by the dimerization of 5 either ScFv-ScFv tandems with a linker containing a helix-loop-helix motif (DiBi miniantibodies, see Muller et al. (1998) *FEBS Lett* 432: 45-49) or a single chain molecule comprising four antibody variable domains (V<sub>H</sub> and V<sub>L</sub>) in an orientation preventing intramolecular pairing (tandem diabody, see Kipriyanov et al. (1999) *J. Mol. Biol.* 293: 41-56). Bispecific F(ab')<sub>2</sub> fragments can be created by chemical 10 coupling of Fab' fragments or by heterodimerization through leucine zippers (see Shalaby et al. (1992) *J. Exp. Med.* 175: 217-225; and Kostelny et al. (1992), *J. Immunol.* 148: 1547-1553). Also available are isolated V<sub>H</sub> and V<sub>L</sub> domains (Domantis plc), see US 6,248,516; US 6,291,158; and US 6,172,197.

#### Heteroconjugate antibodies

15 Heteroconjugate antibodies are composed of two covalently joined antibodies formed using any convenient cross-linking methods. See, for example, US 4,676,980.

#### Other Modifications

The antigen binding proteins of the present invention may comprise other modifications to enhance or change their effector functions. The interaction between 20 the Fc region of an antibody and various Fc receptors (Fc $\gamma$ R) is believed to mediate the effector functions of the antibody which include antibody-dependent cellular cytotoxicity (ADCC), fixation of complement, phagocytosis and half-life/clearance of the antibody. Various modifications to the Fc region of antibodies may be carried out depending on the desired property. For example, specific mutations in the Fc region to 25 render an otherwise lytic antibody, non-lytic is detailed in EP 0629 240 and EP 0307 434 or one may incorporate a salvage receptor binding epitope into the antibody to increase serum half life see US 5,739,277. Human Fc $\gamma$  receptors include Fc $\gamma$ R (I), Fc $\gamma$ RIIa, Fc $\gamma$ RIIb, Fc $\gamma$ RIIIa and neonatal FcRn. Shields et al. (2001) *J. Biol. Chem.* 276: 6591-6604 demonstrated that a common set of IgG1 residues is involved in 30 binding all Fc $\gamma$ Rs, while Fc $\gamma$ RII and Fc $\gamma$ RIII utilize distinct sites outside of this common set. One group of IgG1 residues reduced binding to all Fc $\gamma$ Rs when altered to alanine: Pro-238, Asp-265, Asp-270, Asn-297 and Pro-239. All are in the IgG CH2

domain and clustered near the hinge joining CH1 and CH2. While Fc $\gamma$ RI utilizes only the common set of IgG1 residues for binding, Fc $\gamma$ RII and Fc $\gamma$ RIII interact with distinct residues in addition to the common set. Alteration of some residues reduced binding only to Fc $\gamma$ RII (e.g. Arg-292) or Fc $\gamma$ RIII (e.g. Glu-293). Some variants 5 showed improved binding to Fc $\gamma$ RII or Fc $\gamma$ RIII but did not affect binding to the other receptor (e.g. Ser-267Ala improved binding to Fc $\gamma$ RII but binding to Fc $\gamma$ RIII was unaffected). Other variants exhibited improved binding to Fc $\gamma$ RII or Fc $\gamma$ RIII with reduction in binding to the other receptor (e.g. Ser-298Ala improved binding to Fc $\gamma$ RIII and reduced binding to Fc $\gamma$ RII). For Fc $\gamma$ RIIIa, the best binding IgG1 variants 10 had combined alanine substitutions at Ser-298, Glu-333 and Lys-334. The neonatal FcRn receptor is believed to be involved in both antibody clearance and the transcytosis across tissues (see Junghans (1997) Immunol. Res 16: 29-57; and Ghetie et al. (2000) Annu. Rev. Immunol. 18: 739-766). Human IgG1 residues determined to interact directly with human FcRn includes Ile253, Ser254, Lys288, Thr307, Gln311, 15 Asn434 and His435. Substitutions at any of the positions described in this section may enable increased serum half-life and/or altered effector properties of the antibodies.

Other modifications include glycosylation variants of the antibodies. Glycosylation of antibodies at conserved positions in their constant regions is known to have a profound effect on antibody function, particularly effector functioning such 20 as those described above, see for example, Boyd et al. (1996) Mol. Immunol. 32: 1311-1318. Glycosylation variants of the antibodies or antigen binding fragments thereof wherein one or more carbohydrate moiety is added, substituted, deleted or modified are contemplated. Introduction of an asparagine-X-serine or asparagine-X-threonine motif creates a potential site for enzymatic attachment of carbohydrate 25 moieties and may therefore be used to manipulate the glycosylation of an antibody. In Raju et al. (2001) Biochemistry 40: 8868-8876 the terminal sialylation of a TNFR-IgG immunoadhesin was increased through a process of regalactosylation and/or resialylation using beta-1, 4-galactosyltransferase and/or alpha, 2,3 sialyltransferase. Increasing the terminal sialylation is believed to increase the half-life of the 30 immunoglobulin. Antibodies, in common with most glycoproteins, are typically produced as a mixture of glycoforms. This mixture is particularly apparent when antibodies are produced in eukaryotic, particularly mammalian cells. A variety of methods have been developed to manufacture defined glycoforms, see Zhang et al.

(2004) *Science* 303: 371; Sears et al. (2001) *Science* 291: 2344; Wacker et al. (2002) *Science* 298: 1790; Davis et al. (2002) *Chem. Rev.* 102: 579; Hang et al. (2001) *Acc. Chem. Res.* 34: 727. The antibodies (for example of the IgG isotype, e.g. IgG1) as herein described may comprise a defined number (e.g. 7 or less, for example 5 or less, 5 such as two or a single) of glycoform(s).

The antibodies may be coupled to a non-proteinaceous polymer such as polyethylene glycol (PEG), polypropylene glycol or polyoxyalkylene. Conjugation of proteins to PEG is an established technique for increasing half-life of proteins, as well as reducing antigenicity and immunogenicity of proteins. The use of PEGylation with 10 different molecular weights and styles (linear or branched) has been investigated with intact antibodies as well as Fab' fragments, see Koumenis et al. (2000) *Int. J. Pharmaceut.* 198: 83-95.

### **Production Methods**

15 Antigen binding proteins may be produced in transgenic organisms such as goats (see Pollock et al. (1999) *J. Immunol. Methods* 231: 147-157), chickens (see Morrow (2000) *Genet. Eng. News* 20: 1-55, mice (see Pollock et al.) or plants (see Doran (2000) *Curr. Opinion Biotechnol.* 11: 199-204; Ma (1998) *Nat. Med.* 4: 601-606; Baez et al. (2000) *BioPharm* 13: 50-54; Stoger et al. (2000) *Plant Mol. Biol.* 42: 583-590).

20 Antigen binding proteins may also be produced by chemical synthesis. However, antigen binding proteins are typically produced using recombinant cell culturing technology well known to those skilled in the art. A polynucleotide encoding the antigen binding protein is isolated and inserted into a replicable vector such as a plasmid for further cloning (amplification) or expression. One expression 25 system is a glutamate synthetase system (such as sold by Lonza Biologics), particularly where the host cell is CHO or NS0. Polynucleotide encoding the antigen binding protein is readily isolated and sequenced using conventional procedures (e.g. oligonucleotide probes). Vectors that may be used include plasmid, virus, phage, transposons, minichromosomes of which plasmids are typically used. Generally such 30 vectors further include a signal sequence, origin of replication, one or more marker genes, an enhancer element, a promoter and transcription termination sequences operably linked to the antigen binding protein polynucleotide so as to facilitate

expression. Polynucleotide encoding the light and heavy chains may be inserted into separate vectors and introduced (for example by transformation, transfection, electroporation or transduction) into the same host cell concurrently or sequentially or, if desired both the heavy chain and light chain can be inserted into the same vector 5 prior to said introduction.

Codon optimisation may be used with the intent that the total level of protein produced by the host cell is greater when transfected with the codon-optimised gene in comparison with the level when transfected with the wild-type sequence. Several methods have been published (Nakamura et al. (1996) Nucleic Acids Research 24: 10 214-215; W098/34640; W097/11086). Due to the redundancy of the genetic code, alternative polynucleotides to those disclosed herein (particularly those codon optimised for expression in a given host cell) may also encode the antigen binding proteins described herein. The codon usage of the antigen binding protein of this invention thereof can be modified to accommodate codon bias of the host cell such to 15 augment transcript and/or product yield (eg Hoekema et al Mol Cell Biol 1987 7(8): 2914-24). The choice of codons may be based upon suitable compatibility with the host cell used for expression.

#### Signal sequences

Antigen binding proteins may be produced as a fusion protein with a 20 heterologous signal sequence having a specific cleavage site at the N-terminus of the mature protein. The signal sequence should be recognised and processed by the host cell. For prokaryotic host cells, the signal sequence may be for example an alkaline phosphatase, penicillinase, or heat stable enterotoxin II leaders. For yeast secretion the signal sequences may be for example a yeast invertase leader,  $\alpha$  factor leader or acid 25 phosphatase leaders see e.g. WO90/13646. In mammalian cell systems, viral secretory leaders such as herpes simplex gD signal and a native immunoglobulin signal sequence may be suitable. Typically the signal sequence is ligated in reading frame to DNA encoding the antigen binding protein. A signal sequence such as that shown in SEQ ID NO: 9 may be used.

30 Origin of replication

Origin of replications are well known in the art with pBR322 suitable for most gram-negative bacteria,  $2\mu$  plasmid for most yeast and various viral origins such as

SV40, polyoma, adenovirus, VSV or BPV for most mammalian cells. Generally the origin of replication component is not needed for mammalian expression vectors but the SV40 may be used since it contains the early promoter.

#### Selection marker

5       Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins e.g. ampicillin, neomycin, methotrexate or tetracycline or (b) complement auxotrophic deficiencies or supply nutrients not available in the complex media or (c) combinations of both. The selection scheme may involve arresting growth of the host cell. Cells, which have been successfully transformed with the  
10      genes encoding the antigen binding protein, survive due to e.g. drug resistance conferred by the co-delivered selection marker. One example is the DHFR selection marker wherein transformants are cultured in the presence of methotrexate. Cells can be cultured in the presence of increasing amounts of methotrexate to amplify the copy number of the exogenous gene of interest. CHO cells are a particularly useful cell line  
15      for the DHFR selection. A further example is the glutamate synthetase expression system (Lonza Biologics). An example of a selection gene for use in yeast is the trp1 gene, see Stinchcomb et al. (1979) Nature 282: 38.

#### Promoters

20       Suitable promoters for expressing antigen binding proteins are operably linked to DNA/polynucleotide encoding the antigen binding protein. Promoters for prokaryotic hosts include phoA promoter, beta-lactamase and lactose promoter systems, alkaline phosphatase, tryptophan and hybrid promoters such as Tac. Promoters suitable for expression in yeast cells include 3-phosphoglycerate kinase or other glycolytic enzymes e.g. enolase, glyceraldehyde 3 phosphate dehydrogenase, 25      hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose 6 phosphate isomerase, 3-phosphoglycerate mutase and glucokinase. Inducible yeast promoters include alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, metallothionein and enzymes responsible for nitrogen metabolism or maltose/galactose utilization.

30       Promoters for expression in mammalian cell systems include viral promoters such as polyoma, fowlpox and adenoviruses (e.g. adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus (in particular the immediate early gene promoter), retrovirus, hepatitis B virus, actin, rous sarcoma virus (RSV) promoter and

the early or late Simian virus 40. Of course the choice of promoter is based upon suitable compatibility with the host cell used for expression. A first plasmid may comprise a RSV and/or SV40 and/or CMV promoter, DNA encoding light chain variable region (V<sub>L</sub>), κC region together with neomycin and ampicillin resistance 5 selection markers and a second plasmid comprising a RSV or SV40 promoter, DNA encoding the heavy chain variable region (V<sub>H</sub>), DNA encoding the γ1 constant region, DHFR and ampicillin resistance markers.

Enhancer element

Where appropriate, e.g. for expression in higher eukaryotes, an enhancer element 10 operably linked to the promoter element in a vector may be used. Mammalian enhancer sequences include enhancer elements from globin, elastase, albumin, fetoprotein and insulin. Alternatively, one may use an enhancer element from a eukaryotic cell virus such as SV40 enhancer (at bp100-270), cytomegalovirus early promoter enhancer, polyoma enhancer, baculoviral enhancer or murine IgG2a locus 15 (see WO04/009823). The enhancer may be located on the vector at a site upstream to the promoter. Alternatively, the enhancer may be located elsewhere, for example within the untranslated region or downstream of the polyadenylation signal. The choice and positioning of enhancer may be based upon suitable compatibility with the host cell used for expression.

20 Polyadenylation/termination

In eukaryotic systems, polyadenylation signals are operably linked to DNA/polynucleotide encoding the antigen binding protein. Such signals are typically placed 3' of the open reading frame. In mammalian systems, non-limiting examples include signals derived from growth hormones, elongation factor-1 alpha and viral (eg 25 SV40) genes or retroviral long terminal repeats. In yeast systems non-limiting examples of polyadenylation/termination signals include those derived from the phosphoglycerate kinase (PGK) and the alcohol dehydrogenase 1 (ADH) genes. In prokaryotic system polyadenylation signals are typically not required and it is instead usual to employ shorter and more defined terminator sequences. The choice of 30 polyadenylation/ termination sequences may be based upon suitable compatibility with the host cell used for expression.

Other methods/elements for enhanced yields

In addition to the above, other features that can be employed to enhance yields include chromatin remodelling elements, introns and host-cell specific codon modification.

5 Host cells

Suitable host cells for cloning or expressing vectors encoding antigen binding proteins are prokaryotic, yeast or higher eukaryotic cells. Suitable prokaryotic cells include eubacteria e.g. enterobacteriaceae such as *Escherichia* e.g. *E. coli* (for example ATCC 31,446; 31,537; 27,325), Enterobacter, *Erwinia*, *Klebsiella* *Proteus*, 10 *Salmonella* e.g. *Salmonella typhimurium*, *Serratia* e.g. *Serratia marcescans* and *Shigella* as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (see DD 266 710), *Pseudomonas* such as *P. aeruginosa* and *Streptomyces*. Of the yeast host cells, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* (e.g. ATCC 16,045; 12,424; 24178; 56,500), yarrowia (EP402, 226), *Pichia pastoris* (EP 183 070, 15 see also Peng et al. (2004) J. Biotechnol. 108: 185-192), *Candida*, *Trichoderma reesia* (EP 244 234), Penicillin, *Tolypocladium* and *Aspergillus* hosts such as *A. nidulans* and *A. niger* are also contemplated.

Higher eukaryotic host cells include mammalian cells such as COS-1 (ATCC No.CRL 1650) COS-7 (ATCC CRL 1651), human embryonic kidney line 293, baby 20 hamster kidney cells (BHK) (ATCC CRL.1632), BHK570 (ATCC NO: CRL 10314), 293 (ATCC NO.CRL 1573), Chinese hamster ovary cells CHO (e.g. CHO-K1, ATCC NO: CCL 61, DHFR-CHO cell line such as DG44 (see Urlaub et al. (1986) Somatic Cell Mol. Genet.12: 555-556), particularly those CHO cell lines adapted for suspension culture, mouse sertoli cells, monkey kidney cells, African green monkey 25 kidney cells (ATCC CRL-1587), HE LA cells, canine kidney cells (ATCC CCL 34), human lung cells (ATCC CCL 75), Hep G2 and myeloma or lymphoma cells e.g. NS0 (see US 5,807,715), Sp2/0, Y0.

Such host cells may also be further engineered or adapted to modify quality, 30 function and/or yield of the antigen binding protein. Non-limiting examples include expression of specific modifying (e.g. glycosylation) enzymes and protein folding chaperones.

### Cell Culturing Methods

Host cells transformed with vectors encoding antigen binding proteins may be cultured by any method known to those skilled in the art. Host cells may be cultured in spinner flasks, roller bottles or hollow fibre systems but for large scale production that stirred tank reactors are used particularly for suspension cultures. The stirred tankers may be adapted for aeration using e.g. spargers, baffles or low shear impellers. For bubble columns and airlift reactors direct aeration with air or oxygen bubbles maybe used. Where the host cells are cultured in a serum free culture media, the media is supplemented with a cell protective agent such as pluronics F-68 to help prevent cell damage as a result of the aeration process. Depending on the host cell characteristics, either microcarriers maybe used as growth substrates for anchorage dependent cell lines or the cells maybe adapted to suspension culture (which is typical). The culturing of host cells, particularly invertebrate host cells may utilise a variety of operational modes such as fed-batch, repeated batch processing (see 10 Drapeau et al. (1994) Cytotechnology 15: 103-109), extended batch process or perfusion culture. Although recombinantly transformed mammalian host cells may be cultured in serum-containing media such as fetal calf serum (FCS), for example such host cells are cultured in synthetic serum –free media such as disclosed in Keen et al. (1995) Cytotechnology 17: 153-163, or commercially available media such as 15 ProCHO-CDM or UltraCHO™ (Cambrex NJ, USA), supplemented where necessary with an energy source such as glucose and synthetic growth factors such as recombinant insulin. The serum-free culturing of host cells may require that those cells are adapted to grow in serum free conditions. One adaptation approach is to culture such host cells in serum containing media and repeatedly exchange 80% of the 20 culture medium for the serum-free media so that the host cells learn to adapt in serum free conditions (see e.g. Scharfenberg et al. (1995) in Animal Cell Technology: Developments towards the 21st century (Beuvery et al. eds, 619-623, Kluwer Academic publishers)).

Antigen binding proteins secreted into the media may be recovered and 30 purified using a variety of techniques to provide a degree of purification suitable for the intended use. For example the use of antigen binding proteins for the treatment of human patients typically mandates at least 95% purity, more typically 98% or 99% or greater purity (compared to the crude culture medium). Cell debris from the culture

media is typically removed using centrifugation followed by a clarification step of the supernatant using e.g. microfiltration, ultrafiltration and/or depth filtration. A variety of other techniques such as dialysis and gel electrophoresis and chromatographic techniques such as hydroxyapatite (HA), affinity chromatography (optionally 5 involving an affinity tagging system such as polyhistidine) and/or hydrophobic interaction chromatography (HIC, see US 5, 429,746) are available. The antibodies, following various clarification steps, can be captured using Protein A or G affinity chromatography. Further chromatography steps can follow such as ion exchange and/or HA chromatography, anion or cation exchange, size exclusion chromatography 10 and ammonium sulphate precipitation. Various virus removal steps may also be employed (e.g. nanofiltration using e.g. a DV-20 filter). Following these various steps, a purified (for example a monoclonal) preparation comprising at least 75mg/ml or greater, or 100mg/ml or greater, of the antigen binding protein is provided. Such preparations are substantially free of aggregated forms of antigen binding proteins.

15 Bacterial systems may be used for the expression of antigen binding fragments. Such fragments can be localised intracellularly, within the periplasm or secreted extracellularly. Insoluble proteins can be extracted and refolded to form active proteins according to methods known to those skilled in the art, see Sanchez et al. (1999) J. Biotechnol. 72: 13-20; and Cupit et al. (1999) Lett Appl Microbiol 29: 20 273-277.

Deamidation is a chemical reaction in which an amide functional group is removed. In biochemistry, the reaction is important in the degradation of proteins because it damages the amide-containing side chains of the amino acids asparagine and glutamine. Deamidation reactions are believed to be one of the factors that can 25 limit the useful lifetime of a protein, they are also one of the most common post-translational modifications occurring during the manufacture of therapeutic proteins. For example, a reduction or loss of *in vitro* or *in vivo* biological activity has been reported for recombinant human DNase and recombinant soluble CD4, whereas other recombinant proteins appear to be unaffected. The ability of the antigen binding 30 proteins described herein to bind to myostatin seems to be unaffected under stress conditions that induce deamidation. Thus, the biological activity of the antigen binding proteins described herein and their useful lifetime is unlikely to be affected by deamidation.

## **Pharmaceutical Compositions**

The terms diseases, disorders and conditions are used interchangeably. Purified preparations of an antigen binding protein as described herein may be incorporated into pharmaceutical compositions for use in the treatment of the human diseases described herein. The pharmaceutical composition can be used in the treatment of diseases where myostatin contributes to the disease or where neutralising the activity of myostatin will be beneficial. The pharmaceutical composition comprising a therapeutically effective amount of the antigen binding protein described herein can be used in the treatment of diseases responsive to neutralisation of myostatin.

The pharmaceutical preparation may comprise an antigen binding protein in combination with a pharmaceutically acceptable carrier. The antigen binding protein may be administered alone, or as part of a pharmaceutical composition.

Typically such compositions comprise a pharmaceutically acceptable carrier as known and called for by acceptable pharmaceutical practice, see e.g. Remingtons Pharmaceutical Sciences, 16th edition (1980) Mack Publishing Co. Examples of such carriers include sterilised carriers such as saline, Ringers solution or dextrose solution, optionally buffered with suitable buffers to a pH within a range of 5 to 8.

Pharmaceutical compositions may be administered by injection or continuous infusion (e.g. intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular or intraportal). Such compositions are suitably free of visible particulate matter. Pharmaceutical compositions may comprise between 1mg to 10g of antigen binding protein, for example between 5mg and 1g of antigen binding protein. Alternatively, the composition may comprise between 5mg and 500mg, for example between 5mg and 50mg.

Methods for the preparation of such pharmaceutical compositions are well known to those skilled in the art. Pharmaceutical compositions may comprise between 1mg to 10g of antigen binding protein in unit dosage form, optionally together with instructions for use. Pharmaceutical compositions may be lyophilised (freeze dried) for reconstitution prior to administration according to methods well known or apparent to those skilled in the art. Where antibodies have an IgG1 isotype, a chelator of copper, such as citrate (e.g. sodium citrate) or EDTA or histidine, may be added to

the pharmaceutical composition to reduce the degree of copper-mediated degradation of antibodies of this isotype, see EP0612251. Pharmaceutical compositions may also comprise a solubiliser such as arginine base, a detergent/anti-aggregation agent such as polysorbate 80, and an inert gas such as nitrogen to replace vial headspace oxygen.

5        Effective doses and treatment regimes for administering the antigen binding protein are generally determined empirically and may be dependent on factors such as the age, weight and health status of the patient and disease or disorder to be treated. Such factors are within the purview of the attending physician. Guidance in selecting appropriate doses may be found in e.g. Smith et al (1977) *Antibodies in human*  
10      *diagnosis and therapy*, Raven Press, New York. Thus the antigen binding protein of the invention may be administered at a therapeutically effective amount.

15      The dosage of antigen binding protein administered to a subject is generally between 1 µg/kg to 150 mg/kg, between 0.1 mg/kg and 100 mg/kg, between 0.5 mg/kg and 50 mg/kg, between 1 and 25 mg/kg or between 1 and 10 mg/kg of the subject's body weight. For example, the dose may be 10 mg/kg, 30 mg/kg, or 60 mg/kg. The antigen binding protein may be administered parenterally, for example subcutaneously, intravenously or intramuscularly.

20      If desired, the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals, optionally, in unit dosage forms. For example, the dose may be administered subcutaneously, once every 14 or 28 days in the form of multiple sub-doses on each day of administration.

25      The administration of a dose may be by intravenous infusion, typically over a period of from 15 minutes to 24 hours, such as of from 2 to 12 hours, or from 2 to 6 hours. This may result in reduced toxic side effects.

30      The administration of a dose may be repeated one or more times as necessary, for example, three times daily, once every day, once every 2 days, once a week, once a fortnight, once a month, once every 3 months, once every 6 months, or once every 12 months. The antigen binding proteins may be administered by maintenance therapy, for example once a week for a period of 6 months or more. The antigen binding proteins may be administered by intermittent therapy, for example for a period of 3 to 6 months and then no dose for 3 to 6 months, followed by

administration of antigen binding proteins again for 3 to 6 months, and so on in a cycle.

The dosage may be determined or adjusted by measuring the amount of circulating anti-myostatin antigen binding proteins after administration in a biological sample by using anti-idiotypic antibodies which target the anti-myostatin antigen binding proteins. Other means of determining or adjusting dosage may be utilized, including but not limited to biologic markers ('biomarkers') of pharmacology, measures of muscle mass and/or function, safety, tolerability, and therapeutic response. The antigen binding protein can be administered in an amount and for a duration effective to down-regulate myostatin activity in the subject.

The antigen binding protein may be administered to the subject in such a way as to target therapy to a particular site. For example, the antigen binding protein may be injected locally into muscle, for example skeletal muscle.

The antigen binding protein may be used in combination with one or more other therapeutically active agents, for example Mortazapine (Remeron, Zispin: Organon), Megestrol acetate (Megace: BMS), Dronabinol (Marinol: Solvay Pharmaceutical Inc.), Oxandrolone (Oxandrin: Savient), testosterone, recombinant growth hormone (for example Somatropin (Serostim: Serono), Nutropin (Genentech), Humatrop (Lilly), Genotropin (Pfizer), Norditropin (Novo), Saizen (Merck Serono), and Omnitrope (Sandoz)), Cyproheptadine (Periactin: Merck), ornithine oxoglutarate (Cetornan), Methylphenidate (Ritalin: Novartis), and Modafinil (Provigil: Cephalon), orlistat (alli: GSK), sibutramine (Meridia, Reductil), rimonabant (Acomplia, Monaslim, Slimona), used in the treatment of the diseases described herein. Such combinations may be used in the treatment of diseases where myostatin contributes to the disease or where neutralising the activity of myostatin will be beneficial.

When the antigen binding protein is used in combination with other therapeutically active agents, the individual components may be administered either together or separately, sequentially or simultaneously, in separate or combined pharmaceutical formulations, by any appropriate route. If administered separately or sequentially, the antigen binding protein and the therapeutically active agent(s) may be administered in any order.

The combinations referred to above may be presented for use in the form of a single pharmaceutical formulation comprising a combination as defined above optionally together with a pharmaceutically acceptable carrier or excipient.

When combined in the same formulation it will be appreciated that the 5 components must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, for example in such a manner as known for antigen binding proteins in the art.

When in combination with a second therapeutic agent active against the same 10 disease, the dose of each component may differ from that when the antigen binding protein is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

The antigen binding protein and the therapeutically active agent(s) may act 15 synergistically. In other words, administering the antigen binding protein and the therapeutically active agent(s) in combination may have a greater effect on the disease, disorder, or condition described herein than the sum of the effect of each alone.

The pharmaceutical composition may comprise a kit of parts of the antigen 20 binding protein together with other medicaments, optionally with instructions for use. For convenience, the kit may comprise the reagents in predetermined amounts with instructions for use.

The terms "individual", "subject" and "patient" are used herein interchangeably. The subject is typically a human. The subject may also be a mammal, such as a mouse, rat or primate (e.g. a marmoset or monkey). The subject 25 can be a non-human animal. The antigen binding proteins may also have veterinary use. The subject to be treated may be a farm animal for example, a cow or bull, sheep, pig, ox, goat or horse or may be a domestic animal such as a dog or cat. The animal may be any age, or a mature adult animal. Where the subject is a laboratory animal such as a mouse, rat or primate, the animal can be treated to induce a disease or 30 condition associated with muscle wasting, myopathy, or muscle loss.

Treatment may be therapeutic, prophylactic or preventative. The subject may be one who is in need thereof. Those in need of treatment may include individuals

already suffering from a particular medical disease in addition to those who may develop the disease in the future.

Thus, the antigen binding protein described herein can be used for prophylactic or preventative treatment. In this case, the antigen binding protein described herein is administered to an individual in order to prevent or delay the onset of one or more aspects or symptoms of the disease. The subject can be asymptomatic. The subject may have a genetic predisposition to the disease. A prophylactically effective amount of the antigen binding protein is administered to such an individual. A prophylactically effective amount is an amount which prevents or delays the onset of one or more aspects or symptoms of a disease described herein.

The antigen binding protein described herein may also be used in methods of therapy. The term "therapy" encompasses alleviation, reduction, or prevention of at least one aspect or symptom of a disease. For example, the antigen binding protein described herein may be used to ameliorate or reduce one or more aspects or symptoms of a disease described herein.

The antigen binding protein described herein is used in an effective amount for therapeutic, prophylactic or preventative treatment. A therapeutically effective amount of the antigen binding protein described herein is an amount effective to ameliorate or reduce one or more aspects or symptoms of the disease. The antigen binding protein described herein may also be used to treat, prevent, or cure the disease described herein.

The antigen binding protein described herein may have a generally beneficial effect on the subject's health, for example it can increase the subject's expected longevity.

The antigen binding protein described herein need not affect a complete cure, or eradicate every symptom or manifestation of the disease to constitute a viable therapeutic treatment. As is recognised in the pertinent field, drugs employed as therapeutic agents may reduce the severity of a given disease state, but need not abolish every manifestation of the disease to be regarded as useful therapeutic agents. Similarly, a prophylactically administered treatment need not be completely effective in preventing the onset of a disease in order to constitute a viable prophylactic agent. Simply reducing the impact of a disease (for example, by reducing the number or

severity of its symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or reducing the likelihood that the disease will occur (for example by delaying the onset of the disease) or worsen in a subject, is sufficient.

5        The disorder, disease, or condition include sarcopenia, cachexia, muscle-wasting, disuse muscle atrophy, HIV, AIDS, cancer, surgery, burns, trauma or injury to muscle bone or nerve, obesity, diabetes (including type II diabetes mellitus), arthritis, chronic renal failure (CRF), end stage renal disease (ESRD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), elective joint 10 repair, multiple sclerosis (MS), stroke, muscular dystrophy, motor neuron neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, osteoporosis, osteoarthritis, fatty acid liver disease, liver cirrhosis, Addison's disease, Cushing's syndrome, acute respiratory distress syndrome, steroid induced muscle wasting, myositis and scoliosis.

15        Age-related muscle wasting (also called myopathy), or *sarcopenia*, is the progressive loss of muscle mass and muscle strength that occurs with age. This condition is thought to be a consequence of decreased muscle synthesis and repair in addition to increased muscle breakdown. In age-related muscle wasting the bundles of muscle fibers can shrink because individual fibers are lost. Furthermore, due to disuse muscle atrophy in such subjects, muscle fibers also get smaller. Treatments may 20 reverse this muscle atrophy. Thus, the antigen binding proteins described herein may be used to treat sarcopenia.

25        Age-related muscle wasting begins at middle age and accelerates throughout the remainder of life. The most commonly used definition for the condition is appendicular skeletal mass/height<sup>2</sup> (kg/m<sup>2</sup>) less than two standard deviations below the mean value for young adults. This disorder can lead to decreased mobility, functional disability and loss of independence.

30        Disuse muscle atrophy can be associated with a number of different conditions, diseases or disorders, for example immobilization, post-operative surgery, dialysis, critical care (e.g. burns, ICU), trauma or injury to muscle or bone. Disuse atrophy can result from numerous causes or incidents which lead to prolonged periods of muscle disuse. Muscle atrophy involves the decrease in size and/or number and/or function of muscle fibers.

Cachexia is a condition which is associated with any one or a combination of loss of weight, loss of muscle mass, muscle atrophy, fatigue, weakness and loss of appetite in an individual not actively trying to lose weight. Cachexia can be associated with various other disorders, including any one of the diseases mentioned herein. For 5 example, cachexia may be associated with cancer, infection (for example by HIV or AIDS), renal failure, autoimmunity, and drug or alcohol addiction. Furthermore, cardiac cachexia may be treated using the antigen binding proteins described herein, for example in patients who have experienced myocardial infarction or patients with congestive heart failure. Thus, a patient with cancer cachexia may be treated by the 10 antigen binding proteins described herein.

Chronic obstructive pulmonary disease (COPD) patients may display mild, moderate or severe symptoms of the disease. COPD includes patients with emphysema and bronchitis. Patients with emphysema are generally very thin or frail, and their disease is generally considered to be irreversible. Therefore, the antigen 15 binding proteins described herein can be used to treat patients with emphysema since it is more difficult to improve the patient's underlying lung function. Patients with bronchitis are generally more robust, although they may also lack muscle, and their disease is thought to have some degree of reversibility. Therefore, the antigen binding proteins described herein can be used to treat patients with bronchitis, optionally in 20 combination with treatment of the patient's underlying lung function. Treatment with the antigen binding proteins described herein can have a direct effect on improving the function of muscles involved in respiration in patients with emphysema or bronchitis.

Cancer patients often display muscle wasting which can lead to 25 hospitalization, infection, dehydration, hip fracture, and ultimately death. For example, a 10% loss of muscle mass can be associated with a dramatically inferior prognosis of the cancer patient. Treatment with the antigen binding proteins described herein may improve the performance status of the cancer patient, for example to allow full chemotherapy or a more aggressive use of chemotherapy, and to improve patient 30 quality of life. Thus the antigen binding proteins described herein may be used to treat cancer cachexia.

Cancer includes, for example, prostate, pancreatic, lung, head and neck, colorectal cancer and lymphoma. For example in prostate cancer, the subject may

have metastatic prostate cancer and/or may be undergoing androgen deprivation therapy (ADT). Subjects with cancer may have locally advanced or metastatic cancer, for example early stage metastatic cancer. Thus a patient undergoing ADT following prostate cancer may be treated by the antigen binding proteins of the invention.

5 Patients with chronic renal failure (CRF) or end stage renal disease (ESRD) may be treated with the antigen binding proteins described herein. For example, patients may be treated pre-dialysis to delay the start of dialysis. Alternatively, patients who have been on dialysis for 1 year or more, 2 years or more, or 3 years or more may be treated with the antigen binding proteins described herein. Use of the  
10 antigen binding proteins described herein may prevent or treat muscle wasting in the short term, or long-term via chronic use of the antigen binding proteins.

Examples of trauma or injury to muscle, bone or nerve include hip fractures and acute knee injuries. Patients with hip fractures often have muscle atrophy prior to fracture and muscle wasting is a key contributor to hip fracture in many patients.  
15 Following hip fracture, muscle and strength is lost due to disuse, and often hip fracture patients do not return to pre-fracture levels of ambulation or function. Furthermore, many hip fracture patients are also afflicted with conditions such as COPD, ESRD and cancer, which can contribute to significant muscle wasting and predispose them to hip fracture. Therefore, patients may be treated with the antigen  
20 binding proteins described herein if they are at risk of hip fracture. There is considerable therapeutic urgency associated with hip fracture patients since these patients must be operated on immediately. Therefore, post operative treatment with the antigen binding proteins described herein can help aid the recovery of hip fracture patients by diminishing the loss of muscle mass and strength, and/or improving the  
25 recovery of muscle mass and strength. A subject at risk of hip fracture or a subject with a hip fracture may be treated by the antigen binding protein of the invention.

Antigen binding proteins described herein can help to treat elective surgery patients to build muscle in the patient prior to surgery.

Muscular dystrophy refers to a group of genetic, hereditary muscle diseases  
30 that cause progressive muscle weakness. Muscular dystrophies are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue. Examples of muscular dystrophies include Duchenne (DMD),

Becker, limb-girdle (LGMD), congenital, facioscapulohumeral (FSHD), myotonic, oculopharyngeal, distal, and Emery-Dreifuss. For example the antigen binding proteins described herein can be used to treat Duchenne, Becker or limb-girdle muscular dystrophies. Also, diffuse muscle atrophy rather than local atrophy may be 5 treated by the antigen binding proteins described herein. In particular, myotonic dystrophy may be treated by the antigen binding proteins described herein because of more focalized muscle atrophy/dysfunction and the role of skeletal/bone and cardiac issues in the disease.

10 Obesity is a condition in which excess body fat has accumulated to such an extent that health may be negatively affected. It is commonly defined as a body mass index (BMI = weight divided by height squared) of  $30 \text{ kg/m}^2$  or higher. This distinguishes obesity from overweight which is defined by a BMI of between  $25\text{--}29.9 \text{ kg/m}^2$ . Obesity can be associated with various diseases, including cardiovascular diseases, diabetes mellitus type 2, obstructive sleep apnea, cancer, and osteoarthritis. 15 As a result, obesity has been found to reduce life expectancy. Typical treatments for obesity include dieting, physical exercise and surgery. Obesity may be treated by the antigen binding proteins described herein which increase muscle mass and as a result can increase basal metabolic rates. For example, improved serum chemistries and insulin sensitivity may result from such treatment.

20 Typical aspects or symptoms of decreases in muscle mass, muscle strength, and muscle function include any one or any combination of general weakness, fatigue, reduction in physical activities, vulnerability to falls, functional disability, loss of autonomy, depression due to decreasing mobility, loss of appetite, malnutrition, and abnormal weight loss.

25 The disease may be associated with high levels of myostatin. The antigen binding proteins described herein can be used to modulate the level of myostatin and/or the activity of myostatin.

30 Multiple endpoints can be used to demonstrate changes in muscle mass, muscle strength, and muscle function. Such endpoints include the Short Physical Performance Battery, Leg Press, a directed quality of life survey, activities of daily living (ADLs), functional independence measure (FIM), functional tests and scales (e.g. walk test, stair climb, cycle ergometer), strength tests and scales (e.g. hand grip

test, manual muscle testing scales), bioimpedance analysis, electromyogram, dynamometer, dual-energy X-ray absorptiometry, computed tomography tests, magnetic resonance imaging, muscle biopsy, muscle histology, blood/biochemistry tests, anthropometry, skin thickness measurements, body mass index assessment, and 5 weight monitoring. Muscle strength can be assessed using bilateral limb muscles, neck muscles or abdominal muscles.

Short Physical Performance Battery (SPPB) is a multi-component measure of lower extremity function that is assessed by measures of standing balance, walking speed, and ability to rise from a chair, rated on a scale of 0-4. Walk test is an 10 assessment of lower extremity function that times how long it takes a patient to walk a certain distance. Leg Press measures leg strength using weights and assessment of force. Multiple scales and systems are used in the art to qualitatively assess a patient's quality of life. Dual-energy X-ray absorptiometry (DEXA) is a measure of estimated skeletal muscle mass.

15 A number of assays in animals can also be used to demonstrate changes in muscle mass and muscle strength, and muscle function. For example, the grip strength test measures an animal's strength when pulled against a grip strength meter. The inclined plane test measures an animal's ability to suspend itself. The swim test measures functional ability through a representative activity, for example swimming, 20 and is similar to the walk test in humans. The Hindlimb Exertion Force Test (HEFT) measures the maximum force exerted following applied tail stimulus. Other physical performance tests in animals include walking speed and wheel running. These tests/models can be used alone or in any combination.

25 A High Fat Diet (HFD) induced insulin resistance mouse model may be used as a model for obesity.

Glucocorticoids are commonly used in the treatment of a vast array of chronic inflammatory illnesses, such as systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, and bronchial asthma. However, administration of high doses of glucocorticoids causes muscle atrophy in human and animals. Similarly, 30 hypercortisolism plays a major role in muscle atrophy in Cushing's disease. Dexamethasone (dex)-induced muscle atrophy is associated with a dose-dependent marked induction of muscle myostatin mRNA and protein expression (Ma K, et al.

2003 Am J Physiol Endocrinol Metab 285:E363–E371). Increased myostatin expression has been also reported in several models of muscle atrophy such as immobilization and burn injuries, in which glucocorticoids play a major role (Lalani R, et al. 2000 J Endocrinol 167:417–428; Kawada S, et al. 2001 J Muscle Res Cell Motil 22:627–633; and Lang CH, et al. 2001 FASEB J 15:NIL323–NIL338). Therefore, a mouse model of glucocorticoid-induced muscle wasting may be used to study the antigen binding proteins of the invention.

Human disuse muscle atrophy commonly occurs in association with orthopedic disorders such as chronic osteoarthritis of a joint or cast immobilization for treatment of fracture as well as in situations of prolonged bed rest for other medical or surgical reasons. Disuse muscle atrophy results in reduced muscle strength and disability. Physical rehabilitation remains the only treatment option, and it is often required for long periods and does not always restore the muscle to normal size or strength. Therefore, a mouse model using sciatic nerve crush to induce muscle atrophy may be used to study the antigen binding proteins of the invention.

A significant portion of cancer patient suffers from weight loss due to progressive atrophy of adipose tissue and muscle wasting. It is estimated that about 20% of cancer deaths are caused by muscle loss. Muscle wasting is generally a good predictor of mortality in many diseases conditions. Data from research on AIDS, starvation and cancer indicate that loss of more than 30-40% of individual pre-illness lean body mass is fatal (DeWye WD.. In *Clinics in Oncology*. Edited by Calman KC and fearon KCH. London: Saunders, 1986, Vol. 5, no 2, p.251-261; Kotter DP, et al. 1990 J Parent Enteral Nutr 14:454-358; and Wigmore SJ, et al. 1997 Br J Cancer 75:106-109). Thus, the possible mitigation of muscle atrophy through the inhibition of signalling pathways involved in muscle wasting is very appealing. Therefore, a C-26 tumour bearing mouse model may be used to study the antigen binding proteins of the invention.

In the clinic, tenotomy refers to surgical transection of a tendon due to congenital and/or acquired deformations in the myotendinous unit, although loss of tendon continuity may also occur during trauma or degenerative musculoskeletal diseases. Tenotomy results in an immediate loss of resting tension, sarcomere shortening, and subsequent decreases in muscle mass and force generation capacity (Jamali et al. 2000 Muscle Nerve 23: 851–862). Therefore, a mouse tenotomy model

which induces skeletal muscle atrophy may be used to study the antigen binding proteins of the invention.

The antigen binding proteins described can be used for acute, chronic, and/or prophylactic therapy. Acute therapy can quickly build strength and bring the patient to an adequate level of functional ability that could then be maintained by exercise or chronic therapy. Chronic therapy could be used to maintain or slowly build muscle strength over time. Prophylactic therapy could be used to prevent the declines in muscle mass and strength that typically occur over time in the patient populations described. Improvement of muscle function is not always necessary to define successful treatment since early intervention in less severe muscle wasting requires only maintenance of muscle function.

The antigen binding proteins described may also have cosmetic uses for increasing muscle strength, mass and function. The antigen binding proteins described may also have uses during space flight and training exercises for astronauts.

The antigen binding proteins described may have a direct biological effect on muscle, such as skeletal muscle. Alternatively, the antigen binding proteins described may have an indirect biological effect on muscle, such as skeletal muscle.

For example, the antigen binding proteins may have an effect on one or more of muscle histology, muscle mass, muscle fibre number, muscle fibre size, muscle regeneration and muscle fibrosis. For example muscle mass may be increased. In particular, lean mass of a subject may be increased. The mass of any one or a combination of the following muscles: quadriceps, triceps, soleus, tibialis anterior (TA), and extensor digitorum longus (EDL); may be increased. The antigen binding proteins described may increase muscle fibre number and/or muscle fibre size. The antigen binding proteins described may enhance muscle regeneration and/or reduce muscle fibrosis. The antigen binding proteins described may increase the proliferation rate of myoblasts and/or activate myogenic differentiation. For example, the antigen binding proteins may increase the proliferation and/or differentiation of muscle precursor cells.

The antigen binding proteins described may have one or a combination of the following effects on satellite cells: activate, increase proliferation and promote self renewal. The antigen binding proteins described may modulate myostatin levels. The

antigen binding proteins described may increase body weight of the subject. The antigen binding proteins described may increase muscle contractility and/or improve muscle function. The antigen binding proteins may increase bone density.

The antigen binding proteins described herein may modulate the synthesis and/or catabolism of proteins involved in muscle growth, function and contractility. For example protein synthesis of muscle-related proteins such as myosin, dystrophin, myogenin may be upregulated by use of the antigen binding proteins described herein. For example protein catabolism of muscle-related proteins such as myosin, dystrophin, myogenin may be downregulated by use of the antigen binding proteins described herein.

10

### **Diagnostic methods of use**

The antigen binding proteins described herein may be used to detect myostatin in a biological sample *in vitro* or *in vivo* for diagnostic purposes. For example, the anti-myostatin antigen binding proteins can be used to detect myostatin in cultured cells, in a tissue or in serum. The tissue may have been first removed (for example a biopsy) from a human or animal body. Conventional immunoassays may be employed, including ELISA, Western blot, immunohistochemistry, or immunoprecipitation.

By correlating the presence or level of myostatin with a disease, one of skill in the art can diagnose the associated disease. Furthermore, detection of increased levels of myostatin in a subject may be indicative of a patient population that would be responsive to treatment with the antigen binding proteins described herein. Detection of a reduction in myostatin levels may be indicative of the biological effect of increased muscle strength, mass and function in subjects treated with the antigen binding proteins described herein.

20  
25

The antigen binding proteins may be provided in a diagnostic kit comprising one or more antigen binding proteins, a detectable label, and instructions for use of the kit. For convenience, the kit may comprise the reagents in predetermined amounts with instructions for use.

## Gene therapy

Nucleic acid molecules encoding the antigen binding proteins described herein may be administered to a subject in need thereof. The nucleic acid molecule may express the CDRs in an appropriate scaffold or domain, the variable domain, or the full length antibody. The nucleic acid molecule may be comprised in a vector which allows for expression in a human or animal cell. The nucleic acid molecule or vector may be formulated for administration with a pharmaceutically acceptable excipient and/or one or more therapeutically active agents as discussed above.

10

## EXAMPLES

### 1. GENERATION OF RECOMBINANT PROTEINS

#### 1.1 Purification of mature dimeric myostatin

The HexaHisGB1Tev/ (D76A) mouse myostatin polyprotein sequence (SEQ ID NO: 101) was expressed in a CHO secretion system. The GB1 tag (SEQ ID NO: 102) is described in WO2006/127682 and was found to enable the expression of myostatin at higher levels and enabled the proper folding of myostatin compared with constructs which used an Fc tag. The mouse polyprotein sequence (SEQ ID NO: 103) was used to generate the mature myostatin sequence (SEQ ID NO: 104) because the sequences of human and mouse mature myostatin are 100% identical. To reduce any potential degradation of myostatin, the mouse polyprotein sequence was engineered with a D76A mutation in the region “DVQRADSSD”.

The expressed HexaHisGB1Tev/ (D76A) mouse myostatin polyprotein, minus the signal sequence, was captured from the CHO medium using Ni-NTA agarose (Qiagen) in 50 mM Tris-HCl buffer, pH 8.0 with 0.5M NaCl. The Ni eluate was buffer exchanged into Furin cleavage buffer (50mM HEPES, pH 7.5, 0.1M NaCl, 0.1% Triton X-100, 1mM CaCl<sub>2</sub>), followed by cleavage by Furin (expressed in-house, sequence of Furin shown in SEQ ID NO: 105) at 1:25 V/V of Furin/protein ratio, overnight at room temperature. Furin cleaves polyprotein between the pro-peptide and mature myostatin (between “TPKRSRR” and “DFGLDCD”) to generate pro-peptide and mature myostatin.

The whole mixture of the Furin cleavage reaction was put into 6M Gdn-HCl to dissociate the aggregate. Mature myostatin was isolated from the mixture using C8

RP-HPLC (Vydac 208TP, Grace, Deerfield, IL, USA) at 60°C with 15-60% buffer B gradient in 40 minutes (C8 RP-HPLC buffer A: 0.1% TFA in H<sub>2</sub>O, buffer B: 0.1% TFA in 100% Acetonitrile). The fractions in the front of the peak, which contain mature myostatin, were pooled and used for subsequent *in vitro* assays. Figure 1  
5 shows the LC/MS analysis for mature myostatin and Figure 2 shows a NuPAGE gel with the reduced and non-reduced myostatin samples.

### 1.2 *In vitro* biological activity of recombinant myostatin

The myostatin responsive reporter gene assay (Thies et al., (2001) Growth Factors 18(4) 251-259) was used to assess *in vitro* activity of myostatin in  
10 Rhabdomyosarcoma cells (A204). A204 cells (LGC Promochem HTB-82) were grown in DMEM high glucose without phenol red (Invitrogen), 5% charcoal stripped FCS (Hyclone) and 1X Glutamax (Invitrogen). Cells were then trypsinised to generate a suspension and transfected with a pLG3 plasmid containing a luciferase gene under the control of 12x CAGA boxes of the PAI-1 promoter using Gemini transfection  
15 reagent (in-house reagent, described in patent WO2006/053782). Cells were seeded at 40,000 cells per well of a 96 well Fluoronunc Plate (VWR) and allowed to settle and grow overnight. The following day, recombinant mature myostatin, either R&D Systems myostatin (788-G8-010/CF) or in-house myostatin (as described above at 1.1), both having the sequence shown in SEQ ID NO: 104, was added to the medium  
20 of each well by serial dilution and cells were left to incubate for a further 6 hours prior to the addition of SteadyLite (Perkin Elmer LAS) which was incubated at room temperature for 20 minutes and read in a SpectraMax M5 reader (Molecular Devices). Dose response curves demonstrating myostatin activation of cell signalling, resulting in luciferase expression are shown in Figure 3A. It can clearly be seen that both the  
25 R&D Systems and in-house mature dimeric myostatin species activate A204 cells resulting in luciferase signal in a dose dependent manner. The in-house purified myostatin demonstrates a preferential lower background in the assay and improved dynamic range over the R&D Systems myostatin.

In an alternative method, A204 cells (LGC Promochem HTB-82) were grown  
30 in McCoys media (Invitrogen) and 10% heat inactivated FBS (Invitrogen). Cells were then detached with a 1:1 mixture of versene (Invitrogen) and TrypLE (Invitrogen) and resuspended in DMEM high glucose without phenol red, 5% charcoal-stripped serum

(Hyclone) and 2mM glutamax (Invitrogen) (Assay Media).  $14 \times 10^6$  cells were transfected by mixing 18.2 $\mu$ g of pLG3 plasmid - containing a luciferase gene under the control of 12x CAGA boxes of the PAI-1 promoter - with 182 $\mu$ l of 1mM Gemini transfection reagent (in-house reagent, described in patent WO2006/053782) in suspension. Cells were transferred into a T175 culture flask and incubated overnight. The following day, recombinant myostatin, either R&D Systems myostatin (788-G8-010/CF) or in-house myostatin (as described above at 1.1), was added to 96 well, black FluoroNUNC assay plate (VWR) either by serial dilution or at a constant concentration in the presence of a serial dilution of test antibody in a final volume of 20 $\mu$ l. Myostatin antibody mixtures were allowed to preincubate for 30 minutes. The transfected cells were detached from flasks with versene:TrypLE, resuspended in assay media at  $2.2 \times 10^5$  cells/ml and dispensed into the assay plate at 180 $\mu$ l/well. Plates were incubated for a further 6 hours prior to the addition of 50 $\mu$ l of SteadyLite reagent (Perkin Elmer LAS) which was incubated at room temperature for 20 minutes and read in a SpectraMax M5 reader (Molecular Devices). Dose response curves demonstrating mature dimeric myostatin activation of cell signalling, resulting in luciferase expression are shown in Figure 3B. The in-house myostatin species activates A204 cells resulting in luciferase signal in a dose dependent manner and reproducibly on different test occasions as represented by data obtained on different days.

## 2. GENERATION OF MONOCLONAL ANTIBODIES AND CHARACTERISATION OF MOUSE MONOCLONAL ANTIBODY 10B3

### 2.1 Monoclonal antibodies

SJL/J mice (Jackson Laboratories) were immunised by intraperitoneal injection each with mature myostatin (prepared as described above in Example 1.1). Before immunisation, the myostatin was conjugated to C. parvum and mice immunised with the conjugate (2.5  $\mu$ g myostatin conjugated to 10  $\mu$ g C.parvum) and a further 7.5  $\mu$ g of soluble myostatin. Spleen cells from the mice were removed and B lymphocytes fused with mouse myeloma cells derived from P3X63BCL2-13 cells (generated in-house, see Kilpatrick et al., 1997 Hybridoma 16(4) pages 381-389) in the presence of PEG1500 (Boehringer) to generate hybridomas. Individual hybridoma cell lines were cloned by limiting dilution (using the method described in E Harlow

and D Lane). Wells containing single colonies were identified microscopically and supernatants tested for activity.

Initially, hybridoma supernatants were screened for binding activity against recombinant myostatin in an FMAT sandwich assay format. A secondary screen of 5 these positives was completed using a BIAcore™ method to detect binding to recombinant myostatin (R&D Systems, 788-G8-010/CF) and in-house expressed purified myostatin (see 1.1 above).

Positives identified from the myostatin binding assay were subcloned by 10 limiting dilution to generate stable monoclonal cell lines. Immunoglobulins from these hybridomas, grown in cell factories under serum free conditions, were purified using immobilised Protein A columns. These purified monoclonal antibodies were then re-screened for myostatin binding by ELISA and BIAcore™.

Monoclonal antibody 10B3 was identified as a potent antibody that bound to recombinant myostatin.

15 2.2 Sequencing of monoclonal antibody 10B3 and cloning of the 10B3 chimera

Total RNA was extracted from the 10B3 hybridoma cells and the cDNA of the 20 heavy and light variable domains was produced by reverse transcription using primers specific for the leader sequence and the antibody constant regions according to the pre-determined isotype (IgG2a/κ). The cDNA of the variable heavy and light domains was then cloned into a plasmid for sequencing. The 10B3 V<sub>H</sub> region amino acid sequence is shown in SEQ ID NO: 7. The 10B3 V<sub>L</sub> region amino acid sequence is shown in SEQ ID NO: 8. The Kabat CDR sequences for 10B3 are shown in Table 3 and Table 4.

25 Table 3: Heavy chain CDR sequences

Antibody	CDR H1	CDR H2	CDR H3
10B3	GYFMH (SEQ ID NO: 1)	NIYPYNGVSYNQRFKA (SEQ ID NO: 2)	YYYYGTGPADWYFDV (SEQ ID NO: 3)

Table 4: Light chain CDR sequences

Antibody	CDR L1	CDR L2	CDR L3
10B3	KASQDINSYLS (SEQ ID NO: 4)	RANRLVD (SEQ ID NO: 5)	LQCDEFPLT (SEQ ID NO: 6)

5 A chimeric antibody was constructed by taking variable regions from the 10B3 murine monoclonal antibody (V<sub>H</sub>: SEQ ID NO: 7; V<sub>L</sub>: SEQ ID NO: 8) and grafting these on to human IgG1/k wild type constant regions. A signal sequence (as shown in SEQ ID NO: 9) was used in the construction of these constructs.

In brief, the cloned murine variable regions were amplified by PCR to introduce restriction sites required for cloning into mammalian expression vectors (Rld\_Ef1 and Rln\_Ef1). Hind III and Spe I sites were designed to frame the V<sub>H</sub> domain and allow cloning into a vector (Rld\_Ef1) containing the human  $\gamma$ 1 wild type constant region. Hind III and BsiW I sites were designed to frame the V<sub>L</sub> domain and allow cloning into a vector (Rln\_Ef1) containing the human  $\kappa$  constant region. Clones with the correct V<sub>H</sub> (SEQ ID NO: 25) and V<sub>L</sub> (SEQ ID NO: 8) sequences were 10 identified and plasmids prepared (using standard molecular biology techniques) for expression in CHOK1 cell supernatants. Antibodies were purified from the cell supernatant using immobilised Protein A columns and quantified by reading the absorbance at 280nm.

15

The resulting chimeric antibody was termed 10B3 chimera (10B3C or HCLC). 20 The 10B3 chimeric antibody has a heavy chain amino acid sequence as set out in SEQ ID NO: 26. The 10B3 chimeric antibody has a light amino acid sequence as set out in SEQ ID NO: 27.

### 2.3 Binding to recombinant myostatin

10B3 and 10B3 chimera (10B3C) bound myostatin (R&D Systems, 788-G8-25 010/CF) in a sandwich ELISA. Plates were coated with myostatin at 10ng/well and blocked with Block solution (PBS, 0.1% TWEEN and 1% BSA). Following washing (PBS, 0.1% TWEEN), antibody was incubated at 37°C for 2 hours over a dilution series and plates washed again prior to incubation at 37°C for 1 hour with anti-mouse HRP or anti-human HRP (Dako, P0161 & Sigma, A-8400, respectively). Plates were

again washed and OPD substrate (Sigma, P9187) added until colourometric reaction occurred and the reaction stopped by the addition of H<sub>2</sub>SO<sub>4</sub>. Plates were read at an absorbance of 490 nm and EC50 determined (see Table 5).

5 Table 5. EC50 of parental 10B3 and chimeric 10B3 antibodies

Antibody	Mean EC50 (ng/ml)	95% confidence levels (ng/ml)
10B3	69	46 - 102
10B3 Chimera	49	33 - 73

The affinity of 10B3 mouse parental and 10B3C for recombinant myostatin was assessed by BIACore™ (surface plasmon resonance) analysis. Analysis was carried out by the use of a capture surface: anti-mouse IgG was coupled to a C1 chip 10 by primary amine coupling for 10B3 mouse parental; and a protein A surface was created on a C1 chip by primary amine coupling for 10B3 chimera.

After capture, recombinant myostatin was passed over the surface at 64nM, 16nM, 4nM, 1nM, 0.25nM and 0.0625nM, with a buffer injection (i.e. 0nM) used for double referencing. There was a regeneration step between each analyte injection, 15 after which the new antibody capture event occurred before the next injection of myostatin. The data was analysed using both the 1:1 model and the Bivalent model inherent to the T100 machines analysis software (see Table 6). Both capture surfaces could be regenerated using 100mM phosphoric acid, the work was carried out using HBS-EP as the running buffer and using 25°C as the analysis temperature.

20 Table 6. T100 data for parental 10B3 and chimeric 10B3 binding to myostatin

Kinetic Model	Equilibrium Constant (KD) for 10B3 Chimera	Equilibrium Constant (KD) for 10B3 Mouse Parental
All Curves 1:1 Model	88pM	1nM
All Curves Bivalent Model	3.6nM	5.9nM

To further analyse the binding capability of 10B3, ELISA based assays were undertaken to determine whether binding was specific for pure mature myostatin or if

binding could still occur with other myostatin antigens including latent complex, and mature myostatin released from latent complex following BMP-1 cleavage between Arg 75 and Asp 76 of the myostatin pro-peptide (Wolfman *et al* (2003) PNAS 100: pages 15842-15846).

5 Purification of human myostatin pro-peptide was carried out using a HexaHisGB1Tev/Human Myostatin pro-peptide sequence (SEQ ID NO: 106). This sequence was expressed in the CHO secretion system, and expressed protein was captured by Ni-NTA (GE Healthcare, NJ) from the CHO medium. The HexaHisGB1tag was cleaved by Tev protease (expressed in-house, sequence shown in  
10 SEQ ID NO: 107). Tev protease cleaves between the tag and the pro-peptide (between “ENLYFQ” and “ENSEQK”) of SEQ ID NO: 106 to yield the sequence of SEQ ID NO: 108.

15 The cleaved tag and non-cleaved hexaHisGB1Tev/Human Myostatin polyprotein were captured on Ni-NTA in the presence of 6M Guanidine HCL, with the tag cleaved human myostatin polyprotein in the unbound flowthrough. The flowthrough was applied on Superdex 200 column (GE Healthcare, NJ) in 1xPBS buffer and the aggregated, dimer and monomer forms were separated on the column. The human myostatin pro-peptide (SEQ ID NO: 108) dimer form was used in latent complex formation.

20 Myostatin latent complex was prepared by mixture of the purified human myostatin pro-peptide (SEQ ID NO: 108) and mature myostatin (SEQ ID NO: 104) in 6M Guanidine HCl at 3:1(w/w) ratio for 2 hours at room temperature, followed by dialysis into 1xPBS overnight at 4°C, and loaded onto Superdex 200 (GE Healthcare, NJ) in 1xPBS buffer. The fractions in the peak which contained both myostatin pro-peptide and mature myostatin were pooled. The latent complex was confirmed by both LC/MS and SDS-PAGE (data not shown). For the BMP-1 digestion, 150µl of human myostatin latent complex (1.5mg/ml) was incubated with 225µl of BMP-1 (0.217mg/ml), 75µl of 25mM HEPES (pH 7.5) and 150µl of: 20mM CaCl<sub>2</sub>, 4µM ZnCl<sub>2</sub> and 0.04% Brij 35. The reaction was incubated at 30°C overnight. BMP-1  
25 protein was expressed in-house (sequence shown in SEQ ID NO: 111) using a CHO secretion system.

30

The myostatin antigens were coated onto wells of an EIA/RIA plate (Costar) at 100ng/well at 4°C overnight in PBS, prior to blocking (PBS, 3% BSA) for 30 minutes at room temperature. Plates were washed (PBS, 1% BSA and 0.1% Tween20), prior to the addition of a dilution series of 10B3 in wash buffer and 5 incubation for 2 hours at room temperature. Plates were again washed prior to addition of peroxidase-conjugated Affinipure F(ab')2 fragment donkey anti-mouse IgG (Jackson Laboratories cat 715-036-151) diluted 1:10,000 in wash buffer and incubated for 1 hour at room temperature. A final wash step preceded addition of 10 TMB substrate and colorimetric change which was stopped with Sulphuric acid and plates read at 450nm. Figure 4 shows that 10B3 is able to bind mature dimeric myostatin, latent complex (tetramer), and myostatin released from the latent complex following BMP-1 cleavage. It was also found that 10B3 does not bind to the pro-peptide dimer (data not shown).

#### 2.4 Crude mapping of the 10B3 binding epitope on myostatin

15 Biotinylated 14 mer peptides overlapping by 10 amino acids (offset by 4 amino acids) were synthesised based on the myostatin amino acid sequence to map the location of the binding epitope recognised by 10B3 (supplied by Mimotopes, Australia).

20 Work was carried out on an SRU BIND reader (SRU Biosystems). A streptavidin biosensor plate was washed, a baseline reading taken, and biotinylated peptides captured onto the streptavidin coated biosensor plate. The plate was washed again, and a new baseline reading taken, antibody was then added and binding monitored.

25 The details of the 14 mer custom designed artificial peptide sequences, overlapping by 10 amino acids (offset by 4 amino acids) are provided in Table 7.

Table 7: myostatin artificial peptides

Peptide No	NTerm	Sequence	CTerm	Hydro	MWt
1	H-	DFGLDCDEHSTESRGSG (SEQ ID NO: 56)	-NH2	-0.045	2164.84
3	Biotin-	SGSGDCDEHSTESRCCRY (SEQ ID NO: 57)	-NH2	0.118	2217.09
5	Biotin-	S GSGHSTESRCCRYPLTV (SEQ ID NO: 58)	-NH2	0.346	2165.17
7	Biotin-	S GSGSRCRYPLTVDFEA	-NH2	0.394	2173.18

		(SEQ ID NO: 59)			
9	Biotin-	SGSGRYPLTVDFEAFCGWD (SEQ ID NO: 60)	-NH2	0.456	2229.16
11	Biotin-	SGSGTVDFEAFCGWDWIIA (SEQ ID NO: 61)	-NH2	0.646	2183.13
13	Biotin-	SGSGEAFGWDWIIAPKRY (SEQ ID NO: 62)	-NH2	0.505	2265.28
15	Biotin-	SGSGWDWIIAPKRYKANY (SEQ ID NO: 63)	-NH2	0.416	2337.39
17	Biotin-	SGSGIAPKRYKANYCSGE (SEQ ID NO: 64)	-NH2	0.183	2113.11
19	Biotin-	SGSGRYKANYCSGECEFV (SEQ ID NO: 65)	-NH2	0.286	2182.15
21	Biotin-	SGSGNYCSGECEFVFLQK (SEQ ID NO: 66)	-NH2	0.436	2180.17
23	Biotin-	SGSGGECEFVFLQKYPHT (SEQ ID NO: 67)	-NH2	0.447	2211.21
25	Biotin-	SGSGFVFLQKYPHTHLVH (SEQ ID NO: 68)	-NH2	0.593	2279.36
27	Biotin-	SGSGQKYPHTHLVHQANP (SEQ ID NO: 69)	-NH2	0.279	2183.14
29	Biotin-	SGSGHTHLHVHQANPRGSA (SEQ ID NO: 70)	-NH2	0.218	2037.94
31	Biotin-	SGSGVHQANPRGSAGPCC (SEQ ID NO: 71)	-NH2	0.297	1909.85
33	Biotin-	SGSGNPRGSAGPCCTPTK (SEQ ID NO: 72)	-NH2	0.238	1901.87
35	Biotin-	SGSGSAGPCCTPTKMSPI (SEQ ID NO: 73)	-NH2	0.468	1905.96
37	Biotin-	SGSGCCTPTKMSPINMLY (SEQ ID NO: 74)	-NH2	0.582	2115.27
39	Biotin-	SGSGTKMSPINMLYFNGK (SEQ ID NO: 75)	-NH2	0.39	2157.27
41	Biotin-	SGSGPINMLYFNGKEQII (SEQ ID NO: 76)	-NH2	0.504	2193.28
43	Biotin-	SGSGLYFNGKEQIIYGKI (SEQ ID NO: 77)	-NH2	0.434	2199.26
45	Biotin-	SGSGGKEQIIYGKIPAMV (SEQ ID NO: 78)	-NH2	0.416	2060.17
47	Biotin-	SGSGIIYGKIPAMVVDRC (SEQ ID NO: 79)	-NH2	0.558	2091.25
49	Biotin-	SGSGGKIPAMVVDRCGCS (SEQ ID NO: 80)	-OH	0.396	1950.02

Analysis of the 14 mer peptide binding data demonstrated that 10B3 was unable to bind any linear epitope within myostatin. Control anti-myostatin antibodies however, were shown to bind epitopes within the peptide set (data not shown).

5 Subsequent analysis of the myostatin binding site of 10B3C using Pepscan, Chemically Linked Immunogenic Peptides on Scaffolds (CLIPS) technology, suggest that the “PRGSAGPCCTPTKMS” amino acid sequence of myostatin may be the binding site for the chimeric antibody (data not shown).

## 2.5 Neutralisation of myostatin ActRIIb receptor binding

Recombinant soluble ActRIIb (R&D Systems 339-RBB) was coated in wells of an ELISA plate at 1 $\mu$ g/ml in carbonate buffer overnight at 4°C. Plates were blocked (see Block solution above at 2.3) and washed following standard ELISA protocols. In parallel, 2nM biotinylated myostatin (in-house, as described in 1.1, biotinylated material) was pre-incubated with an antibody dilution series consisting of 10B3, 10B3C, and a negative control (IgG1 isotype control) for 2 hours at 37°C. The biotinylated myostatin:antibody reactions were then added to the ActRIIb coated plate for 1 hour at 37°C. Standard wash procedures were followed prior to addition of 1:1000 diluted streptavidin-HRP conjugate (Dako P0397) and a further 37°C incubation for 1 hour. Plates were again washed and assayed at absorbance 490nm following OPD substrate (Sigma) and acid stop solution treatment. Inhibition curves and IC50 values for the inhibition of myostatin activity are shown in Figure 5 and Table 8 respectively.

15

Table 8. IC50 of ActRIIb receptor neutralisation

Antibody	Mean IC50 (ng/ml)	95% confidence levels (ng/ml)
10B3	132	99 - 176
10B3 Chimera	138	97 - 196

The receptor neutralisation assay is the most sensitive method available for differentiating molecules with IC50s lower than 1nM on the basis of potency. It is, however, itself sensitive to the precise concentration of binding-competent biotinylated myostatin. Hence on different occasions other IC50 values have been determined for 10B3 using the same methodology, for example 0.13nM, 0.108nM, 0.109nM, or 0.384 nM (note that in Table 8, 132ng/ml = 0.88nM).

## 2.6 Inhibition of biological activity of myostatin *in vitro*

The myostatin responsive reporter gene assay, described above at 1.2, was used to assess the *in vitro* effect of anti-myostatin antibodies on the activity of myostatin. The assay was modified so that myostatin at a concentration of 2.8nM

(equivalent to ED70 in cell activation assays) was pre-incubated with varying concentrations of 10B3 or 10B3C antibody (0.1-20nM) at 37°C prior to addition to transfected A204 cells. Luciferase readouts were performed, from which the inhibition curves shown in Figure 6 were generated. Table 9 shows the IC50 values 5 determined for the antibodies following 3 repeats of the assay and ANOVA analysis. The data clearly demonstrate a dose dependant inhibition of myostatin activation of the A204 muscle cell line, whereas the control antibody showed no inhibition of myostatin activity.

10 Table 9. IC50 of in vitro myostatin responsive reporter gene assay (A204 cells)

Antibody	Mean IC50 (nM)	95% confidence levels (nM)
10B3	10.0	6.5 – 15.5
10B3 Chimera	6.2	3.9 – 9.9

### 2.7 In vivo efficacy of 10B3

To demonstrate efficacy of parental 10B3, a 35 day study in 8 week old female 15 CB17 SCID mice was undertaken for 5 weeks. Treatment groups (10 animals per group) were dosed on days 1, 4, 8, 15, 22, and 29 by intraperitoneal injection with either, 3, 10 or 30mg/kg 10B3, whilst control groups received either PBS or isotype control antibody (IgG2a). Upon completion of the study, total body weight (A) and total lean muscle mass (B) of animals were determined by weighing animals and 20 QMRI analysis respectively (Figure 7). Upon culling of animals (day 35) individual muscles (gastrocnemius (A), quadriceps (B), and extensor digitorum longus (EDL) (C)) were dissected from animals for mass determination (Figure 8). To determine effects on muscle function *ex vivo* contractility testing was performed on EDL muscles (Figure 9), in which tetanic force was determined for muscle (Figure 9A) and 25 the tetanic force per milligram of muscle mass (Figure 9B).

A clear dose dependant response to 10B3 was observed in the treatment groups with the 30mg/kg dose representing the most significant improvement in body weight and lean muscle mass (8% and 8.5%, respectively) following the 35 day study. Analysis of muscle mass demonstrated the same trend with the gastrocnemius,

quadriceps and EDL all showing dose dependant increases in mass, again with the 30mg/kg dosing groups showing greatest significance.

Also, studies (not described) have demonstrated that significant improvement in grip strength can not be seen at an early time point such as 35 days. However, the 5 *ex vivo* contractility testing demonstrates that significant improvement can be demonstrated in tetanic force measures of the EDL. Furthermore the improvement was demonstrated to be independent of muscle mass. Thus 10B3 exhibits the ability to improve the function of existing muscle mass.

### 3. HUMANISATION OF 10B3

#### 10 3.1 Sequence analysis

A comparison was made between the sequences of the 10B3 variable regions and other murine and human immunoglobulin sequences. This was done using the FASTA and BLAST programs and by visual inspection.

15 A suitable human acceptor framework for the 10B3 V<sub>H</sub> was identified (IGHV1\_18 and the JH3 human J segment sequence): SEQ ID NO: 10. A suitable human acceptor framework for the 10B3 V<sub>L</sub> was identified (IGKV1\_16 and the JK2 human J segment sequence): SEQ ID NO: 11. In SEQ ID NO: 10, CDRH1 and CDRH2 of the acceptor framework are present, and CDRH3 is represented by XXXXXXXXXX. In SEQ ID NO: 11, CDRL1 and CDRL2 of the acceptor framework are present, and CDRL3 is represented by XXXXXXXXXX. (The 10 X residues are a placeholder for the location of the CDR, and is not a measure of the 20 number of amino acid sequences in each CDR).

25 In CDR grafting, it is typical to require one or more framework residues from the donor antibody to be included in place of their orthologues in the acceptor frameworks in order to obtain satisfactory binding. The following murine framework residues in 10B3 were identified as being potentially important in the design of a CDR-grafted (humanised) version of the antibody (position is according to the Kabat *et al* numbering convention):

30	<u>Position (Kabat)</u>	<u>mouse 10B3 V<sub>H</sub></u>	<u>Human V<sub>H</sub></u>
	28	S	T
	105	T	Q

<u>Position (Kabat)</u>	<u>mouse 10B3 V<sub>L</sub></u>	<u>Human V<sub>L</sub></u>
16	R	G
71	Y	F
5 100	A	Q

Three humanised V<sub>H</sub> constructs with different back-mutations were designed to obtain a humanised antibody with satisfactory activity. These are numbered H0 to H2. H0 (SEQ ID NO: 12) consists of a CDR graft of the 10B3 V<sub>H</sub> CDRs into the specified acceptor sequence, using the Kabat definition of CDRs. H1 (SEQ ID NO: 13) is identical to H0, but with a back-mutation where the amino acid at position 105 is threonine instead of glutamine. H2 (SEQ ID NO: 14) is identical to H0, but with a back-mutation where the amino acid at position 28 is serine instead of threonine.

Note that for all humanised V<sub>H</sub> regions (and corresponding heavy chains), the sequence of framework 4 (WGQGTMVTVSS) has been modified, whereby the methionine amino acid residue (Kabat position 108) has been substituted for a leucine amino acid residue. This results from the inclusion of a Spe1 cloning site in the DNA sequences encoding the humanised V<sub>H</sub> regions.

Four humanised V<sub>L</sub> constructs with different back-mutations were designed to obtain a humanised antibody with satisfactory activity. These are numbered L0 to L3. L0 (SEQ ID NO: 15) consists of a CDR graft of the 10B3 V<sub>L</sub> CDRs into the specified acceptor sequence, using the Kabat definition of CDRs. L1 (SEQ ID NO: 16) is identical to L0, but with a back-mutation where the amino acid at position 16 is arginine in place of glycine. L2 (SEQ ID NO: 17) is identical to L0, but with a back-mutation where the amino acid at position 71 is tyrosine in place of phenylalanine. L3 (SEQ ID NO: 18) is identical to L0, but with a back-mutation where the amino acid at position 100 is alanine in place of glutamine.

### 3.2 Humanisation of 10B3

Humanised V<sub>H</sub> and V<sub>L</sub> constructs were prepared by *de novo* build up of overlapping oligonucleotides including restriction sites for cloning into Rld Efl and Rln Efl mammalian expression vectors as well as a signal sequence. Hind III and Spe I restriction sites were introduced to frame the V<sub>H</sub> domain containing the signal sequence (SEQ ID NO: 9) for cloning into Rld Efl containing the human IgG1 wild

type constant region. Hind III and BsiW I restriction sites were introduced to frame the  $V_L$  domain containing the signal sequence (SEQ ID NO: 9) for cloning into Rln Efl containing the human kappa constant region. This is essentially as described in WO 2004/014953.

5 4. EXPRESSION AND CHARACTERISATION OF HUMANISED ANTIBODIES

4.1 Preparation of antibodies

Humanised  $V_H$  constructs (H0, H1 and H2) and humanised  $V_L$  constructs (L0, L1, L2 and L3) were prepared in Rld\_Efl and Rln\_Efl mammalian expression vectors. Plasmid heavy chain-light chain combinations (H0L0, H0L1, H0L2, H0L3, 10 H1L0, H1L1, H1L2, H1L3, H2L0, H2L1, H2L2, H2L3) were transiently co-transfected into CHOK1 cells and expressed at small scale to give twelve different humanised antibodies.

The plasmids for each antibody were transfected into CHOK1 cells in duplicate and in two separate experiments. In addition, 10B3 chimera was expressed 15 as a positive control. Antibodies produced in the CHOK1 cell supernatant were analysed for activity in the myostatin binding ELISA (see 4.2). The ELISA data for just one experiment are illustrated in the graph in Figure 10A. All twelve humanised mAbs show binding to recombinant myostatin in this ELISA. Across both experiments, the mAbs containing the H2 or L2 chains tended to have better binding 20 activity for myostatin which was similar to that observed for 10B3 chimera.

Figure 10B is derived from Figure 10A and displays antibodies containing the H2 and/or L2 chains and 10B3 chimera.

H0L0, H1L2 and H2L2 were selected for larger scale expression, purification and further analysis.

25 Purified H0L0, H1L2 and H2L2 bound recombinant myostatin by direct ELISA. The method was carried out as described in 4.2 and the ELISA data are illustrated in the graph in Figure 11. H2L2 and H0L0 were generated in both CHOE1a and CHOK1 cell expression systems. The low concentration of the antibodies obtained from the CHOK1 preparation made accurate quantification difficult. High 30 concentrations of purified antibodies were obtained from the CHOE1a preparation. 10B3 chimeric antibody was included in the ELISA as a positive control (this material

was made in CHO1a). H2L2 binding activity for myostatin was equivalent to 10B3 chimera and better than that observed for H0L0.

#### 4.2 Myostatin binding ELISA

The myostatin binding ELISA was carried out approximately according to this protocol. A 96-well ELISA plate was coated at 4°C overnight with 10ng/well recombinant myostatin. This plate was then washed 3-times in wash buffer (PBS, 0.1% Tween-20). The wells were blocked for 1 hour at room temperature with block solution (PBS, 0.1% Tween-20 + 1% bovine serum albumin [BSA]), before washing 3-times in wash buffer. Antibodies were then titrated out to a suitable concentration range (approximately 100 to 0.001 µg/ml), added to the plate and incubated for 1 hour at room temperature. The plate was then washed 3-times in wash buffer. An anti-mouse IgG HRP-conjugated antibody (P0260 by Dako, this reagent was used according to the manufacturer's instructions) was used to detect binding of mouse antibodies, such as 10B3. An anti-human kappa light chain HRP-conjugated antibody (A7164 by Sigma Aldridge, this reagent was used according to the manufacturer's instructions) was used to detect binding of humanized or chimeric antibodies, such as 10B3 chimera or H0L0. The plate was then washed 3-times in wash buffer and developed with an OPD substrate (from Sigma, used according to the manufacturer's instructions) and read at 490nm on a plate reader.

#### 20 4.3 Binding to recombinant myostatin by BIAcore™

Purified H0L0, H1L2 and H2L2 bound recombinant myostatin by BIAcore™. Recombinant myostatin was immobilised at three different densities (low, medium and high, to give R-max values of approximately 35, 120 and 350 RU's respectively) onto a BIAcore™ chip. Antibodies were passed over at 256, 64, 16, 4 and 1nM. 0nM antibody was used for double referencing and data was fitted to the 1:1 model.

There are a number of caveats that are applicable to data generated from this assay; immobilising myostatin onto the chip surface may cause a conformation change in the protein, or it may obscure the antibody binding epitope on the protein, and will lead to a heterogeneous surface (possibly generating multiple binding events). Low density immobilisation of myostatin should give 1:1 binding (predominantly), medium and high density immobilisation of myostatin are likely to

be affected by bivalent (avidity) binding events. The correct antibody concentration is essential for the determination of accurate values in this assay.

Therefore data generated using the BIAcore™ is generally to be used to rank constructs, rather than to provide definitive kinetics. The BIAcore™ data are 5 illustrated in Tables 10 to 12.

Table 10: BIAcore™ analysis of 10B3 chimera, H0L0, H1L2 and H2L2 binding to a low density myostatin surface

Construct	On-rate, $ka$ ( $Ms^{-1}$ )	Off-rate, $kd$ ( $s^{-1}$ )	Binding affinity, KD (nM)
10B3 chimera	$5.987 \times 10^5$	$9.668 \times 10^{-4}$	1.615
H0L0	$8.012 \times 10^5$	$6.615 \times 10^{-3}$	8.255
H1L2	$2.205 \times 10^5$	$3.324 \times 10^{-3}$	15.08
H2L2	$3.206 \times 10^5$	$2.682 \times 10^{-3}$	8.366

Note: dissociation phase shortened to approximately 250 seconds for the analysis, to improve curve fitting

10

Table 11: BIAcore™ analysis of 10B3 chimera, H0L0, H1L2 and H2L2 binding to a medium density myostatin surface.

Construct	On-rate, $ka$ ( $Ms^{-1}$ )	Off-rate, $kd$ ( $s^{-1}$ )	Binding affinity, KD (nM)
10B3 chimera	$4.129 \times 10^5$	$5.593 \times 10^{-4}$	1.355
H0L0	$2.575 \times 10^5$	$9.301 \times 10^{-4}$	3.612
H1L2	$1.369 \times 10^5$	$6.932 \times 10^{-4}$	5.064
H2L2	$2.456 \times 10^5$	$7.368 \times 10^{-4}$	3.000

Note: curve fits were generally poor

15

Table 12: BIAcore™ analysis of 10B3 chimera, H0L0, H1L2 and H2L2 binding to a high density myostatin surface.

Construct	On-rate, $ka$ ( $Ms^{-1}$ )	Off-rate, $kd$ ( $s^{-1}$ )	Binding affinity, KD (nM)
10B3 chimera	$2.478 \times 10^5$	$2.185 \times 10^{-4}$	0.882
H0L0	$1.463 \times 10^5$	$3.375 \times 10^{-4}$	2.307
H1L2	$9.224 \times 10^4$	$2.232 \times 10^{-4}$	2.420
H2L2	$1.473 \times 10^5$	$2.160 \times 10^{-4}$	1.467

Note: curve fits were generally poor

These data indicate that binding affinity improves with the increase in myostatin surface density on the BIAcore™ chip, which is likely to be due to avidity binding. However, rank order stays approximately the same and is independent of the surface used to measure affinity (rank order of binding affinity = 10B3 chimera > 5 H2L2 > H0L0 > H1L2). These data are in broad agreement with the myostatin ELISA data.

#### 4.4 Neutralisation of recombinant myostatin in a reporter cell bioassay

Humanised antibodies were tested in the myostatin responsive reporter gene assay, described above (1.2), to assess *in vitro* efficacy. Myostatin at a concentration 10 of 2.8nM was pre-incubated with varying concentrations of antibody (0.1-20nM) at 37°C prior to addition to transfected A204 cells and subsequent luciferase readout. The resulting data are shown in Figure 12 and the determined IC50s (ANOVA analysis) are shown in Table 13.

15 Table 13. IC50 of humanised antibodies in A204 *in vitro* activity assay

Antibody	Mean IC50 (nM)	95% confidence levels (nM)
10B3	8.5	7.2 – 10.1
10B3 Chimera	5.1	4.2 – 6.1
H0L0	10.2	7.9 – 13.1
H2L2	8.6	6.8 – 10.7

20 The humanised antibodies inhibit myostatin-induced activation of A204 cells, however, compared to the chimeric 10B3 some loss in activity has been observed, possibly due to the effects of the human framework region. Losses in activity are minimal however and are certainly within 2 fold in the assay.

#### 5. DEVELOPABILITY ANALYSIS OF THE HUMANISED ANTIBODIES

In silico analysis for potential deamidation sites in both the heavy and light chains of 10B3 chimera and the humanised antibodies identified asparagine at Kabat position 54 (N54) in heavy chain CDRH2 as having a high potential for deamidation.

In order to characterise this residue further, we generated 10B3 chimeric antibodies and humanised H2L2 antibodies where N54 was substituted for aspartate (D) or glutamine (Q) amino acid residues.

The light chain of 10B3 chimera and the humanised antibodies have a cysteine (C) residue at Kabat position 91 in CDRL3. Unpaired cysteines can be chemically reactive leading to modifications during antibody process development, resulting in possible heterogeneity of product and potential variations in affinity. In addition this residue might be able to promote misfolding or aggregation due to mis-pairing with other cysteines in the variable regions which are essential for making the immunoglobulin fold. In order to characterise this residue further, we generated 10B3 chimeric antibodies and humanised H2L2 antibodies where C91 was substituted for a serine (S) amino acid residue.

In addition, we also combined the deamidation substitutions made in heavy chain CDRH2 with the substitution at position 91 in light chain CDRL3. The antibodies generated as part of these analyses are illustrated in Table 14.

Table 14: Humanised antibody variants generated for developability analysis

Antibody molecule name	Heavy chain variable region: SEQ ID NO:	Light chain variable region: SEQ ID NO:
10B3 chimera N54D (HCLC-N54D)	19	8
10B3 chimera N54Q (HCLC-N54Q)	20	8
10B3 chimera N54D & C91S (HCLC-N54D-C91S)	19	21
10B3 chimera N54Q & C91S (HCLC-N54Q-C91S)	20	21
10B3 chimera C91S (HCLC-C91S)	25	21
H2L2 N54D (H2L2-N54D)	22	17
H2L2 N54Q (H2L2-N54Q)	23	17
H2L2 N54D & C91S (H2L2-N54D-C91S)	22	24
H2L2 N54Q & C91S (H2L2-N54Q-C91S)	23	24
H2L2 C91S (H2L2-C91S)	14	24

20 5.1 Expression and characterisation of the developability variants

The heavy and light chain constructs necessary to express these antibodies were prepared by site directed mutagenesis of the relevant H2 heavy chain and L2 light chain expression vectors. Plasmid heavy chain-light chain combinations (H2L2-N54D; H2L2-N54Q; H2L2-N54D-C91S; H2L2-N54Q-C91S; H2L2-C91S) were

transiently co-transfected into CHO cells and expressed at small scale to give five different humanised antibodies. In addition, 10B3 chimera (HCLC) and H2L2 were expressed as positive controls.

The plasmids for each antibody were transfected into CHOK1 cells in 5 duplicate and in two separate experiments. Antibodies produced in the CHOK1 cell supernatant were analysed for activity in the myostatin binding ELISA. The ELISA method was carried out as described in 4.2 and the ELISA data for just one experiment are illustrated in the graph in Figure 13. H2L2 mAbs containing the N54Q and / or the C91S substitution showed binding to recombinant myostatin in this 10 ELISA, and this binding was approximately equivalent to 10B3 chimera (HCLC) or H2L2 respectively. 10B3 chimera and H2L2 mAbs containing the N54D substitution alone (or in combination with the C91S substitution) did not bind to recombinant myostatin in this ELISA.

H2L2-N54Q, H2L2-C91S, and H2L2-N54Q C91S were selected for larger 15 scale expression (in both CHOK1 and CHOE1a expression systems), purification and further analysis. These antibodies were analysed for activity in the myostatin binding ELISA. The ELISA method was carried out as described in section 4.2 and the ELISA data for just one experiment (from a total of three) are illustrated in the graph in Figure 14. H2L2 C91S appeared to have similar binding activity to myostatin as 10B3 20 chimera, H0L0 and H2L2. However, H2L2 N54Q and H2L2 N54Q C91S appeared to have reduced binding activity for myostatin.

Developability constructs were also tested to determine any changes in myostatin binding affinity by BIACore using similar methods described above at 4.3 (see Table 15). The data (for low density surface) demonstrate that substitution of the 25 predicted deamidation site (N54Q) results in at least a 2 fold loss in affinity in the H2L2 humanised variant.

Table 15. Kinetics of myostatin binding of myostatin developability variants

Construct	ka	kd	KD (nM)
10B3 Chimera (HCLC)	3.323E+5	1.477E-3	4.44
H2L2	3.113E+5	3.735E-3	12.0
H0L0	1.922E+5	4.363E-3	22.7
H2L2-C91S	1.903E+5	3.153E-3	16.6
H2L2-N54Q	1.590E+5	4.447E-3	28.0
H2L2-N54Q-C91S	1.389E+5	4.623E-3	33.3

The affinity of 10B3 mouse parental and H2L2-C91S developability variant for recombinant myostatin was also assessed by FORTEbio™ (bio-layer inferometry) analysis. FORTEbio™ analyses were carried out by antigen capture. Myostatin (in-house, see above at 1.1) was coupled onto amine reactive biosensors by primary amine coupling in accordance with the manufacturer's instructions. Antibodies were then captured onto this surface at 20nM concentrations. The data was analysed using the evaluation software inherent in the machine and the data analysed using 1:1 fit (see Table 16). Due to the limited number of myostatin molecules bound to the sensor surface and the low antibody concentration, avidity effects are reduced, enabling a more accurate measure of affinity compared to the Biacore analyses. The data show that the parental antibody (10B3) has an affinity of 310pM whilst the developability variant H2L2-C91S has an affinity of 73pM. However, due to the nature of the binding of the antibodies to myostatin, these values are mainly used for ranking purposes, and the affinity may not be representative of the affinity *in vivo*.

Table 16. Affinity of 10B3 parental and H2L2-C91S developability variant for myostatin

20

Antibody	Molar Conc [M]	k <sub>d</sub> [1/s]	k <sub>a</sub> [1/Ms]	K <sub>D</sub> [M]	Assoc R <sup>2</sup>
10B3 parental	2E-8	1.31E-4	4.24E5	3.10E-10	0.9981
H2L2-C91S	2E-8	2.99E-5	4.10E5	7.30E-11	0.99652

The effect of developability mutations on *in vitro* neutralisation assays was also undertaken using the A204 luciferase assay described above at 1.2. A graphical representation of inhibition curves is shown in Figure 15 and corresponding IC50 values are presented in Table 17. The humanised variants have lost no apparent 5 neutralisation potency relative to developability variants according to this assay.

Table 17. IC50 of developability antibody variants in A204 *in vitro* activity assay

Antibody	Mean IC50 (nM)	95% confidence levels (nM)
10B3 Chimera	8.45	5.36 – 13.31
H0L0	10.07	5.74 – 17.65
H2L2	10.14	5.87 – 17.49
H2L2-C91S	9.26	5.17 – 16.62
H2L2-N54Q	11.98	6.35 – 22.59
H2L2-N54Q-C91S	10.42	5.99 – 18.11

10 5.2 Deamidation potential of the developability variants

H0L0, H2L2, H2L2-C91S, H2L2-N54Q and H2L2-N54Q-C91S antibodies were subjected to stress conditions that induce deamidation, by incubation with 1% ammonium bicarbonate at pH9.0 at 37°C for 48 hours. Following treatment, H0L0, H2L2, H2L2-C91S, H2L2-N54Q and H2L2-N54Q-C91S were analysed for functional 15 activity in a myostatin binding ELISA (as described in 4.2). The ELISA data for just one experiment (from a total of two) are illustrated in Figures 16 to 20. These data clearly indicate that the treatment procedure did not affect the ability of any of the antibodies to bind to myostatin.

6. CDRH3 VARIANT HUMANISED ANTIBODIES

20 6.1 Construction of CDRH3 variant humanised antibodies

Site-directed mutagenesis of CDRH3 (SEQ ID NO: 3) of each residue to an alternative amino acid residue was carried out using the antibody H2L2-C91S (variable sequences: SEQ ID NO: 14 and 24 respectively; full-length sequences: SEQ ID NO: 30 and 40 respectively) as a base molecule. Full length DNA expression

constructs including human constant regions for the base sequences of H2 and L2-C91S (SEQ ID NO: 45 and 55 respectively) were produced using pTT vectors (National Research Council Canada, with a modified Multiple Cloning Site (MCS)).

5 Approximately 300 CDRH3 variants were generated and approximately 200 variants were tested in the subsequent analysis (see 6.2 and 6.3).

### 6.2 CDRH3 variant expression in HEK 293 6E cells

pTT plasmids encoding the heavy and light chains respectively of the approximately 200 CDRH3 variants were transiently co-transfected into HEK 293 6E cells and expressed at small scale to produce antibody. The heavy chains have the 10 base sequence of H2 with variant CDRH3 sequences and the light chains have the base sequence of L2-C91S, as described above. Antibodies were assessed directly from the tissue culture supernatant.

### 6.3 Initial Scan-ProteOn XPR36- on Tissue Culture Supernatants

The initial kinetic analyses for the CDRH3 screen were carried out on the 15 ProteOn XPR36 (Biorad Laboratories). For residues R95 to P100\_B, analysis was carried out using a Protein A/G capture surface (Pierce 21186) was used and for residues A100\_C to V102, an anti-human IgG surface was used (Biacore/GE Healthcare BR-1008-39). Both capture surfaces were prepared similarly using primary amine coupling to immobilise the capture molecule on a GLM chip (Biorad 20 Laboratories 176-5012). CDRH3 variants were captured directly on either the Protein A/G or anti-human IgG surface (depending on the residue mutated) from tissue culture supernatants from transient transfections expressing the particular variant of interest. After capture, in-house recombinant human myostatin (see 1.1 above) was used as an analyte at 256nM, 32nM, 4nM, 0.5nM and 0.0625nM, with a buffer 25 injection alone (i.e. 0nM) used to double reference the binding curves. Following the myostatin binding event, the capture surfaces were regenerated: for the Protein A/G capture surface, 100mM phosphoric acid was used to regenerate the capture surface; and for the anti-human IgG surface, 3M MgCl<sub>2</sub> was used to regenerate the capture surface; the regeneration removed the previously captured antibody ready for another 30 cycle of capture and binding analysis. The data was then fitted to the 1:1 model (with mass transport) inherent to the ProteOn analysis software. The run was carried out

using HBS-EP (Biacore/GE-Healthcare BR-1006-69) and the analysis temperature was 25°C.

The results were difficult to interpret due to the nature of the interaction, since it is unlikely that the 1:1 model adequately describes the interaction, however by 5 judging the sensorgrams it was possible to make a selection of constructs that may have improved affinity over the base molecule. We judged the screen to have identified eleven CDRH3 variants that appeared to have a better kinetic profile than the base molecule. The heavy chains of the eleven CDRH3 variants are described below in Table 18 (using Kabat numbering). All of the variants had the light chain 10 L2-C91S (variable sequence: SEQ ID NO: 24; full-length sequence: SEQ ID NO: 40, full length DNA sequence SEQ ID NO: 55). A further CDRH3 variant that was identified to have a better kinetic profile than the base molecule was F100G\_S (SEQ ID NO: 110), but this was not analysed further.

Table 18. CDRH3 variant sequences

Name	Sequence of CDRH3
H2L2-C91S	RYYYGTGPADWYFDV (SEQ ID NO:3)
H2L2-C91S_Y96L	RLYYGTGPADWYFDV (SEQ ID NO:82)
H2L2-C91S_G99D	RYYYDTGPADWYFDV (SEQ ID NO:83)
H2L2-C91S_G99S	RYYYSTGPADWYFDV (SEQ ID NO:84)
H2L2-C91S_G100A_K	RYYYGTPADWYFDV (SEQ ID NO:85)
H2L2-C91S_P100B_F	RYYYGTGFADWYFDV (SEQ ID NO:86)
H2L2-C91S_P100B_I	RYYYGTGIADWYFDV (SEQ ID NO:87)
H2L2-C91S_W100E_F	RYYYGTGPADFYFDV (SEQ ID NO:88)
H2L2-C91S_F100G_N	RYYYGTGPADWYNDV (SEQ ID NO:89)
H2L2-C91S_F100G_Y	RYYYGTGPADWYYDV (SEQ ID NO:90)
H2L2-C91S_V102N	RYYYGTGPADWYFDN (SEQ ID NO:91)
H2L2-C91S_V102S	RYYYGTGPADWYFDS (SEQ ID NO:92)

15

Reference to the antibodies by code (i.e. H2L2-C91S\_Y96L) means the antibody generated by co-transfection and expression of a first and second plasmid encoding the light and heavy chains, for example a plasmid containing the pTT5\_H2

\_Y96L sequence and a plasmid containing the pTT5\_L2-C91S sequence in a suitable cell line.

#### 6.4 Expression of a selected panel of CDRH3 variants

Heavy and light chains of the eleven CDRH3 variants set out in Table 18 were  
5 expressed in HEK 293 6E cells (as described in 6.2), affinity purified using immobilised Protein A columns (GE Healthcare), and quantified by reading absorbance at 280nm.

#### 6.5 Binding to recombinant myostatin by BIACore™

To judge whether the selection of constructs from the initial screen on the  
10 ProteOn XPR36 had been successful, an off-rate ranking experiment was performed on purified recombinant antibodies. Myostatin (recombinant in-house, see 1.1 above) was covalently immobilised on a CM5 chip (Biacore/GE Healthcare BR-1000-14) by primary amine coupling at three different densities, low, medium and high, which resulted in surfaces that gave a maximal binding signal of approximately 60 resonance  
15 units (RU's), 250 RU's and 1000 RU's respectively with the concentration of antibody used. A single concentration of antibody, 256nM, was used with a buffer injection to double reference the binding interaction. The initial rate of dissociation (off-rate) was calculated using the software inherent to the Biacore 3000 machine for the interaction of all the antibodies against each density of myostatin surface.  
20 Regeneration was by using 100mM phosphoric acid, and the assay was run using HBS-EP buffer at 25°C.

It was found that all the constructs tested showed a better off-rate (dissociation rate constant) than the base molecule (H2L2 C91S), in that the off rate was slower than H2L2 C91S. On the high density surface the top 5 constructs, excluding the  
25 10B3 chimera were H2L2-C91S\_P100B\_I, H2L2-C91S\_W100E\_F, H2L2-C91S\_F100G\_Y, H2L2-C91S\_G99S, and H2L2-C91S\_P100B\_F.

#### 6.6 Full kinetic analysis of binding to recombinant myostatin by BIACore™

Myostatin (recombinant in-house, see 1.1 above) was immobilised on Series S CM5 chip (Biacore/GE Healthcare BR-1006-68) at low, medium and high density  
30 which resulted in surfaces that gave a maximal binding signal of approximately 15 RUs, 37 RUs and 500 RUs respectively. The CDRH3 variants were passed over all

three surfaces at 256nM, 64nM, 16nM, 4nM, 1nM with a buffer injection (i.e. 0nM) used for double referencing, regeneration was using 100mM phosphoric acid. The data was fitted to the Bivalent model inherent to the T100 Biacore machine and was run using HBS-EP at 25°C.

5 In general the fits for the base H2L2-C91S were poor compared to the CDR variants on all three density surfaces, such that an accurate baseline value was hard to obtain. Of the three surfaces, the highest density surface gave the best separation between base antibody and CDR variants, though again the fit for the base H2L2-C91S molecule is poor. However, this surface might be expected to give most  
10 separation between the constructs as well as being the surface most likely to provide the best surface for true bivalent binding, since it is likely that avidity binding and rebinding events are more frequent and hence may “magnify” small differences in affinity. In general, all the CDR variants appeared better than the base H2L2-C91S, mainly because of a superior (i.e. slower) off-rate, especially on the high density  
15 surface.

Due to the methodology involved in this assay, in covalently coupling the target antigen to the biosensor chip surface, the actual affinities derived may not reflect the affinity that may be seen *in vivo*. However, this data is useful for ranking purposes. Using the data from the high density surface of this assay, the top 5  
20 constructs, based on overall affinity (equilibrium constant KD) but excluding the chimera 10B3, were F100G\_Y, P100B\_I, P100B\_F, F100G\_N and W100E\_F. However all other constructs affinities were within two fold of F100G\_Y.

### 6.7 Myostatin capture ELISA

25 The eleven affinity purified CDRH3 variants were also analyzed for binding activity in the myostatin capture ELISA.

A 96-well ELISA plate was coated at 4°C overnight with 2.5 µg/ml polyclonal Antibody to Myostatin (R&D Systems AF788). This plate was then washed 3-times in wash buffer (PBS, 0.1% Tween-20) and blocked for 1 hour at room temperature with block solution (PBS, 0.1% Tween-20 + 1% bovine serum albumin [BSA]). Then,  
30 myostatin was added at 1 µg/ml in block buffer during 1 hour followed by 3-times in wash buffer. Antibodies were then titrated out to a suitable concentration range (approximately 10 to 0.01 µg/ml), added to the plate and incubated for 1 hour at room

temperature. The plate was then washed 3-times in wash buffer. An anti-human kappa light chain HRP-conjugated antibody (Sigma A7164, used according to the manufacturer's instructions) was used to detect binding of humanized or chimeric antibodies, such as 10B3 chimera (HcLc) or H0L0. The plate was then washed 3-times in wash buffer and developed with an OPD substrate (according to the manufacturer's instructions) and read at 490nm on a plate reader.

5 The experiment is illustrated in Figure 21 where H2L2-C91S, H0L0, HcLc (10B3 chimera) and a negative control monoclonal antibody were used as control antibodies. All eleven CDRH3 variant antibodies bound to recombinant myostatin in 10 this ELISA. H2L2-C91S \_P100B\_I, H2L2-C91S \_V102N, H2L2-C91S \_G100A\_K, H2L2-C91S \_P100B\_F and H2L2-C91S \_F100G\_Y tended to have better binding activity for myostatin than base H2L2-C91S and H0L0.

## 6.8 Myostatin competition ELISA

15 The CDRH3 variants were further investigated in three different myostatin competition ELISAs. The purified antibodies were analyzed for the ability to compete with the 10B3 murine mAb.

### 6.8.1 Using polyclonal Ab as capture method

20 The protocol set out in 6.7 was used with the addition of 10B3 (final concentration of 0.3µg/ml) to each well and mixed with the antibodies titrated out to a suitable concentration range (approximately 10 to 0.01 µg/ml). An anti-mouse HRP-conjugated antibody (DAKO P0260, used according to the manufacturer's instructions) was used to detect binding of the 10B3 antibody. The ranking obtained from the ELISA data is shown in Table 19.

### 6.8.2 Using biotinylated myostatin as capture method

25 The protocol set out in 6.7 was used but the plates were initially coated at 4°C overnight with 5 µg/ml of streptavidin. Biotinylated myostatin was added at 0.3 µg/ml block buffer during 1 hour followed by 3-times in wash buffer. 10B3 (final concentration of 0.2µg/ml) was added into each well and mixed with antibodies titrated out to a suitable concentration range (approximately 10 to 0.01 µg/ml). An 30 anti-mouse HRP-conjugated antibody (DAKO P0260, used according to the

manufacturer's instructions) was used to detect binding of the 10B3 antibody. The ranking obtained from the ELISA data is shown in Table 19.

### 6.8.3 Using myostatin as capture method (direct capture)

The protocol set out in 6.7 was used but the plates were initially coated at 4°C  
 5 overnight with 0.2 µg/ml of myostatin (recombinant in-house, see 1.1 above). 10B3  
 (final concentration of 0.3µg/ml) was added into each well and mixed with antibodies  
 titrated out to a suitable concentration range (approximately 10 to 0.01 µg/ml). An  
 anti-mouse HRP-conjugated antibody (DAKO P0260, used according to the  
 manufacturer's instructions) was used to detect binding of the 10B3 antibody. The  
 10 ranking obtained from the ELISA data is shown in Table 19.

All the CDRH3 variants were able to compete against 10B3. The five most potent molecules from each of the different competition ELISAs are listed in Table 19.

Table 19: Ranking order top (1) to bottom (5) of five most potent CDRH3 variant  
 15 molecules

Myostatin competition ELISA		
Biotinylated myostatin	Polyclonal Abs	Direct capture
H2L2-C91S_V102S	H2L2-C91S_P100B_F	H2L2-C91S_P100B_F
H2L2-C91S_F100G_Y	H2L2-C91S_V102N	H2L2-C91S_F100G_Y
H2L2-C91S_P100B_I	H2L2-C91S_V102S	H2L2-C91S_V102N
H2L2-C91S_V102N	H2L2-C91S_F100G_Y	H2L2-C91S_V102S
H2L2-C91S_Y96L	H2L2-C91S_G99D	H2L2-C91S_P100B_I

On the basis of the analysis in this section (6.8) and the previous BIACore data in 6.6 and 6.7, the variants H2L2-C91S\_P100B\_F, H2L2-C91S\_P100B\_I, H2L2-C91S\_F100G\_Y, H2L2-C91S\_V102N and H2L2-C91S\_V102S were selected for  
 20 further analyses.

### 6.9 Inhibition of biological activity of myostatin *in vitro*

5 The five selected CDRH3 variants of 6.8 were tested in the myostatin responsive reporter gene assay (see 1.2 above), to assess *in vitro* efficacy. Myostatin at a concentration of 5nM was pre-incubated with varying concentrations of antibody at 37°C prior to addition to transfected A204 cells. The cells were incubated at 37°C for a further 6 hours before relative luciferase expression was determined by luminescence. The resulting IC50s are shown in Table 20.

Table 20: IC50 of humanised antibodies in A204 *in vitro* activity assay

Antibody	Mean IC50 (nM)	Lower 95% CI (nM)	Upper 95% CI (nM)
10B3 Chimera	3.534	1.941	6.435
H2L2-C91S	5.137	2.350	11.230
H2L2-C91S _P100B_F	4.235	2.295	7.818
H2L2-C91S _P100B_I	4.525	1.837	11.140
H2L2-C91S _F100G_Y	3.639	1.908	6.940
H2L2-C91S _V102N	5.514	3.023	10.060
H2L2-C91S _V102S	4.221	2.234	7.975

10 The data demonstrate that all the antibodies tested neutralised myostatin with a similar potency to the 10B3 chimera with H2L2-C91S \_F100G\_Y having the highest potency although not significantly so in this assay.

### 7. CONSTRUCTION AND EXPRESSION OF FC DISABLED CONSTANT REGION VARIANT

15 As the mode of action of anti-myostatin *in vivo* will be the simple binding and neutralisation of myostatin, it may not be necessary that the molecule retain its Fc-function to elicit ADCC and CDC responses. Furthermore, disabling Fc function may help mitigate against the potential for infusion-related immune reactions. The mutation to disable Fc function involves the following substitutions, using EU  
20 numbering system: Leu 235 Ala; and Gly 237 Ala.

Using standard molecular biology techniques, the gene encoding the sequence for the variable heavy region of the CDRH3 variant H2 \_F100G\_Y was transferred

from the existing construct to an expression vector containing the hIgG1 Fc disabled constant region. Full length DNA expression constructs encoding the heavy chain (SEQ ID NO: 98 H2 \_F100G\_Y\_Fc Disabled) and the light chain (SEQ ID NO: 40 L2-C91S) were produced using pTT vectors. Details of the heavy chain are in Table 5 21.

Table 21. Sequence of CDRH3 variant Fc disabled

Name	Full length Protein Seq ID
H2L2-C91S _F100G_Y Fc Disabled	98

The effect of the Fc disabled constant region was analyzed in the myostatin responsive reporter gene assay, (described above at 1.2). The resulting IC50 data are 10 shown in Table 22.

Table 22. IC50 of CDRH3 variant Fc disabled antibody in A204 *in vitro* activity assay

Antibody	Mean IC50 (nM)	Lower 95%CI (nM)	Upper 95%CI (nM)
H2L2-C91S	4.083	1.319	12.640
H2L2-C91S _F100G_Y Fc Disabled	1.239	0.524	2.932

These data demonstrate that disabling the Fc-function of “H2L2-C91S \_F100G\_Y Fc Disabled” as described above has no significant effect on the 15 antibody’s potency to neutralise myostatin.

## 8. CDRH2 VARIANT HUMANISED ANTIBODIES

### 8.1 Construction of CDRH2 variant humanised antibodies

As described above at Example 5, the asparagine at Kabat position 54 (N54) in heavy chain CDRH2 has potential for deamidation. In order to mitigate this potential 20 risk this amino acid was mutated to generate a number of CDRH2 variants of H2 \_F100G\_Y. These all differed in CDRH2 (SEQ ID NO: 2) and were generated by site directed mutagenesis using the pTT vector coding for the H2 \_F100G\_Y heavy chain. The light chain (SEQ ID NO: 40 L2-C91S) was expressed with each of the heavy chains. These constructs were not disabled in the Fc region.

### 8.2 CDRH2 variant expression in HEK293 6E cells

The pTT plasmids encoding the heavy and light chains respectively were transiently co-transfection in HEK 293 6E cells as described above at 6.2. In addition H2L2-C91S \_F100G\_Y was expressed as a positive control. Antibodies produced in the HEK293 cell supernatant were analyzed for binding to recombinant myostatin by BIACore. The screen of the CDRH2 variants indicated that all bind to recombinant myostatin.

Using the affinity data obtained and the in silico analysis for potential deamidation risk, a panel of five CDRH2 variants (listed in Table 23) were selected for larger scale expression, purification and further analysis.

Table 23. CDRH2 variant sequences

Name	Sequence of CDRH2
H2L2 C91S	NIYPYNGVSНЫNQRFKA (SEQ ID NO: 2)
H2L2 C91S_G55D F100G_Y	NIYPYNDVSНЫNQRFKA (SEQ ID NO: 93)
H2L2 C91S_G55L F100G_Y	NIYPYNLVSНЫNQRFKA (SEQ ID NO: 94)
H2L2 C91S_G55S F100G_Y	NIYPYNSVSНЫNQRFKA (SEQ ID NO: 95)
H2L2 C91S_G55T F100G_Y	NIYPYNTVSНЫNQRFKA (SEQ ID NO: 96)
H2L2 C91S_G55V F100G_Y	NIYPYNVVSНЫNQRFKA (SEQ ID NO: 97)

### 8.3 Characterization of CDRH2 variants

All five antibodies were analyzed for binding activity in the myostatin binding ELISA (as described in example 4.2). Figure 22 shows the results for H2L2-C91S \_F100G\_Y, H2L2 C91S, HcLc (10B3C) and a negative control mAb; and all five CDRH2 variant antibodies. The CDRH2 variants had better or similar binding activity for myostatin as H2L2-C91S \_F100G\_Y.

### 8.4 CDRH2 variant BIACore Analysis

The CDRH2 variants were also tested to determine any changes in myostatin binding affinity by BIACore. Protein A was immobilised on a C1 BIACore biosensor chip, purified antibodies were captured at a low density so that maximal binding of myostatin resulted in less than 30 resonance units. Myostatin was passed over the captured antibody surface at a concentration of 256nM only; a buffer injection (i.e.

0nM) was used to double reference the binding data. Regeneration of the Protein A surface was using 100mM phosphoric acid. Data was fitted to the Bivalent model and to the Two State Model, both inherent to the T100 Biacore analysis software. However since myostatin is a dimer more weight was given to the Bivalent model 5 data. The run was carried out using HBS-EP and at a temperature of 25°C.

The models used may not reflect the true binding *in vivo* and the models themselves may not accurately reflect the interaction, so the calculated values were for ranking only. The data suggests that compared to H2L2-C91S\_F100G\_Y, the CDRH2 variants do not impact too significantly on affinity, with the worst construct 10 by the Bivalent model (H2L2 C91S\_G55L F100G\_Y) showing a 6.8 fold worsening of overall affinity.

#### 8.5 Inhibition of biological activity of myostatin *in vitro*

The effect of the CDRH2 variants on *in vitro* neutralisation assays was also undertaken using the A204 luciferase assay (described in section 1.2). The IC50 15 values of the inhibition curves are presented in Table 24.

Table 24. IC50 of antibody variants in A204 *in vitro* activity assay

Antibody	Mean IC50 (nM)	Lower 95%CI (nM)	Upper 95%CI (nM)
10B3 Chimera	3.570	1.473	8.654
H2L2-C91S_F100G_Y	11.070	3.686	33.230
H2L2 C91S_G55D F100G_Y	5.530	1.649	18.540
H2L2 C91S_G55L F100G_Y	5.581	1.601	19.460
H2L2 C91S_G55S F100G_Y	4.425	1.730	11.310
H2L2 C91S_G55T F100G_Y	6.892	2.452	19.370
H2L2 C91S_G55V F100G_Y	3.840	1.044	14.130

The data indicate that all the CDRH2 variant antibodies inhibit myostatin-induced activation of A204 cells with a similar potency to H2L2-C91S\_F100G\_Y in 20 this assay.

#### 8.6 Fc-disabled CDRH2 variant

H2L2 C91S\_G55S F100G\_Y, the developability enhanced molecule with the highest apparent potency in the A204 assay was Fc-disabled (by making the following

substitutions, using EU numbering system: Leu 235 Ala; and Gly 237 Ala) as exemplified in SEQ ID NO: 99. The receptor binding assay (Example 2.5) was used to demonstrate that this new molecule H2L2 C91S\_G55S F100G\_Y-Fc disabled had slightly improved potency relative to H2L2 C91S\_G55S F100G\_Y (see Table 25).

5 Table 25. IC50 values of antibody variants in ActRIIb receptor binding assay

<b>mAb</b>	<b>Mean IC50 (nM)</b>	<b>Lower 95%CI (nM)</b>	<b>Upper 95%CI (nM)</b>
10B3	0.161	0.087	0.295
H2L2 C91S_G55S F100G_Y	0.786	0.326	1.898
H2L2 C91S_G55S F100G_Y-Fc disabled	0.518	0.206	1.298

#### 9. EFFICACY OF 10B3 IN GLUCOCORTICOID-INDUCED MUSCLE WASTING

10 In the present study, we investigated whether 10B3 treatment could prevent steroid induced muscle loss in mice. C57BL mice were treated with PBS, mIgG2a or 10B3. Dexamethasone was used as the steroid to induce muscle loss

15 Dexamethasone treatment caused body weight loss in animals pre-treated with the control antibody. The dexamethasone-induced weight loss was attenuated by pre-treatment with 10B3. Animals pre-treated with the control antibody showed muscle atrophy in extensor digitorum longus (EDL), tibialis anterior (TA), and gastrocnemius. In contrast, dexamethasone treatment in animals pre-treated with 10B3 did not cause atrophy in TA, EDL, and gastrocnemius. Animals pre-treated with the control antibody showed an increase in body fat accumulation. However, there was no increase in % body fat after dexamethasone treatment in animals pre-treated with 20 10B3.

These results in Example 9 suggest that 10B3 or the humanised antibody thereof may be used for treatment of glucocorticoids-induced muscle wasting. For example, prophylactic treatment of muscle wasting in patients on glucocorticoid therapy may be advantageous.

### 10. 10B3 TREATMENT ATTENUATED MUSCLE ATROPHY IN SCIATIC NERVE CRUSH MODEL

Here we used the nerve injury model to evaluate the efficacy of 10B3 in prevention of disuse atrophy in mice.

5 C57BL mice were treated with mIgG2a control or 10B3 antibody. The right sciatic nerve in the mid thigh was exposed and either left intact (sham group) or injured by crushing for 10 seconds using a haemostatic forceps (nerve crush group).  
10 Sciatic nerve crush injury resulted in decreases in the mass of extensor digitorum longus (EDL), tibialis anterior (TA), gastrocnemius and soleus as compared to the sham control. In sham surgery groups, 10B3 treatment increased the mass of TA, EDL, gastrocnemius and quadriceps when compared to IgG2a control group. Animals treated with 10B3 retained more muscle than IgG2a control treated animals. 10B3 treatment also increased total body weight in both sham-operated and nerve crushed animals.

15 These results demonstrate that 10B3 or the humanised antibody thereof may have the potential for prevention and/or treatment of human disuse muscle atrophy.

### 11. 10B3 TREATMENT ATTENUATED MUSCLE WASTING IN C-26 TUMOUR-BEARING MICE

20 In the current study, the effect of 10B3 treatment on body weight change, muscle mass and function were studies in Colon-26 tumour bearing mice, a widely used preclinical model for cancer cachexia studies.

25 Thirty eight 8-week-old male CD2F1 mice were randomly divided into 4 groups: mIgG2a (n=9) 10B3 (n=9), mIgG2a+C-26 (n=10), and 10B3+C-26 (n=10). Colon-26 (C-26) tumour cells were subcutaneously implanted into 20 mice at  $1 \times 10^6$  cells/mouse. Several hours later, animals began to receive antibody injections. Mice were injected i.p. with either mouse IgG2a control antibody or 10B3 at the dose of 30 mg/kg on day 0, 3, 7, 14, 21. Body weight and fat mass were monitored throughout the experiment. Shortly before sacrifice on day 25, lower limb muscle strength was assessed by measuring the contraction force upon the electrical stimulation of sciatic nerve in the mid thigh. The tumour weight, and individual muscle mass and epididymal fat pad mass were determined at the end of the experiment.

Figure 23 shows the effect of antibody treatment on body weight in C-26 tumour bearing mice from day 0 to day 25. Tumour bearing mice start to lose body weight dramatically at 21 days after tumour implantation. Treatment with 10B3 effectively mitigated weight loss in tumour bearing mice. The average body weight of 5 the tumour bearing mice treated with 10B3 was 8% higher than that of tumour bearing mice treated with mIgG2a control antibody. There was no significant difference in tumour size (2.2 g for IgG2a vs 1.9 g for 10B3) between 10B3 treated and mIgG2a control treated groups.

10 Figure 24 shows the effect of antibody treatment on total body fat (A), epididymal fat pad (B) and lean mass (C) in C-26 tumour bearing mice. Tumour bearing mice had significantly less total body fat (Figure 24A). Epididymal fat pad almost completely disappeared in both 10B3 and mIgG2a control treated tumour bearing mice (Figure 24B), suggesting that 10B3 does not protect tumour bearing animals against body fat loss.

15 As shown in Figure 24C, 10B3 treatment causes significant ( $p<0.01$ ) increase in lean mass in both normal animals as well as tumour bearing mice. Tumour bearing mice treated with control IgG2a had significantly lower lean mass after tumour removal. In contrast, tumour bearing mice treated with 10B3 had significantly (p<0.01) greater lean mass than IgG2a treated tumour bearing mice. In fact, there was 20 no significant difference in lean mass between 10B3 treated tumour bearing mice and normal animals.

25 Table 26 shows the effect of antibody treatment on muscle mass. As expected, tumour bearing mice had significant loss of TA, EDL, quadriceps, soleus and gastrocnemius muscle (Table 26). 10B3 treatment increased muscle mass in normal animals. Most importantly, 10B3 treatment attenuated muscle loss in tumor bearing mice. In tumour bearing mice treated with 10B3, the weights of TA, EDL, quadriceps, soleus and gastrocnemius muscles were 17.8%, 11.3%, 16.9%, 13.4% and 14.6% greater than those of tumour bearing mice treated with IgG2a control, respectively.

Table 26: 10B3 treatment attenuated muscle loss in tumor bearing mice. Data are mean muscle mass (mg) +/- SEM. The means with the superscripts \* and # indicates significantly (p<0.05) different from IgG2a group and C-26+IgG2a group, respectively according to Student T tests.

5

Groups	quadriceps	gastrocnemius	TA	EDL	soleus
IgG2a	216+/-2.1	159+/-2.2	51+/-0.5	11.1+/-0.5	8.0+/-0.4
10B3	244+/-4.7 *	173+/-4.8	58+/-1.2 *	12.6+/-0.6 *	8.5+/-0.2
C-26 + IgG2a	174+/-3.7 *	123+/-4.5 *	40+/-1.6 *	8.9+/-0.3 *	6.9+/-0.3 *
C-26 + 10B3	204+/-8.6 #	140+/-5.8 *	47+/-1.8 #	9.9+/-0.6 #	7.9+/-0.5 #

Figure 25 shows the effect of antibody treatment on lower limb muscle strength, which was assessed by measuring the contraction force upon the electrical stimulation of sciatic nerve in the mid thigh. After 25 days of tumour implant, lower limb muscle contraction force was significantly (p<0.001) reduced by 20% in the control antibody groups. 10B3 treatment increased maximum contraction force by 10.2% and 17.5% in healthy animals and tumour bearing mice, respectively, as compared to the control groups (p<0.05). There was no significant difference in maximum force measurement between 10B3 treated tumour bearing mice and healthy controls. Thus, 10B3 treatment improved muscle function in both healthy and tumour bearing mice.

These data indicate that 10B3 or the humanised antibody thereof treatment could attenuate muscle loss and functional decline associated with cancer cachexia.

20 12. EFFECTS OF 10B3 TREATMENT ON SKELETAL MUSCLE ATROPHY IN MOUSE TENOTOMY MODEL

Here, we determined the effects of the myostatin antibody 10B3 on muscle mass in a mouse tenotomy model.

Young adult male C57BL mice were randomly divided into mIgG2a or 10B3 treatment groups (n = 6/group) and dosed i.p. at 30 mg/kg on day 1, 4, 8, and 15. On the morning prior to dosing (day 0), all mice received the following surgical protocol: tibialis anterior (TA) tendons were separated at their distal insertion in left legs (tenotomy) while all right TA tendons were exposed but left intact (sham). After 3 weeks (day 21), mice were euthanized to assess changes in TA muscle mass.

Three-week treatment of 10B3 significantly increased TA muscle mass following both sham and tenotomy surgeries in mice (Figure 26). Interestingly, the effect of 10B3 was more pronounced in the presence of tenotomy (+21%) compared to the intact sham condition (+14%).

5 These data indicate that 10B3 or the humanised antibody thereof treatment could attenuate muscle loss and functional decline associated with trauma/injury.

#### SEQUENCES

- 10 SEQ ID NO: 1 (CDRH1)  
GYFMH
- 15 SEQ ID NO: 2 (CDRH2)  
NIYPYNGVSNYNQRFKA
- SEQ ID NO: 3 (CDRH3)  
RYYYGTGPADWYFDV
- 20 SEQ ID NO: 4 (CDRL1)  
KASQDINSYLS
- SEQ ID NO: 5 (CDRL2)  
RANRLVD
- 25 SEQ ID NO: 6 (CDRL3)  
LQCDEFPLT
- SEQ ID NO: 7 (mouse monoclonal 10B3 V<sub>H</sub>)  
30 EVQLQQSGPELVKPGASVKISCKASGYSFTGYFMHWVKQSHGNILDWIGNIY  
PYNGVSNYNQRFKAKATLTVDKSSSTAYMELRSLTSEDSAVYYCARRYYYG  
TGPADWYFDVWGTGTTVTVSS
- SEQ ID NO: 8 (mouse monoclonal 10B3 and 10B3 chimera V<sub>L</sub>)  
35 DIKMTQSPSSMYASLRERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANR  
LVDGVPSRFSGSGSQDYSLTISSLEYEDMGIYYCLQCDEFPLTFGAGTKLEL  
K
- SEQ ID NO: 9 (artificial signal sequence)  
40 MGWSCIILFLVATATGVHS
- SEQ ID NO: 10 (human acceptor framework for V<sub>H</sub>)  
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI  
SAYNGNTNYAQKLQGRVTMTDTSTSTAYMELRSLSRSDDTAVYYCARXXX  
45 XXXXXXXWQGQTMVTVSS

SEQ ID NO: 11 (human acceptor framework for V<sub>L</sub>)  
 DIQMTQSPSSLSASVGDRVITCRASQGISNYLAWFQQKPGKAPKSLIYAASSL  
 QSGVPSKFGSGSGTDFTLTISSLQPEDFATYYCXXXXXXXXXFGQGTKLEIK

5

SEQ ID NO: 12 (humanised V<sub>H</sub> : H0)  
 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYFMHWVRQAPGQGLEWMG  
 NIYPYNGVSYNQRFKARVTMTTDSTSTAYMELRSLSRSDDTAVYYCARRY  
 YYGTGPADWYFDVVGQGTLTVSS

10

SEQ ID NO: 13 (humanised V<sub>H</sub> : H1)  
 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYFMHWVRQAPGQGLEWMG  
 NIYPYNGVSYNQRFKARVTMTTDSTSTAYMELRSLSRSDDTAVYYCARRY  
 YYGTGPADWYFDVVGQGTLTVSS

15

SEQ ID NO: 14 (humanised V<sub>H</sub> : H2)  
 QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYFMHWVRQAPGQGLEWMG  
 NIYPYNGVSYNQRFKARVTMTTDSTSTAYMELRSLSRSDDTAVYYCARRY  
 YYGTGPADWYFDVVGQGTLTVSS

20

SEQ ID NO: 15 (humanised V<sub>L</sub> : L0)  
 DIQMTQSPSSLSASVGDRVITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 LVDGVPSKFGSGSGTDFTLTISSLQPEDFATYYCLQCDEFPLTFGQGTKLEIK

25

SEQ ID NO: 16 (humanised V<sub>L</sub> : L1)  
 DIQMTQSPSSLSASVRDRVITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 VDGVPSPKFGSGSGTDFTLTISSLQPEDFATYYCLQCDEFPLTFGQGTKLEIK

30

SEQ ID NO: 17 (humanised V<sub>L</sub> : L2)  
 DIQMTQSPSSLSASVGDRVITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 LVDGVPSKFGSGSGTDFTLTISSLQPEDFATYYCLQCDEFPLTFGQGTKLEIK

35

SEQ ID NO: 18 (humanised V<sub>L</sub> : L3)  
 DIQMTQSPSSLSASVGDRVITCKASQDINSYLSWFQQKPGKAPKSLIYRANR

LVDGVPSKFGSGSGTDFTLTISSLQPEDFATYYCLQCDEFPLTFGAGTKLEIK

40

SEQ ID NO: 19 (10B3 chimera V<sub>H</sub> : N54D)  
 EVQLQQSGPELVKPGASVKISCKASGYSFTGYFMHWVKQSHGNILDWIGNIY  
 PYDGVSNYNQRFKAKATLTVDKSSSTAYMELRSLTSEDSAVYYCARRYYYG  
 TGPADWYFDVVGQGTLTVSS

45

SEQ ID NO: 20 (10B3 chimera V<sub>H</sub> : N54Q)  
 EVQLQQSGPELVKPGASVKISCKASGYSFTGYFMHWVKQSHGNILDWIGNIY  
 PYQGVSNYNQRFKAKATLTVDKSSSTAYMELRSLTSEDSAVYYCARRYYYG  
 TGPADWYFDVVGQGTLTVSS

50

SEQ ID NO: 21 (10B3 chimera V<sub>L</sub> : C91S)  
 DIKMTQSPSSMYASLRERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANR  
 LVDGVPSRFSGSGSGDYSLTISSELEYDMGIYYCLQSDEFPLTFGAGTKLEIK

SEQ ID NO: 22 (humanised V<sub>H</sub> : H2 : N54D)  
 QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYFMHWVRQAPGQGLEWMG  
 NIYPYDGVSYNQRFKARVTMTDTSTSTAYMELRSRSDDTAVYYCARRY  
 YYGTGPADWYFDVWGQGTLTVSS

5

SEQ ID NO: 23 (humanised V<sub>H</sub> : H2 : N54Q)  
 QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYFMHWVRQAPGQGLEWMG  
 NIYPYQGVSYNQRFKARVTMTDTSTSTAYMELRSRSDDTAVYYCARRY  
 YYGTGPADWYFDVWGQGTLTVSS

10

SEQ ID NO: 24 (humanised V<sub>L</sub> : L2 : C91S)  
 DIQMTQSPSSLSASVGDRVITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 LVDGVPSKFSGSGSGTDYTLTISSLQPEDFATYYCLQSDEFPLTFGQGKLEIK

15

SEQ ID NO: 25 (10B3 chimera V<sub>H</sub>)  
 EVQLQQSGPELVKPGASVKISCKASGYSFTGYFMHWVKQSHGNILDWIGNIY  
 PYNGVSYNQRFKAKATLTVDKSSSTAYMELRSLTSEDAVYYCARRYYYG  
 TGPADWYFDVWGTGTLTVSSASTKGPSVFLPAPSSKSTSGGTAAALGCLVKD  
 YFPEPVTVSWNSGALTSGVHTFPAPLQSSGLYSLSSVVTVPSSSLGTQTYICNV

20

SEQ ID NO: 26 (10B3 chimera heavy chain)  
 EVQLQQSGPELVKPGASVKISCKASGYSFTGYFMHWVKQSHGNILDWIGNIY  
 PYNGVSYNQRFKAKATLTVDKSSSTAYMELRSLTSEDAVYYCARRYYYG  
 TGPADWYFDVWGTGTLTVSSASTKGPSVFLPAPSSKSTSGGTAAALGCLVKD  
 YFPEPVTVSWNSGALTSGVHTFPAPLQSSGLYSLSSVVTVPSSSLGTQTYICNV  
 NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEELLGGPSVFLPPKPKDTLMISR  
 TPEVTCVVVDVSHEDPEVKFNWyVDGVEVHNNAKTKPREEQYNSTYRVVSL  
 TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT  
 KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLT  
 DKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

25

30

SEQ ID NO: 27 (10B3 chimera light chain)  
 DIKMTQSPSSMYASLRERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANR  
 LVDGVPSRFSGSGSGDYSLTISSELEYEDMGIYYCLQCDEFPLTFGAGTKLEL  
 KRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGN  
 SQESVTEQDSKDSTYSLSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR  
 GEC

40

SEQ ID NO: 28 (humanised heavy chain: H0)  
 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYFMHWVRQAPGQGLEWMG  
 NIYPYNGVSYNQRFKARVTMTDTSTSTAYMELRSRSDDTAVYYCARRY  
 YYGTGPADWYFDVWGQGTLTVSSASTKGPSVFLPAPSSKSTSGGTAAALGCL  
 VKDYFPEPVTVSWNSGALTSGVHTFPAPLQSSGLYSLSSVVTVPSSSLGTQTY  
 ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEELLGGPSVFLPPKPKDTL  
 MISRTPEVTCVVVDVSHEDPEVKFNWyVDGVEVHNNAKTKPREEQYNSTYRV  
 VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS  
 RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLY  
 SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

50

SEQ ID NO: 29 (humanised heavy chain: H1)

QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYFMHWVRQAPGQGLEWMG  
 NIYPYNGVSYNQRFKARVTMTDTSTSTAYMELRSRSDDTAVYYCARRY  
 YYGTGPADWYFDVWGTGTLTVSSASTKGPSVPLAPSSKSTSGGTAAALGCL  
 5 VKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTY  
 ICNVNHKPSNTKVDKKVEPKSCDKTHCPCPAPELLGGPSVFLFPPPKD  
 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV  
 VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS  
 10 RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLY  
 SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO: 30 (humanised heavy chain: H2)

QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYFMHWVRQAPGQGLEWMG  
 NIYPYNGVSYNQRFKARVTMTDTSTSTAYMELRSRSDDTAVYYCARRY  
 15 YYGTGPADWYFDVWGQGTLTVSSASTKGPSVPLAPSSKSTSGGTAAALGCL  
 VKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTY  
 ICNVNHKPSNTKVDKKVEPKSCDKTHCPCPAPELLGGPSVFLFPPPKD  
 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV  
 VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS  
 20 RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLY  
 SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO: 31 (humanised light chain: L0)

DIQMTQSPSSLSASVGDRVTITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 25 LVDGVPSKFGSGSGTDFLTISLQPEDFATYYCLQCDEFPLTFGQGTKLEIK  
 RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNS  
 QESVTEQDSKDSTYSLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG  
 EC

30 SEQ ID NO: 32 (humanised light chain: L1)

DIQMTQSPSSLSASVRDRVTITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 VDGVPSSKFGSGSGTDFLTISLQPEDFATYYCLQCDEFPLTFGQGTKLEIK  
 TVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNS  
 35 QESVTEQDSKDSTYSLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG  
 EC

SEQ ID NO: 33 (humanised light chain: L2)

DIQMTQSPSSLSASVGDRVTITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 LVDGVPSKFGSGSGTDFLTISLQPEDFATYYCLQCDEFPLTFGQGTKLEIK  
 40 RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNS  
 QESVTEQDSKDSTYSLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG  
 EC

SEQ ID NO: 34 (humanised light chain: L3)

45 DIQMTQSPSSLSASVGDRVTITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 LVDGVPSKFGSGSGTDFLTISLQPEDFATYYCLQCDEFPLTFGAGTKLEIK  
 RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNS  
 QESVTEQDSKDSTYSLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG  
 EC

50

SEQ ID NO: 35 (10B3 chimera N54D heavy chain)

EVQLQQSGPELVKPGASVKISCKASGYSFTGYFMHWVKQSHGNILDWIGNIY  
PYDGVSNYNQRFKAKATLTVDKSSSTAYMELRSLTSEDSAVYYCARRYYG  
TGPADWYFDVWGTGTLTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKD  
5 YFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNV  
NHKPSNTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISR  
TPEVTCVVVDVSHEDPEVFKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSL  
TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT  
10 KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLT  
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO: 36 (10B3 chimera N54Q heavy chain)

EVQLQQSGPELVKPGASVKISCKASGYSFTGYFMHWVKQSHGNILDWIGNIY  
PYQGVSNYNQRFKAKATLTVDKSSSTAYMELRSLTSEDSAVYYCARRYYG  
15 TGPADWYFDVWGTGTLTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKD  
YFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNV  
NHKPSNTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISR  
TPEVTCVVVDVSHEDPEVFKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSL  
20 TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT  
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLT  
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO: 37 (10B3 chimera C91S light chain)

DIKMTQSPSSMYASLRERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANR  
25 LVDGVPSRFSGSGQDYSLTISSLEYEDMGIYYCLQSDFPPLTFGAGTKLELK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNS  
QESVTEQDSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG  
EC

30 SEQ ID NO: 38 (humanised heavy chain: H2 N54D)

QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYFMHWVRQAPGQGLEWMG  
NIYPYDGVSYNQRFKARVTMTDTSTSTAYMELRSLRSDDTAVYYCARRY  
YYGTGPADWYFDVWQGTQTVSSASTKGPSVFLAPSSKSTSGGTAALGCL  
VKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTY  
35 ICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTL  
MISRTPEVTCVVVDVSHEDPEVFKFNWYVDGVEVHNAKTKPREEQYNSTYRV  
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS  
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLY  
SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

40 SEQ ID NO: 39 (humanised heavy chain: H2 N54Q)

QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYFMHWVRQAPGQGLEWMG  
NIYPYQGVSNYNQRFKARVTMTDTSTSTAYMELRSLRSDDTAVYYCARRY  
YYGTGPADWYFDVWQGTQTVSSASTKGPSVFLAPSSKSTSGGTAALGCL  
45 VKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTY  
ICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTL  
MISRTPEVTCVVVDVSHEDPEVFKFNWYVDGVEVHNAKTKPREEQYNSTYRV  
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS  
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLY  
50 SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO: 40 (humanised light chain: L2 C91S)

DIQMTQSPSSLSASVGDRVITCKASQDINSYLSWFQQKPGKAPKSLIYRANR  
 LVDGVPSKFGSGSGTDYTLTISSLQPEDFATYYCLQSDEFPLTFQGQTKLEIK  
 5 RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNS  
 QESVTEQDSKDSTYLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG  
 EC

SEQ ID NO: 41 (10B3 chimera heavy chain, DNA sequence)

10 ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGTC  
 CACTCCGAGGTTCAGCTGCAGCAGTCTGGACCTGAACCTGGTAAGCCTGG  
 GGCTTCAGTGAAGATATCCTGCAAGGCTCTGGTTACTCATTCACTGGCTA  
 CTTCATGCAGTGGGTGAAGCAGAGCCATGGCAATATCCTCGATTGGATTG  
 GAAATATTATCCTTACAATGGTGTCTAAGTACAACACCAGAGATTCAAGG  
 15 CCAAGGCCACATTGACTGTAGACAAGTCCTCTAGTACAGCCTACATGGAG  
 CTCCGCAGCCTTACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGACGC  
 TATTACTACGGTACCGGACCGGCTGATTGGTACTCGATGTCTGGGCACCT  
 GGGACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGT  
 CCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGCACAGCCGCCCTGG  
 20 GCTGCCTGGTGAAGGACTACTCCCCGAACCGGTGACCGTGTCTGGAAC  
 AGCGGAGCCCTGACCAGCGCGTGCACACCTCCCCGCCGTGCTGCAGAG  
 CAGCGGCCTGTACAGCCTGAGCAGCGTGGTACCGTGCAGCAGCAGCC  
 TGGGCACCCAGACCTACATCTGTAACTGAACCACAAGCCCAGCAACACC  
 AAGGTGGACAAGAAGGTGGAGCCAAAGAGCTGTGACAAGACCCACACCT  
 25 GCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCAGCGTGTCTGT  
 TCCCCCCCAGCCTAAGGACACCCCTGATGATCAGCAGAACCCCCGAGGTG  
 ACCTGTGTGGTGGATGTGAGCCACGAGGACCTGAGGTGAAGTTCAA  
 CTGGTACGTGGACGGCGTGGAGGTGCACAAATGCCAAGACCAAGCCCAGG  
 GAGGAGCAGTACAACAGCACCTACCGGGTGGTCCGTGCTGACCGTGCT  
 30 GCACCAAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCCAAC  
 AAGGCCCTGCCCTGCCCCATCGAGAAAACCACATCAGCAAGGCCAAGGGCCA  
 GCCCAGAGAGCCCCAGGTGTACACCCCTGCCCTAGCAGAGATGAGCTGA  
 CCAAGAACCAAGGTGCCCTGACCTGCCCTGGTAAGGGCTTCTACCCCAGC  
 GACATGCCGTGGAGTGGAGAGCAACGGCCAGCCCAGAACAACTACA  
 35 AGACCACCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCTGTACAGC  
 AAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTAGCT  
 GCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAACAGCCTG  
 AGCCTGTCCCCGGCAAGTGA

40 SEQ ID NO: 42 (10B3 chimera light chain, DNA sequence)

ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGTC  
 CACTCCGACATCAAGATGACCCAGTCTCCATCTTCCATGTATGCATCTCA  
 CGAGAGAGAGTCACTATCACTGCAAGGCGAGTCAGGACATTAATAGCTA  
 TTTAAGCTGGTCCAGCAGAAACCAAGGGAAATCTCTAAGACCCCTAATCT  
 45 ATCGTGCAAACAGATTGGTAGATGGGCTCCATCAAGGTTCAAGTGGCAGT  
 GGATCTGGCAAGATTATTCTCTCACCACAGCAGCCTGGAGTATGAAGA  
 TATGGGAATTATTATTGTCTACAGTGTGATGAATTCCGCTCACGTTGG  
 TGCTGGACCAAGCTGGAGCTGAAACGTACGGTGGCCGCCAGCGTGT  
 TCATCTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGT  
 GTGTGTCTGCTGAACAACCTCTACCCCCGGAGGCCAAGGTGCAGTGGAA

GGTGGACAATGCCCTGCAGAGCGGAAACAGCCAGGAGAGCGTGACCGAG  
 CAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCGCTGACCGCTGAG  
 CAAGGCCACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACC  
 AGGGCCTGTCCAGCCCCGTGACCAAGAGCTCAACCGGGGCGAGTGCTGA

5

SEQ ID NO: 43 (humanised heavy chain: H0, DNA sequence)

ATGGGCTGGTCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTG  
 CACAGCCAGGTGCAGCTGGTGAGAGCGGCGAGAGGTGAAGAAGCCCG  
 GCGCCAGCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTCACCGGC

10

TACTTCATGCACTGGGTGAGGCAGGCAGGCTCCCGCCAGGGCTGGAGTGGAT  
 GGGCAACATCTACCCCTACAACCGCGTCAGCAACTACAACCAGAGGTTCA  
 AGGCCAGGGTGACCATGACCACCGACACCTCTACCAGCACCGCCTACATG  
 GAACTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAG

15

GAGGTACTATTACGGCACCGGACCCGCCATTGGTACTTCGACGTGTGGG  
 GACAGGGGACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAG  
 CGTGTCCCCCTGGCCCCCAGCAGCAAGAGCACCGAGCGGCGGCACAGCCG  
 CCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCCT

20

GGAACACAGCGGAGCCCTGACCGAGCGCGTGCACACCTCCCCGCGGTGCTG  
 CAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTACCGTGCCAGCAG  
 CAGCCTGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCAGCA

25

ACACCAAGGTGGACAAGAAGGTGGAGGCCAAGAGAGCTGTGACAAGACCA  
 CACCTGCCCCCCCCTGCCCTGCCCTGGAGCTGCTGGAGGCCCCAGCGTGT  
 CCTGTTCCCCCCCCAAGCTAAGGACACCCCTGATGATCAGCAGAACCCCCG  
 AGGTGACCTGTGTGGTGGATGTGAGGCCACGAGGACCTGAGGTGAAG

30

TTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCC  
 CAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCG  
 TGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCC  
 AACAAAGGCCCTGCCTGCCCTATCGAGAAAACCATCAGCAAGGCCAAGGG  
 CCAGCCCCAGAGAGGCCAGGTGTACACCCCTGCCCTAGCAGAGATGAGC

35

TGACCAAGAACCAAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCC

AGCGACATCGCCGTGGAGTGGAGAGCAACGGCCAGCCCCGAGAACAACT

ACAAGACCACCCCCCTGTGCTGGACAGCGATGGCAGCTTCTCCTGTAC

AGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCA

GCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAACAGAC

CTGAGCCTGTCCCCCTGGCAAGTGA

SEQ ID NO: 44 (humanised heavy chain: H1, DNA sequence)

ATGGGCTGGTCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTG  
 CACAGCCAGGTGCAGCTGGTGAGAGCGGCGAGAGGTGAAGAAGCCCG  
 GCGCCAGCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTCACCGGC

40

TACTTCATGCACTGGGTGAGGCAGGCTCCCGCCAGGGCTGGAGTGGAT  
 GGGCAACATCTACCCCTACAACCGCGTCAGCAACTACAACCAGAGGTTCA  
 AGGCCAGGGTGACCATGACCACCGACACCTCTACCAGCACCGCCTACATG  
 GAACTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAG

45

GAGGTACTATTACGGCACCGGACCCGCCATTGGTACTTCGACGTGTGGG  
 GAACGGGGACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAG  
 CGTGTCCCCCTGGCCCCCAGCAGCAAGAGCACCAAGCGGGCGGCACAGCCG  
 CCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCCT  
 GGAACACAGCGGAGCCCTGACCGAGCGCGTGCACACCTCCCCGCGTGTGCTG

CAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTACCGTGCCCCAGCAG  
CAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCA  
ACACCAAGGTGGACAAGAAGGTGGAGCCCCAAGAGCTGTGACAAGACCCA  
CACCTGCCCCCCCCTGCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGT  
CCTGTTCCCCCCCCAAGCCTAAGGACACCCCTGATGATCAGCAGAACCCCCG  
AGGTGACCTGTGTGGTGGATGTGAGCCACGAGGGACCCTGAGGTGAAG  
TTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCC  
CAGGGAGGAGCAGTACAACACAGCACCTACCGGGTGGTGTCCGTGCTGACCG  
TGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCC  
AACAAAGGCCCTGCCTGCCCTATCGAGAAAACCATCAGCAAGGCCAAGGG  
CCAGGCCAGAGAGCCCCAGGTGTACACCCCTGCCCTAGCAGAGATGAGC  
TGACCAAGAACCAAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCC  
AGCGACATCGCCGTGGAGTGGAGAGCAACGCCAGCCCCGAGAACAACT  
ACAAGACCACCCCCCTGTGCTGGACAGCGATGGCAGCTTCTCTGTAC  
AGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCACGTGTTCA  
GCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAACAGC  
CTGAGCCTGTCCCCCTGGCAAGTGA

SEQ ID NO: 45 (humanised heavy chain: H2, DNA sequence)

20	ATGGGCTGGTCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGGGCGT CACAGCCAGGTGCAGCTGGTGCAGAGCGGCGCAGAGGTGAAGAAGCCCG GCGCCAGCGTAAAAGTGAGCTGCAAGGCCAGCGGCTACTCCTCACCGGC TACTTCATGCACTGGGTGAGGCAGGGCTCCCGGCCAGGGCTGGAGTGGAT GGGCAACATCTACCCCTACAACGGCGTCAGCAACTACAACCAGAGGTTCA
25	AGGCCAGGGTGACCATGACCACCGACACCTTACCCAGCACCACCGCTACATG GAACTGAGGAGCCTGAGGGAGCGACGACACCAGCGTGTACTACTGCGCCAG GAGGTACTATTACGGCACCGAACCGGCCATTGGTACTTCGACGTGTGGG GACAGGGGACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAG CGTGTCCCCCTGGCCCCCAGCAGCAAGAGCACAGCGGCGGCACAGCCG
30	CCCTGGGCTGCCTGGTGAAGGACTACTTCCCCAACCGGTGACCGTGTCC GGAACAGCGGAGCCCTGACCAGCGCGTGCACACCTCCCCGCCGTGCTG CAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTCCCCAGCAG CAGCCTGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCA ACACCAAGGTGGACAAGAAGGTGGAGCCAAAGAGCTGTGACAAGACCCA
35	CACCTCCCCCCCCCTGCCCTGCCCGAGCTGCTGGAGGGCCCAGCGTGT CCTGTTCCCCCCCCAAGCCTAAGGACACCCCTGATGATCAGCAGAACCCCCG AGGTGACCTGTGTGGTGGATGTGAGCCACGAGGACCCCTGAGGTGAAG TTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCC CAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCG
40	TGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCC AACAAAGGCCCTGCCTGCCCTATCGAGAAAACCATCAGCAAGGCCAAGGG CCAGCCCCAGAGAGCCCCAGGTGTACACCCCTGCCCTAGCAGAGATGAGC TGACCAAGAACCAAGGTGTCCCTGACCTGCCTGGTAAAGGGCTTCTACCCC AGCGACATCGCCGTGGAGTGGAGAGCAACGCCAGCCCAGAACAACT
45	ACAAGACCACCCCCCTGTGCTGGACAGCGATGGCAGCAGGGCAACGTGTCA AGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTCA GCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAACAGC CTGAGCCTGTCCCCCTGGCAAGTGA

SEQ ID NO: 46 (humanised light chain: L0, DNA sequence)

ATGGGCTGGCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTGCACAGCGACATTCAAGATGACCCAGAGCCCCAGCTCTGAGCGCCAGCGTGGCGATAGGGTACCACCTGCAAGGCCAGCCAGGACATCAACAGCTACCTGAGCTGGTCCAGCAGAAGCCGGCAAGGCTCCCAAGAGCCTGATCTACAGGGCCAACAGGCTCGGACGGCGTGCCTAGCAAGTTAGCGGCAGCGGAAGCGGCACAGACTTCACCCCTGACCATCAGCTCCCTGCAGCCCGAGGACTCGCCACCTACTACTGCCTGCAGTGCAGCAGAGTTCCCCCTGACCTCGGCCAGGGCACCAAATGGAGATCAAGCGTACGGTGGCCGCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAAGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCCTGTGAGGTGACCCACCAGGGCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGTGA

SEQ ID NO: 47 (humanised light chain: L1, DNA sequence)

ATGGGCTGGCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTGCACAGCGACATTCAAGATGACCCAGAGGCCAGCTCTGAGCGCCAGCGTGGCGATAGGGTACCACCTGCAAGGCCAGCCAGGACATCAACAGCTACCTGAGCTGGTCCAGCAGAAGCCGGCAAGGCTCCCAAGAGCCTGATCTACAGGGCCAACAGGCTCGGACGGCGTGCCTAGCAAGTTAGCGGCAGCGGAAGCGGCACAGACTTCACCCCTGACCATCAGCTCCCTGCAGCCCGAGGACTCGCCACCTACTACTGCCTGCAGTGCAGCAGAGTTCCCCCTGACCTCGGCCAGGGCACCAAATGGAGATCAAGCGTACGGTGGCCGCCCCAGCGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAAGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCCTGTGAGGTGACCCACCAGGGCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGTGA

SEQ ID NO: 48 (humanised light chain: L2, DNA sequence)

ATGGGCTGGCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTGCACAGCGACATTCAAGATGACCCAGAGGCCAGCTCTGAGCGCCAGCGTGGCGATAGGGTACCACCTGCAAGGCCAGCCAGGACATCAACAGCTACCTGAGCTGGTCCAGCAGAAGCCGGCAAGGCTCCCAAGAGCCTGATCTACAGGGCCAACAGGCTCGGACGGCGTGCCTAGCAAGTTAGCGGCAGCGGAAGCGGCACAGACTACACCCTGACCATCAGCTCCCTGCAGCCCGAGGACTCGCCACCTACTACTGCCTGCAGTGCAGCAGAGTTCCCCCTGACCTCGGCCAGGGCACCAAATGGAGATCAAGCGTACGGTGGCCGCCCCAGCGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAAGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCCTGTGAGGTGACCCACCAGGGCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGTGA

SEQ ID NO: 49 (humanised light chain: L3, DNA sequence)

ATGGGCTGGCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTG  
 CACAGCGACATTCACTAGATGACCCAGAGCCCCAGCTCTGAGCGCCAGCGT  
 5 GGGCGATAGGGTACCACATCACCTGCAAGGCCAGGCCAGGACATCAACAGCT  
 ACCTGAGCTGGTCCAGCAGAAGCCGGCAAGGCTCCAAAGAGCCTGATC  
 TACAGGGCCAACAGGCTCGTGACGGCGTGCCTAGCAAGTTAGCGGCAG  
 CGGAAGCGGCACAGACTTCACCCCTGACCATCAGCTCCCTGAGCCCCGAGG  
 ACTTCGCCACCTACTACTGCCTGCAGTGCAGAGTTCCCCCTGACCTTCG  
 10 GCGCGGGCACCAAACGGAGATCAAGCGTACGGTGGCCGCCCCAGCGTG  
 TTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGT  
 GGTGTGTCTGCTGAACAACCTCTACCCCCGGGAGGCCAAGGTGCAGTGGA  
 AGGTGGACAATGCCCTGCAGAGCGCAACAGCCAGGAGAGCGTGACCGA  
 15 GCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACCCCTG  
 AGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCCTGTGAGGTGACCC  
 ACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC  
 TGA

SEQ ID NO: 50 (10B3 chimera N54D heavy chain, DNA sequence)

20 ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGTC  
 CACTCCGAGGTTCACTGCAGCAGTCTGGACCTGAACCTGGTAAGCCTGG  
 GGCTTCAGTGAAGATATCCTGCAAGGCTTCTGGTTACTCATTCACTGGCTA  
 CTTCATGCACTGGGTGAAGCAGAGCCATGGCAATATCCTCGATTGGATTG  
 GAAATATTATCCTTACGATGGTGTCTAACTACAACCAGAGATTCAAGG  
 25 CCAAGGCCACATTGACTGTAGACAAGTCCTCTAGTACAGCCTACATGGAG  
 CTCCGCAGCCTTACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGACGC  
 TATTACTACGGTACCGGACCCGCTGATTGGTACTTCGATGTCTGGGGCACT  
 GGGACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGT  
 30 CCCCTGGCCCCCAGCAGCAAGAGCACAGCGGGCACAGCCGCCCCCTGG  
 GCTGCCTGGTAAGGACTACTCCCCGAACCGGTGACCGTGTCTGGAAC  
 AGCGGAGCCCTGACCAAGCGCGTGCACACCTCCCCGCCGTGCTGCAGAG  
 CAGCGGCCTGTACAGCCTGAGCAGCGTGGTACCGTGCAGCACAGCC  
 TGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACC  
 AAGGTGGACAAGAAGGTGGAGCCAAAGAGCTGTGACAAGACCCACACCT  
 35 GCCCCCCTGCCCTGCCCCGAGCTGCTGGAGGCCAGCGTGTCTGT  
 TCCCCCCCAGCCTAAGGACACCCCTGATGATCAGCAGAACCCCCGAGGTG  
 ACCTGTGTGGTGGATGTGAGCCACGAGGCCAGCTGAGGTGAAGTTCAA  
 CTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGG  
 GAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGT  
 40 GCACCAAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCCAAC  
 AAGGCCCTGCCCTGCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCA  
 GCCCAGAGAGCCCCAGGTGTACACCCCTGCCCTAGCAGAGATGAGCTGA  
 CCAAGAACCAAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGC  
 GACATCGCCGTGGAGTGGAGAGCAACGGCCAGCCCCAGAACAACTACA  
 45 AGACCACCCCCCTGTGCTGGACAGCGATGGCAGCTTCTCCTGTACAGC  
 AAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTAGCT  
 GCTCCGTATGCACGAGGCCCTGCACAATCACTACACCCAGAACAGCCTG  
 AGCCTGTCCCCGGCAAGTGA

SEQ ID NO: 51 (10B3 chimera N54Q heavy chain, DNA sequence)

ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGTC  
 CACTCCGAGGTTCAGCTGCAGCAGTCTGGACCTGAACCTGGTAAGCCTGG  
 5 GGCTTCAGTGAAGATATCCTGCAAGGCTCTGGTTACTCATTCACTGGCTA  
 CTTCATGCAGCTGGGTGAAGCAGAGCCATGGCAATATCCTCGATTGGATTG  
 GAAATATTATCCTTACCAAGGTGTTCTAACTACAACCAGAGATTCAAGG  
 CCAAGGCCACATTGACTGTAGACAAGTCCTCTAGTACAGCCTACATGGAG  
 10 CTCCGCAGCCTTACATCTGAGGAACCTGCAGTCTATTACTGTGCAAGACGC  
 TATTACTACGGTACCGGACCGGCTGATTGGTACTTCGATGTCTGGGGCACT  
 GGGACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGT  
 15 CCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGG  
 GCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCTGGAAC  
 AGCGGAGCCCTGACCAAGCGCGTGCACACCTCCCCGCCGTGCTGCAGAG  
 CAGCGGCCTGTACAGCCTGAGCAGCGTGGTACCGTGCAGCAGCAGCC  
 20 TGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACC  
 AAGTGGACAAGAAGGTGGAGCCAAAGAGACTGTGACAAGACCCACACCT  
 GCCCCCCTGCCCTGCCCCGAGCTGCTGGAGGCCCCAGCGTGTCTGGT  
 TCCCCCCCAGCCTAAGGACACCCCTGATGATCAGCAGAACCCCCGAGGTG  
 25 ACCTGTGTGGTGGATGTGAGCCACGAGGACCTGAGGTGAAGTTCAA  
 CTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGG  
 GAGGAGCAGTACAACAGCACCTACCGGGTGGTCCGTGCTGACCGTGT  
 GCACCAAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCCAAC  
 AAGGCCCTGCCCTGCCCTATCGAGAAAACCATTAGCAAGGCCAAGGGCCA  
 30 GCCCAGAGAGCCCCAGGTGTACACCCCTGCCCTAGCAGAGATGAGCTGA  
 CCAAGAACCAAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGC  
 GACATGCCGTGGAGTGGGAGAGCAACGGCCAGCCCAGAAACAACATACA  
 AGACCACCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCTGTACAGC  
 AAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTAGCT  
 GCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAACAGGCCTG  
 AGCCTGTCCCCCTGGCAAGTGA

SEQ ID NO: 52 (10B3 chimera C91S light chain, DNA sequence)

ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGTC  
 CACTCCGACATCAAGATGACCCAGTCTCCATCTTCCATGTATGCATCTCTA  
 35 CGAGAGAGAGTCACTATCACTTGCAAGGCAGTCAGGACATTAATAGCTA  
 TTTAAGCTGGTCCAGCAGAAACCAGGGAAATCTCCTAAGACCCTAATCT  
 ATCGTCAAACAGATTGGTAGATGGGTCCCATCAAGGTTCAAGTGGCAGT  
 GGATCTGGCAAGATTATTCTCACCATTAGCAGCCTGGAGTATGAAGA  
 40 TATGGGAATTATTATTGTCTACAGTCTGATGAATTCCGCTCACGTTCGG  
 TGCTGGGACCAAGCTGGAGCTGAAACGTACGGTGGCCGCCAGCGTGT  
 TCATCTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGGACCGCCAGCGT  
 GTGTGTCTGCTGAACAACCTACCCCCGGGAGGCCAGGTGCAGTGGAA  
 GGTGGACAATGCCCTGCAGAGGCCAACAGCCAGGAGAGCGTACCGAG  
 45 CAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCAGCACCCTGACCGAG  
 CAAGGCCGACTACGAGAACAGCAAGGTGTACGCCGTGAGGTGACCCACC  
 AGGGCCTGTCCAGCCCCGTGACCAAGAGCTCAACCAGGGCGAGTGCTGA

SEQ ID NO: 53 (humanised heavy chain: H2 N54D, DNA sequence)

ATGGGCTGGTCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTGC  
 CACAGCCAGGTGCAGCTGGTGCAGAGCGCGCAGAGGTGAAGAAGCCCG  
 GCGCCAGCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACTCCTCACCGGC  
 TACTTCATGCACTGGGTGAGGCAGGCTCCCGCCAGGGCTGGAGTGGAT  
 5 GGGCAACATCTACCCCTACGACGGCGTCAGCAACTACAACCAGAGGTTCA  
 AGGCCAGGGTGACCATGACCACCGACACCTTACCCAGCACCGCCTACATG  
 GAACTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAG  
 GAGGTACTATTACGGCACCGGACCCGCCATTGGTACTTCGACGTGTGGG  
 GACAGGGGACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAG  
 10 CGTGTCCCCCTGGCCCCCAGCAGCAAGAGCACCGAGCGCGGCACAGCCG  
 CCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCC  
 GGAACAGCGGAGCCCTGACCGAGCGCGTGCACACCTCCCCGCCGTGCTG  
 CAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCAGCAG  
 CAGCCTGGGACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCA  
 15 ACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGAGCTGTGACAAGACCCA  
 CACCTGCCCCCCCCTGCCCTGCCCTGCCCTGAGCTGCTGGGAGGCCCCAGCGTGT  
 CCTGTTCCCCCCCAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCG  
 AGGTGACCTGTGTGGTGGATGTGAGCCACGAGGACCCCTGAGGTGAAG  
 TTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCC  
 20 CAGGGAGGAGCAGTACAACACAGCACCTACCGGGTGGTGTCCGTGCTGACCG  
 TGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCC  
 AACAAAGGCCCTGCCTGCCCTATCGAGAAAACCATCAGCAAGGCCAACGG  
 CCAGCCCCAGAGAGGCCAGGGTGTACACCCTGCCCTAGCAGAGATGAGC  
 TGACCAAGAACCAAGGGTGTCCCTGACCTGCCTGGTAAGGGCTTCTACCCCC  
 25 AGCGACATGCCGTGGAGTGGAGAGCAACGGCCAGCCGAGAACAACT  
 ACAAGACCACCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTAC  
 AGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCA  
 GCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAACAGC  
 CTGAGCCTGCCCTGGCAAGTGA  
 30 SEQ ID NO: 54 (humanised heavy chain: H2 N54Q, DNA sequence)  
 ATGGGCTGGTCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTGC  
 CACAGCCAGGTGCAGCTGGTGCAGAGCGCGCAGAGGTGAAGAAGCCCG  
 GCGCCAGCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACTCCTCACCGGC  
 35 TACTTCATGCACTGGGTGAGGCAGGCTCCCGCCAGGGCTGGAGTGGAT  
 GGGCAACATCTACCCCTACCAGGGCGTCAGCAACTACAACCAGAGGTTCA  
 AGGCCAGGGTGACCATGACCACCGACACCTTACCCAGCACCGCCTACATG  
 GAACTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAG  
 GAGGTACTATTACGGCACCGGACCCGCCATTGGTACTTCGACGTGTGGG  
 40 GACAGGGGACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAG  
 CGTGTCCCCCTGGCCCCCAGCAGCAAGAGCACCGAGCGGGCAGACAGCCG  
 CCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCC  
 GGAACAGCGGAGCCCTGACCGAGCGCGTGCACACCTCCCCGCCGTGCTG  
 CAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCAGCAG  
 45 CAGCCTGGGACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCA  
 ACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGAGCTGTGACAAGACCCA  
 CACCTGCCCCCCCCTGCCCTGCCCTGCCCTGAGCTGCTGGGAGGCCCCAGCGTGT  
 CCTGTTCCCCCCCAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCG  
 AGGTGACCTGTGTGGTGGATGTGAGCCACGAGGACCCCTGAGGTGAAG

TTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCC  
 CAGGGAGGAGCAGTACAACACAGCACCTACCGGGTGGTCCGTGCTGACCG  
 TGCTGCACCAGGATTGGCTAACGGCAAGGAGTACAAGTGTAAAGGTGTCC  
 ACAAGGCCCTGCCTGCCCTATCGAGAAAACCATCAGCAAGGCCAAGGG  
 5 CCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCTAGCAGAGATGAGC  
 TGACCAAGAACCAAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCC  
 AGCGACATCGCCGTGGAGTGGGAGAGCAACGCCAGGCCAGAACAACT  
 ACAAGACCACCCCCCTGTGCTGGACAGCGATGGCAGCAGGGCAACGTGTTCA  
 10 GCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGC  
 CTGAGCCTGTCCCCGGCAAGTGA

SEQ ID NO: 55 (humanised light chain: L2 C91S, DNA sequence)

ATGGGCTGGTCCTGCATCATCCTGTTCTGGTGGCCACCGCCACCGCGTG  
 15 CACAGCGACATTCAAGATGACCCAGAGCCCCAGCTCTTGAGCGCCAGCGT  
 GGGCGATAGGGTGACCATCACCTGCAAGGCCAGCCAGGACATCAACAGCT  
 ACCTGAGCTGGTCCAGCAGAACAGCCGGCAAGGCTCCAAGAGCCTGATC  
 TACAGGGCCAACAGGCTCGTGGACGGCGTGCCTAGCAAGTTAGCGGCAG  
 CGGAAGCGGCACAGACTACACCCCTGACCATCAGCTCCCTGCAGCCGAGG  
 20 ACTTCGCCACCTACTACTGCCTGCAGAGCGACGAGTTCCCTGACCTTCG  
 GCCAGGGCACCAAACCTGGAGATCAAGCGTACGGTGGCCGCCCCAGCGTG  
 TTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGT  
 GGTGTGTCTGCTGAACAACCTTCTACCCCCGGGAGGCCAAGGTGCAGTGG  
 AGGTGGACAATGCCCTGCAGAGCGCAACAGCCAGGAGAGCGTGACCGA  
 25 GCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACCCCTGA  
 GCAAGGCCGACTACGAGAACAGCAAGGTGTACGCCTGTGAGGTGACCCA  
 CCAGGGCTGTCCAGCCCCGTACCAAGAGCTTCAACCAGGGCGAGTGCT  
 GA

30 SEQ ID NO: 56 (artificial myostatin linear peptide 1)

DFGLDCDEHSTESRGSG

SEQ ID NO: 57 (artificial myostatin linear peptide 3)

SGSGDCDEHSTESRCCRY

35 SEQ ID NO: 58 (artificial myostatin linear peptide 5)  
 SGSGHSTESRCCRYPLTV

SEQ ID NO: 59 (artificial myostatin linear peptide 7)

40 SGSGSRCCRYPLTVDFEA

SEQ ID NO: 60 (artificial myostatin linear peptide 9)

SGSGRYPLTVDFEAFGWD

45 SEQ ID NO: 61 (artificial myostatin linear peptide 11)  
 SGSGTVDFEAFGWDWIIA

SEQ ID NO: 62 (artificial myostatin linear peptide 13)

SGSGEAFGWDWIIAPKRY

50

- SEQ ID NO: 63 (artificial myostatin linear peptide 15)  
SGSGWDWIIAPKRYKANY
- 5 SEQ ID NO: 64 (artificial myostatin linear peptide 17)  
SGSGIAPKRYKANYCSGE
- SEQ ID NO: 65 (artificial myostatin linear peptide 19)  
SGSGRYKANYCSGECEFV
- 10 SEQ ID NO: 66 (artificial myostatin linear peptide 21)  
SGSGNYCSGECEFVFLQK
- SEQ ID NO: 67 (artificial myostatin linear peptide 23)  
SGSGGECEFVFLQKYPHT
- 15 15 SEQ ID NO: 68 (artificial myostatin linear peptide 25)  
SGSGFVFLQKYPHTHLVH
- SEQ ID NO: 69 (artificial myostatin linear peptide 27)  
20 SGSGQKYPHTHLVHQANP
- SEQ ID NO: 70 (artificial myostatin linear peptide 29)  
SGSGHHTHLVHQANPRGSA
- 25 SEQ ID NO: 71 (artificial myostatin linear peptide 31)  
SGSGVHQANPRGSAGPCC
- SEQ ID NO: 72 (artificial myostatin linear peptide 33)  
SGSGNPRGSAGPCCTPTK
- 30 30 SEQ ID NO: 73 (artificial myostatin linear peptide 35)  
SGSGSAGPCCTPTKMSPI
- SEQ ID NO: 74 (artificial myostatin linear peptide 37)  
35 SGSGCCTPTKMSPINMLY
- SEQ ID NO: 75 (artificial myostatin linear peptide 39)  
SGSGTKMSPINMLYFNGK
- 40 SEQ ID NO: 76 (artificial myostatin linear peptide 41)  
SGSGPINMLYFNGKEQII
- SEQ ID NO: 77 (artificial myostatin linear peptide 43)  
SGSGLYFNGKEQIIYGKI
- 45 45 SEQ ID NO: 78 (artificial myostatin linear peptide 45)  
SGSGGKEQIIYGKIPAMV
- SEQ ID NO: 79 (artificial myostatin linear peptide 47)  
50 SGSGIIYGKIPAMVVDRC

SEQ ID NO: 80 (artificial myostatin linear peptide 49)  
SGSGGKIPAMVVDRCGCS

5 SEQ ID NO: 81 (artificial myostatin linear peptide)  
CCTPTKMSPINMLY

SEQ ID NO: 82 (CDRH3 variant Y96L)  
RLYYGTGPADWYFDV

10 SEQ ID NO: 83 (CDRH3 variant G99D)  
RYYYDTGPADWYFDV

15 SEQ ID NO: 84 (CDRH3 variant G99S)  
RYYYSTGPADWYFDV

SEQ ID NO: 85 (CDRH3 variant G100A\_K)  
RYYYGTPADWYFDV

20 SEQ ID NO: 86 (CDRH3 variant P100B\_F)  
RYYYGTGFADWYFDV

SEQ ID NO: 87 (CDRH3 variant P100B\_I)  
RYYYGTGIADWYFDV

25 SEQ ID NO: 88 (CDRH3 variant W100E\_F)  
RYYYGTGPADFYFDV

30 SEQ ID NO: 89 (CDRH3 variant F100G\_N)  
RYYYGTGPADWYNDV

SEQ ID NO: 90 (CDRH3 variant F100G\_Y)  
RYYYGTGPADWYYDV

35 SEQ ID NO: 91 (CDRH3 variant V102N)  
RYYYGTGPADWYFDN

SEQ ID NO: 92 (CDRH3 variant V102S)  
RYYYGTGPADWYFDS

40 SEQ ID NO: 93 (CDRH2 variant G55D)  
NIYPYNDVSNYNQRFKA

45 SEQ ID NO: 94 (CDRH2 variant G55L)  
NIYPYNLVSNYNQRFKA

SEQ ID NO: 95 (CDRH2 variant G55S)

NIYPYNSVSНЫNQRFKA

SEQ ID NO: 96 (CDRH2 variant G55T)

5 NIYPYNTVSНЫNQRFKA

SEQ ID NO: 97 (CDRH2 variant G55V)

NIYPYNVVSНЫNQRFKA

10 SEQ ID NO: 98 (humanised heavy chain: H2\_F100G\_Y Fc disabled)

QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYFMHWVRQAPGQGLEWMG  
 NIYPYNGVSНЫNQRFKARVTMTTDSTSTAYMELRSLSRSDDTAVYYCARRY  
 YYGTGPADWYYDVWGQGTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGC  
 LVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQT  
 15 YICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGAPSVFLFPPPKPKDT  
 LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTPREEQYNSTYR  
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPVYTLPP  
 SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFL  
 YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

20

SEQ ID NO: 99 (humanised heavy chain: H2\_G55S - F100G\_Y Fc disabled)

QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYFMHWVRQAPGQGLEWMG  
 NIYPYNSVSНЫNQRFKARVTMTTDSTSTAYMELRSLSRSDDTAVYYCARRY  
 YYGTGPADWYYDVWGQGTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGC  
 25 LVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQT  
 YICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGAPSVFLFPPPKPKDT  
 LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTPREEQYNSTYR  
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPVYTLPP  
 SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFL  
 30 YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO: 100 (human acceptor framework for V<sub>L</sub>)

DIQMTQSPSSLSASVGDRVITCRASQGISNYLAWFQQKPGKAPKSLIYAASSL  
 QSGVPSKFSGSGSTDFTLTISLQPEDFATYYCQQYNSYPXXXXXXXXXFG  
 35 QGKLEIK

SEQ ID NO: 101 (HexaHisGB1Tev/ (D76A) mouse myostatin polyprotein)

MAAGTAVGAWVLVLSLWGAVVGTHHHHHDTYKLILNGKTLKGETTTEAV  
 DAATAEKVFKQYANDNGVDGEWTYDDATKTFVTGESENLYFQEGSEREEN  
 40 VEKEGLCNACAWRQNTRYRSRIEAIKIQILSKLRLETAPNISKDAIRQLLPRAPPL  
 RELIDQYDVQRADSSDGSLEDDDYHATTETIITMPTESDFLMQADGKPKCCFF  
 KFSSKIQYNKVVKAQLWIYLRPVKPTTVFVQILRLIKPMKDGRYTGIRSLK  
 LDMSPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGE  
 DGLNPFLLEVKTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWII  
 45 APKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPINML  
 YFNGKEQIIYGKIPAMVVDRCGCS

SEQ ID NO: 102 (GB1 tag)

DTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDATK  
5 TFTVTE

SEQ ID NO: 103 (mouse myostatin polyprotein (D76A))

EGSEREENVEKEGLCNACAWRQNTRYRSRIEAIKIQILSKLRLETAPNISKDAIR  
QLLPRAPPLRELIDQYDVQRADSSDGSLEDDDYHATTETIITMPTESDFLMQA  
10 DGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVKTPPTVFVQILRLIKPMKDGT  
RYTGIRSLKLDMSPGTGIWQSIDVKVLQNLKQPESNLGIEIKALDENHDL  
AVTFPGPGEDGLNPLEVKTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDF  
EAFGWDWIIAPKRYKANYCSGECEFVFLQKYPHTHVLVHQANPRGSAGPCCTP  
TKMSPINMLYFNGKEQIYGYKIPAMVVDRCGCS

15 SEQ ID NO: 104 (mature myostatin)

DFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFL  
QKYPHTHVLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIYGYKIPAMVVD  
RCGCS

20 SEQ ID NO: 105 (Furin expression construct)

MELRPWLLVVVAATGTLVLLAADAQGQKVFTNTWAVRIPGGPAVANSVAR  
KHFGLNLGQIFGDYYHFWHRGVTKRSLSPHRPRHSRLQREPQVQWLEQQVA  
KRRTKRDVYQEPDKFPQQWYLSGVTQRDLNVKAAWAQGYTGHGIVVSIL  
25 DDGIEKNHPDLAGNYDPGASFDVNDQDPDPQPRYTQMNDNRHGTRCAGEV  
AAVANNGVCGVGVAYNARIGGVRMLGEVTDAVEARSLGLNPNNHIYAS  
WGPEDDGKTVDGPARLAEAEAFFRGVSQGRGGLGSIFVWASGNGGREHDSCN  
CDGYTNSIYTLSISSATQFGNVPWYSEACSSTLATTYSSGNQNEKQIVTTDLRQ  
KCTESHTGTSASAPLAAGIIALTLEANKNLTwRDMQHLVVQTSKPAHNLAND  
30 WATNGVGRKVSHSYGYGLLAGAMVALAQNWTTVAPQRKCIIDILTEPKDI  
GKRLEVRKTVTACLGEPNHITRLEHAQARLTLTSYNRRGDLAIHLVSPMGRST  
LLAARPHDYSADGFNDWAFMTTHSWDEDPSGEWVLEIENTSEANNYGTLLK  
FTLVLYGTAPEGLPVPESSGCKTLTSSQACENLYFQG

35 SEQ ID NO: 106 (HexaHisGB1Tev/Human Myostatin pro-peptide)

MAAGTAVGAWVLVLSLWGAvgVGTHHHHHDTYKLILNGKTLKGETTTEAV  
DAATAEKVFKQYANDNGVDGEWTYDDATKTFTVTEGSENLYFQENSEQKE  
NVEKEGLCNACTWRQNTKSSRIEAIKIQILSKLRLETAPNISKDVIRQLLPKAPP  
LRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQVDGKPKCCF  
40 FKFSSKIQYNKVVKAQLWIYLRPVETPTVFVQILRLIKPMKDGTYTGIRSLK  
LDMNPGTGIWQSIDVKVLQNLKQPESNLGIEIKALDENHDLAVTFPGPG  
EDGLNPLEVKTDTPKRSRR

SEQ ID NO: 107 (Tev protease expression construct)

45 MHGHHHHHHGESLFKGPRDYNPISSTICHLTNESDGHTTSLYGIGFGPFIITNK  
HFLFRNNNGTLLVQSLHGVFKVKNTTLQQHLIDGRDMIIRMPKDFPPFPQKL  
KFREPQREERICLVTTFQTKSMSSMVSCTSCTFPSSDGIFWKHWIQTKDQGC  
GSPLVSTRDGFIVGIHSASNFTNTNNYFTSVPKNFELLTNQEAQQWVSGWR  
LNADSVLWGGHKVFMVKPEEPFQPVKEATQLMNE

50

SEQ ID NO: 108 (human myostatin pro-peptide)

ENSEQKENVEKEGLCNACTWRQNTKSSRIEAIKIQILSKLRLETAPNISKDVR  
5 QLLPKAPPLRELIDQYDVQRDDSSDGSLEDDYHATTETIITMPTESDFLMQV  
DGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVETPTTVFVQILRLIKPMKDGT  
RYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDL  
AVTFPGPGEDGLNPLEVKTVDTPKRSRR

10 SEQ ID NO: 109 (CDRL3 variant C91S)

LQSDEFPLT

SEQ ID NO: 110 (CDRH3 variant F100G\_S)

RYYYGTGPADWYSDV

15 SEQ ID NO: 111 (BMP-1 expression construct)

MPGVARLPLLLGLLLPRPGRPLDLADTYDLAEEDDSEPLNYKDPCKAAAF  
LGDIALDEEDLRAFQVQQAVDLRRHTARKSSIKAAVPGNTSTPSCQSTNGQPQ  
RGACGRWRGRSRSRRAATSRPERVWPDGVIPFVIGGNFTGSQRAVFRQAMR  
HWEKHTCVTFLERTDED SYIVFTYRPCGCCSYVGRRGGPQAISIGKNCDFKFG  
20 IVVHELGHVVGFWHEHTRPDRDRHVSIVRENIQPGQEYNFLKMEPQEVESELG  
ETYDFDSIMHYARNTFSRGIFLDTIVPKYEVNGVKPPIGQRTRLSKGDIAQARK  
LYKCPACGETLQDSTGNFSSPEYPNGYSAHMHCVWRISVTPGEKIILNFTSLD  
LYRSRLCWYDYVEVRDGFWRKAPLGRFCGSKLPEPIVSTDSDLWVEFRSSS  
NWVGKGFFAVYEAI CGGDVKKDYGHIQSPNYPDDYRPSKVCIWRIQVSEGFH  
25 VGLTFQSFEIERHDSCAYDYLEVRDGHSESSTLIGRYCGYEKDDIKSTSSRLW  
LKFVSDGSINKAGFAVNFFKEVDECSPRNRGCEQRCLNTLSYKCSCDPGY  
ELAPDKRRCEAACGGFLTKLNGSITSPGWPKEYPPNKNCIWQLVAPTQYRISL  
QFDFFETEGNDVCKYDFVEVRSGLTADSKLHGKFCGSEKPEVITSQYNNMRV  
30 EFKSDNTVSKKGFKAHFFSEKRPALQPPRGRPHQLKFRVQKRN RTPQENLYF  
QGWSHPQFEKGTDTYKLILNGKTLGETTEAVDAATAEKVFKQYANDNGV  
DGEWTYDDATKTFTVTE

CLAIMS

1. An antigen binding protein which specifically binds to myostatin and comprises CDRH3 of SEQ ID NO: 3; or a variant CDRH3.

2. The antigen binding protein according to claim 1, wherein the variant CDRH3 is (i) any one of SEQ ID NOs: 82-92, or 110; or (ii) any one of the following Kabat substitutions V102Y, V102H, V102I, V102D or V102G.

3. The antigen binding protein according to claim 1 or 2 which further comprises one or more or all CDRs selected from: CDRH1 (SEQ ID NO: 1) or a variant CDRH1; CDRH2 (SEQ ID NO: 2) or a variant CDRH2; CDRL1 (SEQ ID NO: 4) or a variant CDRL1; CDRL2 (SEQ ID NO: 5) or a variant CDRL2; and CDRL3 (SEQ ID NO: 6 or 109) or a variant CDRL3.

4. The antigen binding protein according to claim 2, wherein the variant CDRH2 is (i) any one of SEQ ID NOs: 93-97; or (ii) any one of the following Kabat substitutions N50R, N50E, N50W, N50Y, N50G, N50Q, N50V, N50L, N50K, N50A, I51L, I51V, I51T, I51S, I51N, Y52D, Y52L, Y52N, Y52S, Y53A, Y53G, Y53S, Y53K, Y53T, Y53N, N54S, N54T, N54K, N54D, N54G, V56Y, V56R, V56E, V56D, V56G, V56S, V56A, N58K, N58T, N58S, N58D, N58R, N58G, N58F or N58Y.

5. The antigen binding protein according to any one of the preceding claims, wherein CDRH3 is SEQ ID NO: 90; and/or CDRH2 is SEQ ID NO: 95; and/or CDRL3 is SEQ ID NO: 109.

6. An antigen binding protein which specifically binds to myostatin and comprises the corresponding CDRH3 of the variable domain sequence of SEQ ID NO: 7, or a variant CDRH3 thereof.

7. The antigen binding protein according to claim 6 which further comprises one or more or all of corresponding CDRs selected from CDRH1 or a variant CDRH1 thereof, or CDRH2 or a variant CDRH2 thereof of the variable domain sequence of SEQ ID NO: 7; or CDRL1 or a variant CDRL1 thereof, CDRL2 or a variant CDRL2 thereof, and CDRL3 or a variant CDRL3 thereof, of the variable domain sequence of SEQ ID NO: 8.

8. An antigen binding protein which specifically binds to myostatin and comprises a binding unit H3 comprising Kabat residues 95-101 of SEQ ID NO: 7, or a variant H3.

9. The antigen binding protein according to claim 8 which further comprises one or more or all binding units selected from: H1 comprising Kabat residues 31-32 of SEQ ID NO: 7 or a variant H1; H2 comprising Kabat residues 52-56 of SEQ ID NO: 7 or a variant H2; L1 comprising Kabat residues 30-34 of SEQ ID NO: 8 or a variant L1; L2 comprising Kabat residues 50-55 of SEQ ID NO: 8 or a variant L2; and L3 comprising Kabat residues 89-96 of SEQ ID NO: 8 or a variant L3.

10 10. The antigen binding protein according to any one of the preceding claims which further comprises any one or a combination of Kabat amino acid residues selected from:

- (a) S or T at position 28 of the variable heavy chain;
- (b) T or Q at position 105 of the variable heavy chain;
- 15 (c) V, I or G at position 2; L or V at position 4; L, I, M or V at position 20; C at position 22; T, A, V, G or S at position 24; G at position 26; I, F, L or S at position 29; W at position 36; W or Y at position 47; I, M, V or L at position 48; I, L, F, M or V at position 69; A, L, V, Y or F at position 78; L or M at position 80; Y or F at position 90; C at position 92; and/or R, K, G, S, H or N at position 94 of the variable heavy chain;
- (d) R or G at position 16 of the variable light chain;
- (e) Y or F at position 71 of the variable light chain;
- (f) A or Q at position 100 of the variable light chain; and/or
- (g) I, L or V at position 2; V, Q, L or E at position 3; M or L at position 4; C at position 23; W at position 35; Y, L or F at position 36; S, L, R or V at position 46; Y, H, F or K at position 49; C at position 88; and/or F at position 98 of the variable light chain.

25 11. The antigen binding protein according to any one of the preceding claims which further comprises a heavy chain variable region acceptor antibody framework having 75% or greater sequence identity to the framework regions as shown in SEQ

ID NO: 10; or a light chain variable domain acceptor antibody framework having 75% or greater sequence identity to the framework regions as shown in SEQ ID NO: 11.

12. An antigen binding protein which specifically binds to myostatin and comprises:

- 5 (i) a heavy chain variable region selected from SEQ ID NO: 7 or SEQ ID NO: 25; and/or a light chain variable region selected from SEQ ID NO: 8 or SEQ ID NO: 21; or a variant heavy chain variable region or light chain variable region with 75% or greater sequence identity; or
- 10 (ii) a heavy chain of SEQ ID NO: 26; and/or a light chain selected from SEQ ID NO: 27 or SEQ ID NO: 37; or a variant heavy chain or light chain with 75% or greater sequence identity.

13. An antigen binding protein which specifically binds to myostatin and comprises:

- 15 (i) a heavy chain variable region selected from any one of SEQ ID NO: 12, 13 or 14; and/or a light chain variable region selected from any one of SEQ ID NO: 15, 16, 17, 18 or 24; or a variant heavy chain variable region or light chain variable region with 75% or greater sequence identity; or
- 20 (ii) a heavy chain selected from any one of SEQ ID NO: 28, 29, 30, 98 or 99; and/or a light chain selected from any one of SEQ ID NO: 31, 32, 33, 34 or 40; or a variant heavy chain or light chain with 75% or greater sequence identity.

14. The antigen binding protein according to claim 12 or 13, wherein the following Kabat substitutions are present:

- 25 (i) Y96L, G99D, G99S, G100A\_K, P100B\_F, P100B\_I, W100E\_F, F100G\_N, F100G\_S, F100G\_Y, V102N, or V102S in the heavy chain variable region or heavy chain; and/or
- (ii) G55D, G55L, G55S, G55T or G55V, in the heavy chain variable region or heavy chain; and/or
- (iii) C91S in the light chain variable region or light chain.

15. The antigen binding protein according to any one of the preceding claims, which is Fc disabled.

16. A nucleic acid molecule which encodes an antigen binding protein as defined in any one of claims 1 to 15.

5 17. The nucleic acid molecule according to claim 16 which comprises:

(i) a heavy chain DNA sequence of SEQ ID NO: 41; and/or a light chain DNA sequence selected from SEQ ID NO: 42 or 52; or a variant heavy chain or light chain with 75% or greater identity; or

10 (ii) a heavy chain DNA sequence selected from any one of SEQ ID NO: 43, 44 or 45; and/or a light chain DNA sequence selected from any one of SEQ ID NO: 46, 47, 48, 49 or 55; or a variant heavy chain or light chain with 75% or greater identity.

18. The nucleic acid molecule according to claim 16, wherein the DNA sequence encodes a heavy or light chain with the following Kabat substitutions:

15 (i) Y96L, G99D, G99S, G100A\_K, P100B\_F, P100B\_I, W100E\_F, F100G\_N, F100G\_S, F100G\_Y, V102N, or V102S in the heavy chain; and/or  
(ii) G55D, G55L, G55S, G55T or G55V, in the heavy chain; and/or  
(iii) C91S in the light chain.

19. An expression vector comprising a nucleic acid molecule as defined in any one of claims 16 to 18.

20 20. A recombinant host cell comprising an expression vector as defined in claim 19.

21. A method for the production of an antigen binding protein as defined in any one of claims 1 to 15 which method comprises the step of culturing a host cell as defined in claim 20 and recovering the antigen binding protein.

25 22. A pharmaceutical composition comprising an antigen binding protein as defined in any one of claims 1 to 15 and a pharmaceutically acceptable carrier.

23. A method of treating a subject afflicted with a disease which reduces any one or a combination of muscle mass, muscle strength and muscle function, which method comprises the step of administering an antigen binding protein as defined in any one of claims 1 to 15 or the composition of claim 22.

5 24. A method of treating a subject afflicted with sarcopenia, cachexia, muscle-wasting, disuse muscle atrophy, HIV, AIDS, cancer, surgery, burns, trauma or injury to muscle bone or nerve, obesity, diabetes (including type II diabetes mellitus), arthritis, chronic renal failure (CRF), end stage renal disease (ESRD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), elective joint  
10 repair, multiple sclerosis (MS), stroke, muscular dystrophy, motor neuron neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, osteoporosis, osteoarthritis, fatty acid liver disease, liver cirrhosis, Addison's disease, Cushing's syndrome, acute respiratory distress syndrome, steroid induced muscle wasting, myositis or scoliosis, which method comprises the step of administering an antigen binding protein as  
15 defined in any one of claims 1 to 15 or the composition of claim 22.

25. A method of increasing muscle mass, increasing muscle strength, and/or improving muscle function in a subject which method comprises the step of administering an antigen binding protein as defined in any one of claims 1 to 15 or the composition of claim 22.

Figure 1




Figure 2

+ DTT




Figure 3A




Figure 3B




Figure 4




Figure 5




Figure 6




Figure 7








Figure 8



A



B



C

Figure 9





Figure 10A




Figure 10B




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24A




Figure 24B




Figure 24C




Figure 25





Figure 26



# INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2009/067515

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. C07K16/22 A61K39/395 A61P21/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
C07K A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/116269 A2 (PFIZER [US]; AMGEN FREMONT INC [US]; CHIN EVA ROSE [US]; IBEBUNJO CHIK) 2 November 2006 (2006-11-02) cited in the application figures 6-7,12-20; examples I-IX,XII-XV -----	1-25
X	WO 2004/037861 A2 (WYETH CORP [US]; CAMBRIDGE ANTIBODY TECH [GB]; VELDMAN GEERTRUIDA M [U] 6 May 2004 (2004-05-06) cited in the application examples 4-5,8-10,13 ----- -----	1-25

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 March 2010

Date of mailing of the international search report

01/04/2010

Name and mailing address of the ISA/  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Luyten, Kattie

## INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2009/067515

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WAGNER KATHRYN R ET AL: "A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy" ANNALS OF NEUROLOGY, JOHN WILEY AND SONS, BOSTON, US, vol. 63, no. 5, 1 May 2008 (2008-05-01), pages 561-571, XP002514515 ISSN: 0364-5134 cited in the application the whole document -----	1-25
X	NADEAU AMELIE ET AL: "Are big muscles necessarily good muscles?" ANNALS OF NEUROLOGY MAY 2008, vol. 63, no. 5, May 2008 (2008-05), pages 543-545, XP007912263 ISSN: 1531-8249 the whole document -----	1-25
X	US 2007/087000 A1 (WALSH FRANK S [US] ET AL) 19 April 2007 (2007-04-19) examples 3-4 -----	1-25
X	HOLZBAUR ET AL: "Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis" NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 23, no. 3, 1 September 2006 (2006-09-01), pages 697-707, XP005599201 ISSN: 0969-9961 the whole document -----	1-25
X	US 2003/138422 A1 (AGHAJANIAN JANE [US] ET AL DUNHAM LEGAL REPRESENTATIVE WI [US] ET AL) 24 July 2003 (2003-07-24) examples 1-6,8-10 -----	1-25
X	BOGDANOVICH SASHA ET AL: "Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C." MUSCLE & NERVE MAR 2008, vol. 37, no. 3, March 2008 (2008-03), pages 308-316, XP007912264 ISSN: 0148-639X the whole document -----	1-25
		-/-

## INTERNATIONAL SEARCH REPORT

International application No PCT/EP2009/067515
---

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BOGDANOVICH SASHA ET AL: "Functional improvement of dystrophic muscle by myostatin blockade." NATURE 28 NOV 2002, vol. 420, no. 6914, 28 November 2002 (2002-11-28), pages 418-421, XP009120477 ISSN: 0028-0836 the whole document	1-25
X	WHITTEMORE LISA-ANNE ET AL: "Inhibition of myostatin in adult mice increases skeletal muscle mass and strength." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 24 JAN 2003, vol. 300, no. 4, 24 January 2003 (2003-01-24), pages 965-971, XP002574357 ISSN: 0006-291X the whole document	1-25
X	WO 2007/047112 A2 (LILLY CO ELI [US]; DAVIES JULIAN [US]; JONES BRYAN EDWARD [US]; KORYTK) 26 April 2007 (2007-04-26) cited in the application examples 1-5,7	1-25
X	BRADLEY L ET AL: "Myostatin as a therapeutic target for musculoskeletal disease" CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 65, no. 14, 21 April 2008 (2008-04-21), pages 2119-2124, XP019619981 ISSN: 1420-9071 page 2121; table 1	1-25
X	TSUCHIDA KUNIHIRO: "Targeting myostatin for therapies against muscle-wasting disorders" CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 11, no. 4, 1 July 2008 (2008-07-01), pages 487-494, XP008120304 ISSN: 1367-6733 abstract page 490, paragraph 4	1-25
		-/-

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2009/067515

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WALSH F S ET AL: "MYOSTATIN: A MODULATOR OF SKELETAL-MUSCLE STEM CELLS" BIOCHEMICAL SOCIETY TRANSACTIONS, PORTLAND PRESS LTD, GB, vol. 33, no. 6, 1 December 2005 (2005-12-01), pages 1513-1517, XP009077202 ISSN: 0300-5127 abstract page 1515 -----	1-25

**INTERNATIONAL SEARCH REPORT**
**Information on patent family members**

 International application No  
**PCT/EP2009/067515**

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 2006116269	A2 02-11-2006	AR 053067 A1		18-04-2007
		AU 2006239860 A1		02-11-2006
		CA 2605723 A1		02-11-2006
		CN 101272802 A		24-09-2008
		EA 200702327 A1		28-04-2008
		EP 1877075 A2		16-01-2008
		JP 2008539241 T		13-11-2008
		KR 20080011403 A		04-02-2008
		NL 1031674 C2		26-04-2007
		NL 1031674 A1		27-10-2006
		NL 1033650 C2		12-01-2009
		NL 1033650 A1		16-05-2007
		NL 2002255 C2		24-09-2009
		NL 2002255 A1		26-03-2009
		US 2006263354 A1		23-11-2006
		ZA 200709291 A		28-01-2009
-----	-----	-----	-----	-----
WO 2004037861	A2 06-05-2004	AR 047392 A1		18-01-2006
		AU 2003274448 A1		13-05-2004
		BR 0315598 A		06-09-2005
		CA 2500490 A1		06-05-2004
		CN 1788019 A		14-06-2006
		CN 101230102 A		30-07-2008
		CN 101220098 A		16-07-2008
		EC SP055739 A		11-08-2005
		EP 1554312 A2		20-07-2005
		IS 7770 A		23-03-2005
		JP 2006519583 T		31-08-2006
		KR 20050049558 A		25-05-2005
		MX PA05004225 A		20-09-2005
		NZ 539084 A		30-05-2008
		RU 2360925 C2		10-07-2009
		ZA 200503249 A		28-11-2007
-----	-----	-----	-----	-----
US 2007087000	A1 19-04-2007	US 2009285827 A1		19-11-2009
-----	-----	-----	-----	-----
US 2003138422	A1 24-07-2003	NONE		-----
-----	-----	-----	-----	-----
WO 2007047112	A2 26-04-2007	AU 2006303921 A1		26-04-2007
		CA 2624935 A1		26-04-2007
		CN 101282992 A		08-10-2008
		EA 200801065 A1		29-08-2008
		EP 1951755 A2		06-08-2008
		JP 2009511579 T		19-03-2009
		KR 20080049104 A		03-06-2008
		US 2009131638 A1		21-05-2009